

Curriculum vitae of Dr. Francesco Massari, M.D.

PERSONAL CONTACT REFERENCES

Full name: Francesco Massari

DOB: January 24th, 1979

Citizenship: Italian

E-mail address: francesco.massari8@unibo.it

E-mail address: francesco.massari@aosp.bo.it

PROFESSIONAL EXPERIENCES TO DATE

- 07/03/2022 to today. Assistant Professor at Bologna University
- 01/01/2016 to today. Physician assistant (specialist in Medical Oncology), at Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna
- 12/01/2011 to 12/31/2015. Physician assistant (specialist in Medical Oncology), at Verona University Hospital (Azienda Ospedaliera Universitaria Integrata Verona)
- 05/01/2013 to 10/31/2013. Command intended for clinical activities and research at the Medical Oncology Department, Institut Gustave Roussy, Villejuif, France (Mentor: Prof. Bernard Escudier). To acquire new and specific expertise in the field of biomolecular individualization cancer therapies in the treatment of tumors of the genitourinary tract, and in particular of renal cell carcinoma.
- 02/01/2011 to 11/30/2011. Professional appointment, as a clinical physician (specialist in Medical Oncology), at Verona University Hospital (Azienda Ospedaliera Universitaria Integrata Verona)
- March 2008 to February 2011. Professional appointment, as a clinical physician (specialist in Medical Oncology), at Bologna University Hospital (Azienda Ospedaliero-Universitaria S.Orsola-Malpighi) – Medical Oncology Unit, via Albertoni no. 15, 40138 Bologna and at Verona University Hospital (Azienda Ospedaliera Universitaria Integrata). I have been carrying out both patient-focused tasks (first-hand patient care responsibility in the Inpatient and Outpatient Department and Ambulatory Treatment Center/Day Hospital), and research-oriented activities. My major clinical and research fields of interest include: male and female urogenital tract cancer; breast cancer; ovarian cancer; uterine cancer; high-dose chemotherapy with autologous stem cell support. Data from my research have been published, as original articles, in various scientific journals. I have also been attending numerous scientific conferences about topics in oncology and hematology, and participating in update meetings as both auditor and lecturer.
- 04/22/09 to 03/31/11. Professional appointment, as a clinical physician (specialist in Medical Oncology), at Bologna University Hospital (Azienda Ospedaliero-Universitaria S.Orsola-Malpighi) – On-call Medical Service, Inpatient Department, Albertoni Pavillion, at Bologna University Hospital (Azienda Ospedaliero-Universitaria S.Orsola-Malpighi) – Medical Oncology Unit, via Albertoni no. 15, 40138 Bologna. I have been carrying out duty doctor-related activities during nights, Sundays and public holidays.
- 08/09/10 – 11/26/2010. Professional appointment, as a clinical physician (specialist in Medical Oncology), at IRST of Meldola (FC). I have been carrying out duty doctor-related activities during nights.

EDUCATION, PROFESSIONAL CERTIFICATIONS AND TRAINING

- 1992-1997. High school student at “Liceo Scientifico G. Banzi Bazoli” (secondary school with an emphasis on sciences) - Lecce, Italy. School-leaving examination in 1997, passed with full marks (60/60).
- 1997-2003. Medical student at Bologna University Medical School (Bologna, Italy). Successful completion of Program (awarding of MD Diploma) in 2003, with the score of 108/110. Dissertation thesis in Medical Oncology with the title: “Role of chemotherapy as part of the treatment strategy for endometrial carcinoma” (translated from Italian). Supervisor: Prof. E. Barbieri.
- 2004. Successful completion of the Italian Medical Licensing Examination. Registered, Medical Doctors Board of Lecce, Italy.
- 2009. Registered, Medical Doctors Board of Bologna, Italy.
- 2003-2007. Undergraduate training (internship, as medical student); postgraduate training (internship, as a medical graduate); Residency/Fellowship Program training (as Resident doctor/Fellow of the School of Specialization in Medical Oncology); at Bologna University Hospital – Medical Oncology Unit (Director: Dr. Andrea Angelo Martoni). As part of my training during the School of Specialization, I have rotated in the following Institutions (part of Bologna University Medical School): - Breast cancer prevention and medical treatment – gynecologic cancer prevention Medical Oncology Unit (Director: Dr. Giuseppe Paladini); Radiation Treatment Center (Director: Prof. Enza Barbieri); Breast Imaging Center (Director: Prof. Stefano Mignani); Hematology Department (Director: Prof. Michele Baccarani); Medical Oncology Unit (Director: Dr. Andrea Martoni). Successful completion of Program (awarding of Diploma of Specialist in Medical Oncology) in 2007, with full marks (70/70) and honors. Dissertation thesis with the title: “Correlations between clinical evaluation criteria and pathologic response in patients with ovarian carcinoma treated with primary chemotherapy (Arianna 02 Project)” (Supervisor: Prof. G. Biasco)

I certify that all my training, professional and educational period I have had experience with clinical trials both as a co-investigator as principal investigator.

SOCIETIES AND ASSOCIATIONS: MEMBER OF THE FOLLOWING BODIES

- Italian Association of Medical Oncology (AIOM)
- European Society for Medical Oncology (ESMO)
- Regional representative for AIOM Young Investigators (Emilia-Romagna region) for the two-year period 2007 – 2009
- Member of the working group for national AIOM Young Investigators for the two-year period 2009 – 2011 and 2011 – 2013
- Member of the AIOM working group about *education continue medicine* (ECM) for the two-year period 2009 – 2011
- Member of the AIOM working group about *Clinical Research* (ECM) for the two-year period 2011 – 2013
- Member of the working group for national SIUO Young Investigators for the two-year period 2011 – 2012 and 2012 – 2014
- National coordinator Aiom Young for the two-year period 2013 – 2015 and 2015 – 2017.

ADDITIONAL PERSONAL SKILLS AND ABILITIES

Languages:

- native speaker of Italian
- foreign languages: good proficiency of English as a second language (reading; writing; speaking)

Computer proficiency:

good computer skills proficiency:

- Windows operating system, specifically Word, Excel, Power Point
- Mac OS X, Leopard

Interpersonal/relational skills:

- good team spirit, adaptability to multicultural environments, good communication skills
- good propensity to team work

Arts and sports:

- excellent electric guitar player
- excellent propensity to team sports, specifically soccer (a sport that I have been practising at a competitive level since I was a 7-year-old child; still currently involved in professional competitions with a Bologna-based local team)

Hobbies and interests:

- reading
- listening to and playing music
- movies
- travelling

Driving licenses:

holder of:

- driving license A (motorbikes)
- driving license B (cars)

I hereby authorise the processing of my personal data pursuant to Italian law no. 196/2003 on privacy

COMPLETE LIST OF SCIENTIFIC PUBLICATIONS

Abstract:

1. P. De Iaco, A. Galuppi, C. Zamagni, S. Ricci Bitti, F. Massari, L. Vicenzi, G. Tolento, A. Bernardi, E. Barbieri, A. Martoni, D. De Aloysio. SOPRAVVIVENZA DI PAZIENTI CON RECIDIVA VAGINALE DI CARCINOMA ENDOMETRIALE: IL RUOLO DELLA RADIOTERAPIA E DELLA CHIRURGIA. Atti della Società Italiana di Ginecologia ed Ostetricia – Vol. LXXXI. Bologna, 20-24 Settembre 2005.
2. C. Zamagni, A. Bernardi, F. Massari, M. Rosati, S. Quercia, N. Cacciari and A. Martoni. INVASIVE BREAST CANCER IN WOMEN AGED 39 OR LESS: A RETROSPECTIVE EVALUATION OF TUMORS CHARACTERISTICS AND CLINICAL OUTCOME. Annals of Oncology Vol. 16, 2005 suppl. 7, abstract A26.
3. P. De Iaco, A. Galuppi, C. Zamagni, S. Ricci Bitti, F. Massari, L. Vicenzi, G. Tolento, A. Bernardi, L. Zazzeroni, E. Barbieri, A. Martoni and D. De Aloysio. SURVIVAL OF PATIENTS WITH VAGINAL RECURRENCE OF ENDOMETRIAL CARCINOMA. THE ROLE OF RADIATION THERAPY AND SURGERY. Annals of Oncology Vol. 16, 2005 suppl. 7, abstract L5.
4. C. Zamagni, A. Bernardi, F. Massari, M. Rosati, S. Quercia, N. Cacciari and A. Martoni. AMENHORREA IN YOUNGER WOMEN TREATED WITH NEOADJUVANT/ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER. European Journal of Cancer Vol. 3, October 2005 No. 2, pag. 377 (abs. 1306).
5. N. Cacciari, A. Bernardi, F. Sperandi, F. Massari, S. Quercia, M. Rosati, P. De Iaco, F. Rosati, C. Zamagni and A. Martoni. EPITHELIAL OVARIAN CANCER IN ELDERLY PATIENTS (70 YEARS OR OVER): ANALYSIS OF EFFICACY AND TOLLERABILITY OF PLATINUM-BASED CHEMOTHERAPY. European Journal of Cancer Vol. 3, October 2005 No. 2, pag. 387-388 (abs. 1345).
6. N. Cacciari, S. Fanti, C. Zamagni, M. Rosati, F. Massari, A. Musto, F. Rosati, P. De Iaco, B. Melotti and A. Martoni. EARLY EVALUATION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN STAGE IIIC-IV EPITHELIAL OVARIAN CANCER PATIENTS BY ¹⁸FDG-PET AND CA 125: PRELIMINARY FINDINGS FROM THE ARIANNA PROJECT 02. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 15039.
7. A. Musto, C. Zamagni, P. Castellucci, C. Nanni, M. Farsad, M. Rosati, S. Quercia, F. Massari, A. Martoni, S. Fanti. EARLY RESPONSE EVALUATION TO NEOADJUVANT CHEMOTHERAPY BY FDG PET IN PATIENTS WITH ADVANCED OVARIAN CANCER: PRELIMINARY ANALYSIS. Abstract Book Supplement to The Journal of Nuclear Medicine, 2006: abs No. 1707.
8. Quercia S., Rosati M., Bernardi A., Cacciari N., Massari F., Paioli A., Zamagni C. and Martoni M. DISCORDANCE BETWEEN MUGA-SCAN AND ECHOCARDIOGRAM IN THE EVALUATION OF LEFT VENTRICULAR EJECTION FRACTION IN HER-2 OVEREXPRESSING ADVANCED BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB (HERCEPTIN®). Annals of Oncology Vol. 17, 2006 suppl. 9, abstract 176P.
9. Quercia S., Bernardi A., Rosati M., Cacciari N., Massari F., Sperandi F., Zamagni C. and Martoni A. BRAIN METASTASIS IN BREAST CANCER PATIENTS OVEREXPRESSING HER-2 AND TREATED WITH TRASTUZUMAB: A SINGLE INSTITUTION EXPERIENCE. Annals of Oncology Vol. 17, 2006 suppl. 11, abstract A20.
10. Bernardi A., Cacciari N., Rosati M., Quercia S., Rosati F., Francesco M., De Iaco P., Zamagni C. and Martoni A. CARBOPLATIN (CBDCA) AND GEMCITABINE (GEM) IN RELAPSED EPITHELIAL OVARIAN CANCER: A NEW TREATMENT SCHEDULE. Annals of Oncology Vol. 17, 2006 suppl. 11, abstract L19.
11. A. Bernardi, C. Zamagni, S. Quercia, F. Massari, N. Cacciari, A. A. Martoni. LONG TERM TOXICITY OF HIGH-DOSE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS HAEMATOPOIETIC STEM CELLS SUPPORT IN VERY HIGH-RISK EARLY BREAST CANCER PATIENTS (PTS). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 11101.

12. C. Zamagni, R.M. Wirtz, P. De Iaco, A. Altimari, K. Roth, F. Rosati, M. Rosati, F. Massari, N. Cacciari, A.A. Martoni. RESPONSE TO PRIMARY CHEMOTHERAPY (CHT) IN ADVANCED EPITHELIAL OVARIAN CANCER (EOC) PATIENTS (PTS) AND MOLECULAR CHARACTERIZATION OF CHT-RESISTANT TUMOR CELL POPULATIONS: FINDINGS FROM THE ARIANNA 02 PROJECT. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 16059.
13. P. De Iaco, F. Rosati, C. Alboni, L. Zazzeroni, L. Orazi, C. Zamagni, M. Rosati, F. Massari and D. De Aloysio. DIAGNOSTIC LAPAROSCOPY IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER. 1st AAGL International congress on minimally invasive gynecology; 4th SEGI Annual Meeting; pag 159 – 162.
14. P. De Iaco, C. Alboni F. Rosati, C. Zamagni, M. Rosati, F. Massari and D. De Aloysio. DIAGNOSTIC LAPAROSCOPY IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER. 1st AAGL International congress in conjunction with SEGI; abs.
15. M. Rosati, C. Zamagni, A. Musto, A. Bernardi, S. Quercia, F. Rosati, N. Cacciari, F. Massari, P. De Iaco, S. Fanti and A.A. Martoni. CORRELATION BETWEEN FDG-PET EVALUATION AND PATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS: FINDINGS FROM THE ARIANNA 02 PROJECT. Annals of Oncology Vol. 18, 2007 suppl. 11, abstract D138.
16. F. Massari, A. Bernardi, M. Rosati, A. Galuppi, S. Quercia, F. Rosati, P. De Iaco, N. Cacciari, C. Zamagni and A.A. Martoni. UTERINE PAPILLARY SEROUS CARCINOMA (UPSC): ADJUVANT CHEMOTHERAPY. Atti del 15th International meeting of the European Society of Gynaecological Oncology (ESGO)
17. S. Quercia, F. Massari, A. Musto, A. Bernardi, M. Rosati, D. Santini, C. Zamagni, S. Fanti, M. Taffurelli and A. A. Martoni. ¹⁸FDG-PET EVALUATION AND PATHOLOGICAL RESPONSE TO PRIMARY SYSTEMIC CHEMOTHERAPY IN BREAST CANCER PATIENTS: ARIANNA 01 PROJECT RESULTS. Atti del 15th International meeting of the European Society of Gynaecological Oncology (ESGO)
18. C. Zamagni M. Rosati, A. Bernardi, A. Musto, N. Cacciari, S. Quercia, F. Rosati, F. Massari, P. De Iaco, S. Fanti and A. A. Martoni EARLY PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY BY ¹⁸FDG –PET IN ADVANCED EPITHELIAL OVARIAN CANCER (OC) PATIENTS: RESULTS FROM THE ARIANNA 02 PROJECT. Atti del 15th International meeting of the European Society of Gynaecological Oncology (ESGO)
19. S. Quercia, C. Zamagni, A. Bernardi, S. Fanti, D. Santini, F. Massari, M. Rosati, N. Cacciari, M. Taffurelli and A. Martoni. NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER: PREDICTION OF PATHOLOGICAL RESPONSE BY FDG PET. European Journal of Cancer Vol. 6, April 2008 No. 7, pag. 62 (abs. 41).
20. E. Capizzi, E. Gabusi, A. Altimari, E. Gruppioni, A. Berselli, F. Massari, M. Rosati, C. Zamagni, P. De Iaco, A. D'Errico-Grigioni, W.F. Grigioni, M. Fiorentino. QUANTIFICATION OF FREE PLASMA DNA AS BIOMARKER FOR DIAGNOSIS AND RESPONSE TO THERAPY IN ADVANCED STAGE OVARIAN CANCER. Atti del First International Conference "Translational Research in Oncology" Forlì, 14-16 maggio 2008.
21. C. Zamagni, R.M. Wirtz, B. Sinn, P. De Iaco, S. Darb-Esfahani, M. Rosati, M. Dietel, F. Massari, A. Martoni and C. Denkert. ESTROGEN RECEPTOR 1 mRNA EXPRESSION AS A STRONG PROGNOSTIC FACTOR IN EPITHELIAL OVARIAN CANCER PATIENTS TREATED WITH CHEMOTHERAPY IN THE ADJUVANT AND NEOADJUVANT SETTING. J Clin Oncol 26: 2008 (May 20 suppl; abstr 16547).
22. M. Rosati, C. Zamagni, P. De Iaco, A. Musto, S. Quercia, A. Bernardi, F. Rosati, F. Massari, N. Cacciari, S. Fanti and A.A. Martoni. PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY BY FDG – PET IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS. Annals of Oncology Vol. 19, 2008 suppl. 9, abstract E9.
23. F. Massari, P. De Iaco, C. Zamagni, A. Galuppi, M. Rosati, N. Cacciari and A.A. Martoni. ADJUVANT CHEMOTHERAPY IN UTERINE PAPILLARY SEROUS CARCINOMA (UPSC): A RETROSPECTIVE ANALYSIS. Annals of Oncology Vol. 119, 2008 suppl. 9, abstract E14.

24. P. De Iaco, M. Rosati, C. Zamagni, S. Quercia, L. Orazi, D. Rubino, L. Ricci Maccarini, A. Bernardi, F. Massari, F. Rosati, N. Cacciari and A.A. Martoni. HIGH RATE OF PATHOLOGICAL COMPLETE REMISSION IN ADVANCED EPITHELIAL OVARIAN CANCER (EOC) AFTER SIX COURSES OF CARBOPLATIN-PACLITAXEL NEO-ADJUVANT CHEMOTHERAPY (NACT). Atti del 16th International meeting of the European Society of Gynaecological Oncology (ESGO).
25. F. Massari, F. Sperandi, A. Cricca, B. Melotti and A. A. Martoni. SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC). Annals of Oncology Vol. 20, 2009 suppl. 8, abstract F26.
26. F. Massari, A. Cricca, F. Sperandi and A. A. Martoni SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE. Anticancer Research 30: 1379 – 80, 2010.
27. F. Massari, A. Cricca, F. Sperandi, B. Melotti and A. A. Martoni. CARDIOVASCULAR TOXICITY IN PATIENTS TREATED WITH SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA (mRCC). Suppl. Tumori Vol. 10, 2010 n.1, abstract E15
28. G. L. Banna, F. Massari, A. Cricca, H. Lipari, C. Buscarino and A. A. Martoni. SUNITINIB-SORAFENIB AS SEQUENTIAL APPROACH FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). Suppl. Tumori Vol. 10, 2010 n.1, abstract E27
29. V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi, F. Di Fabio, F. L. Rojas Llimpe, S. Pini, F. Massari, A. Martoni. PHASE I STUDY OF SORAFENIB AND CISPLATIN/PREMETREXED REGIMEN IN UNTREATED MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS (ITALIAN SoMe STUDY). J Clin Oncol 29: 2011 (suppl; abstr 7087)
30. F. Massari. TRATTAMENTO DI LUNGA DURATA CON SUNITINIB DI PAZIENTE CON METASTASI POLMONARI DA CARCINOMA RENALE A CELLULE CHIARE. i supplementi di Tumori, vol. 11, No 1: S30-S32, 2011
31. F. Maines, F. Massari, S. Cingarlini, GL. Cetto, M. Riolfi, G. Martignoni and G. Tortora. RENAL CELL CARCINOMA WITH Xp11 TRANSLOCATION AND IMMUNOHISTOCHEMICAL CATHEPSIN K EXPRESSION: A CASE REPORT. Anticancer Research 31: 1905, 2011.
32. E. Bria, M. Bonomi, S. Pilotto, F. Massari, I. Sperduti, S. Cingarlini, A. Auriemma, D. Giannarelli, G. Tortora. HOW MUCH IS THE LIKELIHOOD OF BEING HELPED OR HARMED (LHH) WHEN ADOPTING ORAL TARGETED AGENTS (OTA) IN THE TREATMENT OF ADVANCED SOLID TUMORS (AST)? COMPREHENSIVE ASSESSMENT OF THEIR CLINICAL OVERALL IMPACT ACCORDING TO FDA/EMEA REGULATORY APPROVALS. European Journal of Cancer Vol. 47, September 2011 Suppl. 1, pag. S166 (abs. 1309).
33. F. Massari, E. Bria, D. Giannarelli, M. Milella, F. Cognetti, G. Tortora, G. Pappagallo, C. Porta. ADJUVANT TREATMENT FOR RESECTED RENAL CELL CARCINOMA (RCC): ARE ALL STRATEGIES EQUALLY NEGATIVE? META-ANALYSIS OF RANDOMIZED TRIALS (RCTS). European Journal of Cancer Vol. 47, September 2011 Suppl. 1, pag. S524 (abs. 7164).
34. M. Bonomi, E. Bria, S. Pilotto, F. Massari, I. Sperduti, S. Cingarlini, A. Auriemma, GL. Cetto, D. Giannarelli and G. Tortora. How much is the Likelihood of being Helped or Harmed (LHH) when adopting targeted therapy (TT) with Monoclonal Antibodies (MoAb) in addition to standard treatment in the treatment of advanced solid tumors (AST)? Comprehensive assessment of their clinical overall impact according to FDA/EMEA regulatory approvals. Suppl. Tumori Vol. 11, 2011 n.2, abstract M6
35. E. Bria, D. Giannarelli, F. Massari, F. Cognetti, G. Tortora and M. Milella. Is Progression Free Survival (PFS) an adequate surrogate end-point for Overall Survival (OS) in the 1st line treatment of advanced Renal Cell Carcinoma (RCC)? Correlation and Power analysis of Randomized Clinical Trials (RCTs). Suppl. Tumori Vol. 11, 2011 n.2, abstract G2
36. F. La Russa, F. Maines, F. Massari, E. Bria, I. Sperduti, T. Sava, A. Molino, GL. Cetto, W. Artibani, G. Martignoni, and G. Tortora. DOES RESPONSE TO 1st LINE TREATMENT WITH ANTI-VEGF RECEPTORS TYROSINE-KINASE

INHIBITORS (TKIs) FOR ADVANCED RENAL CELL CARCINOMA (A-RCC) PREDICT OUTCOME? RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES. Suppl. Tumori Vol. 11, 2011 n.2, abstract G12

37. G. Pappagallo, F. Grossi, F. Massari, G. Barletta, M. Milella, E. Rijavec, S. Cingarlini, C. Genova, G. Tortora and E. Bria. Balancing the Toxicities of the combination of platinum compounds plus Irinotecan (CPT-11) or Etoposide (VP-16) for the treatment of extended small-cell-lung cancer (E-SCLC): Meta-analysis of randomized clinical trials (RCTs). Suppl. Tumori Vol. 11, 2011 n.2, abstract D28
38. F. Massari, E. Bria, D. Giannarelli, M. Milella, F. Cognetti, G. Tortora, G. Pappagallo and C. Porta. META-ANALYSIS OF RANDOMIZED TRIALS (RCTs) EXPLORING THE EFFICACY OF ADJUVANT CYTOKINES (CK) OR VACCINES (VAX) OR OTHER TREATMENTS (CHEMOTHERAPY, RADIOTHERAPY) AFTER SURGERY FOR RENAL CELL CARCINOMA (RCC). Suppl. Tumori Vol. 11, 2011 n.2, abstract G3
39. Vaccaro V, Bria E, Sperduti I, Pino MS, Massari F, Gelibter A, Auriemma A, Torsello A, Melisi D, Nuzzo C, Frizziero M, Vari S, Lucchini E, Garufi C, Cottini S, Zeuli M, Ferraresi V, Cognetti F, Tortora G, Milella M. OPTIMIZING SUPPORTIVE MEASURES FOR THE SAFE ADMINISTRATION OF FOLFIRINOX AS FIRST-LINE TREATMENT IN ADVANCED, INOPERABLE PANCREATIC CANCER (APDAC) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE. J Clin Oncol 30, 2012 (suppl; abstr e14661)
40. Milella M, Massari F, La Russa F, Maines F, Felici A, Vaccaro V, Porta C, Bracarda S, Cognetti F, Giannarelli D, Tortora G, Bria E. PFS TO PREDICT LONG-TERM OS AFTER FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA (ARCC): CORRELATION AND POWER ANALYSIS OF RANDOMIZED TRIALS (RCT). J Clin Oncol 30, 2012 (suppl; abstr 4541)
41. Furlanetto J, Vaccaro V, Calio C, De Laurentiis M, Bonomi M, Pilotto S, Massari F, Nortilli R, Cianniello D, Cognetti F, Giannarelli D, Tortora G, Bria E. IMPACT OF SINGLE/DUAL HER2 INHIBITION AND CHEMOTHERAPY (CT) BACKBONE UPON PATHOLOGIC COMPLETE RESPONSE (PCR) IN PATIENTS RECEIVING NEOADJUVANT CT FOR OPERABLE/LOCALLY ADVANCED BREAST CANCER (O/LABC): A TREATMENT-INTERACTION ANALYSIS OF RANDOMIZED TRIALS. J Clin Oncol 30, 2012 (suppl; abstr 630)
42. Massari F, La Russa F, Maines F, Bria E, Sperduti I, Brunelli M, Sava T, Molino A, Artibani W, Martignoni G, Tortora G. PREDICTIVE FACTORS OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN ADVANCED RENAL CELL CARCINOMA (A-RCC) PATIENTS TREATED WITH TIROSINE KINASE INHIBITORS (TKIs): A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES. Anticancer Research 32: 1854, 2012.
43. Bria E, Bonomi M, Furlanetto J, Pilotto S, Carbognin L, Massari F, Lucchini E, Melisi D, Giannarelli D, Tortora G. A TREATMENT-INTERACTION ANALYSIS BALANCING PATHOLOGICAL COMPLETE RESPONSE (PCR) AND CARDIOTOXICITY OF SINGLE-(S)/DUAL-(D) HER2 INHIBITION AND NEOADJUVANT CHEMOTHERAPY (CT) BACKBONE IN OPERABLE/LOCALLY ADVANCED BREAST CANCER (O/LABC) PATIENTS. Ann Oncol 23, 2012 (suppl 10; abstr 322PD)
44. Vaccaro V, Bria E, Sperduti I, Massari F, Pino MS, Lucchini E, Gelibter A, Cognetti F, Tortora G, Milella M. FIRST-LINE TREATMENT WITH FOLFIRINOX IN ADVANCED PANCREATIC CANCER (APDCA) PATIENTS (PTS): SUPPORTIVE MEASURES OPTIMIZATION FOR A SAFE ADMINISTRATION IN ROUTINE CLINICAL PRACTICE. Ann Oncol 23, 2012 (suppl 10; abstr 721P)
45. Bria E, Massari F, Maines F, Bonomi M, Porta C, Bracarda S, Cognetti F, Giannarelli D, Tortora G, Milella M. RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN 1-LINE RANDOMIZED CLINICAL TRIALS (RCT) FOR ADVANCED RENAL CELL CARCINOMA (RCC): CORRELATION AND POWER ANALYSIS. Ann Oncol 23, 2012 (suppl 10; abstr 825P)
46. Iacovelli R, Rizzo M, Lorisso V, Atzori F, Zucali PA, Sacco C, Boccardo F, Valduga F, Massari F, Procopio G. PROGNOSTIC FACTORS AND VALIDATION OF PROGNOSTIC NOMOGRAMS IN PATIENTS (PTS) TREATED WITH 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM AN ITALIAN SURVEY. Ann Oncol 23, 2012 (suppl 10; abstr 836P) – **BEST POSTER AWARD**

47. Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G. ANGIOGENIC AND SIGNALLING PROTEINS CORRELATE RESISTANCE AND SEQUENCE OF TREATMENT IN RENAL CELL CANCER. Ann Oncol 23, 2012 (suppl 10; abstr 869)
48. Massari F, Maines F, Bria E, Brunelli M, Sperduti I, La Russa F, Sava T, Molino A, Artibani W, Martignoni G, Tortora G. PREDICTIVE FACTORS OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS TREATED WITH TIROSINE KINASE INHIBITOR (TKIs) FOR ADVANCED RENAL CELL CARCINOMA (ARCC): A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES. BJUI 110, 2012 (suppl. 2; abstr 12)
49. Vaccaro V, Bria E, Sperduti I, Massari F, Pino MS, Lucchini E, Gelibter A, Cognetti F, Tortora G, Milella M. FIRST-LINE TREATMENT WITH FOLFIRINOX IN ADVANCED, INOPERABLE PANCREATIC CANCER (APDAC) PATIENTS: SUPPORTIVE MEASURES OPTIMIZATION FOR A SAFE ADMINISTRATION IN ROUTINE CLINICAL PRACTICE. Suppl. Tumori Vol. 13, 2012 n.3, abstract A13
50. Bonomi M, Bria E, Furlanetto J, Pilotto S, Carbognin L, Massari F, Maines F, Melisi D, Giannarelli D, Tortora G. ADDITION OF ANTHRACYCLINES (ANTHRA) TO TRASTUZUMAB (T)-BASED NEOADJUVANT CHEMOTHERAPY (CT) FOR OPERABLE/LOCALLY ADVANCED BREAST CANCER (O/LABC) PATIENTS: TREATMENT-INTERACTION ANALYSIS BALANCING PATHOLOGICAL COMPLETE RESPONSES (PCR) AND TOXICITIES. Suppl. Tumori Vol. 13, 2012 n.3, abstract E7
51. Collovà E, Porcu L, Massari F, Furlanetto J, Gori S, Alabisio I, Petrelli F, Barni S, Saggia C, Andreis D, Gaudino E, Lipari H, Santini D, Ferzi A, Generali D. RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME IN EARLY BREAST CANCER PATIENTS WITH SMALL (<1 CM) TUMOR. Suppl. Tumori Vol. 13, 2012 n.3, abstract E25
52. Furlanetto J, Bria E, Calio C, Bonomi M, Carbognin L, Massari F, Sperduti I, Brunelli M, Brunello E, Tortora G. HEAT-SHOCK-PROTEIN-90 (HSP90) OVEREXPRESSION, TOPOISOMERASE-2 α -COAMPLIFICATION (TOPO2A), AND KI67 OVEREXPRESSION AS PREDICTORS OF PATHOLOGICAL RESPONSE (PCR) FOR PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL (DOC) AND TRASTUZUMAB (T) FOR HER-2 POSITIVE BREAST CANCER (HER2+ BC). Suppl. Tumori Vol. 13, 2012 n.3, abstract E33
53. Massari F, Maines F, Pilotto S, Bonomi M, Giannarelli D, Melisi D, Brunelli M, Martignoni G, Tortora G, Bria E. DOES PATIENTS' SELECTION STRATEGY ON THE BASIS OF ANGIOGENETIC BIOMARKERS INCREASE THE BENEFIT OF TARGETED AGENTS FOR ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS? INTERACTION AND POWER ANALYSIS OF RANDOMIZED TRIALS (RCTs). Suppl. Tumori Vol. 13, 2012 n.3, abstract F18
54. Maines F, Massari F, Zampini C, Brunelli M, Martignoni G, Bria E, Sava T, La Russa F, Molino A, Tortora G. ASSESSMENT OF EMERGING MOLECULAR PATHWAYS IN METASTATIC CLEAR CELL RENAL CARCINOMA. Suppl. Tumori Vol. 13, 2012 n.3, abstract F24
55. Massari F, Maines F, Pilotto S, Bonomi M, Giannarelli D, Brunelli M, Martignoni G, Tortora G, Bria E. COULD A BIOMARKERS-BASED PATIENT' SELECTION HELP TO PLAN A CLINICAL TRIAL WITH TARGETED AGENTS (TA) FOR METASTATIC RENAL CELL CARCINOMA (mRCC)? INTERACTION AND POWER ANALYSIS OF RANDOMIZED TRIALS (RCTs). J Clin Oncol 31, 2013 (suppl 6; abstr 399)
56. Verzoni E, Iacovelli R, Rizzo M, Felici A, Cascinu S, Di Lorenzo G, Cerbone L, Ortega C, Masini C, Giganti, Vito Lorusso MO, Messina C, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Tassi R, Procopio G. PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING THREE TARGETED THERAPIES (TTs) FOR METASTATIC RENAL CELL CARCINOMA (mRCC). J Clin Oncol 31, 2013 (suppl 6; abstr 431)
57. S. Barni, I. Vallini, M. Bonotto, A. Brunello, M. Indelli, S. Gori, C. Saggia, M. C. Petrella, D. G. Generali, M. Di Pietro Paolo, A. Moretti, F. Massari, V. Fausti, G. Pinotti, F. Puglisi, K. Borgonovo, V. Zagonel, L. Porcu, E. Collovà. TREATMENT EFFECTIVENESS IN ADVANCED BREAST CANCER PATIENTS IN ITALY: TEN YEARS EXPERIENCE. J Clin Oncol 31, 2013 (suppl; abstr e11573)
58. C. Barile, A. P. Fraccon, F. Zustovich, F. Gaion, L. Salvagno, F. Massari, I. Martellucci, C. Modenesi, M. Giusto, R. Segati, A. Bearz, C. Ogliosi, S. Macrini, M. Maruzzo, F. La Russa, L. Nicolardi, G. Bonciarelli, D. Menon, A. Inno, F. Pasini. THE ROLE OF PROGNOSTIC FACTORS IN METASTATIC RENAL CELL CARCINOMA (MRCC)

TREATED WITH TARGETED THERAPIES (TT): DATA FROM AN ITALIAN RETROSPECTIVE MULTICENTRIC STUDY. J Clin Oncol 31, 2013 (suppl; abstr e15512)

59. O. Caffo, C. Ortega, G. Di Lorenzo, F. La Russa, S. L. Burgio, C. Messina, G. Facchini, R. Iacovelli, M. Lodde, F. Morelli, F. Massari, G. Procopio, F. Zustovich, G. Lo Re, C. Pegoraro, T. Gamucci, G. L. Pappagallo, A. Veccia, F. Maines, E. Galligioni. CLINICAL OUTCOME (CO) AND PREDICTIVE FACTORS (PRE) EVALUATION OF YOUNG (≤ 60 YEARS) CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS, TREATED WITH DOCETAXEL (DOC): PRELIMINARY RESULTS OF AN ITALIAN MULTICENTER RETROSPECTIVE STUDY (CYCLOP STUDY). J Clin Oncol 31, 2013 (suppl; abstr e16031)
60. F. Massari, F. Maines, S. Pilotto, C. Porta, P. Carlini, A. Modena, C. Ciccarese, I. Sperduti, D. Giannarelli, G. Tortora, E. Bria. HOW MUCH IS REASONABLE TO EXPECT ABOUT OVERALL SURVIVAL (OS) BENEFIT WHEN DESIGNING STUDIES WITH NEW DRUGS FOR PATIENTS AFFECTED BY CASTRATION RESISTANT PROSTATE CANCER (CRPC)? META-ANALYSIS OF 23 RANDOMIZED CLINICAL TRIALS (RCT) INCLUDING 17,640 PATIENTS. J Clin Oncol 31, 2013 (suppl; abstr e16053)
61. A. Veccia, L. Fratino, U. Basso, M. Donini, A. D'Angelo, F. Massari, G. Procopio, D. Gasparro, F. Verderame, C. Messina, F. Zustovich, R. Iacovelli, A.P. Fraccon, G. L. Pappagallo, F. Maines, O. Caffo, E. Galligioni. CLINICAL OUTCOME (CO) AND PREDICTIVE FACTORS (PRE) EVALUATION OF A COHORT OF CASTRATION RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS) TREATED WITH ABIRATERONE ACETATE (AA) IN A NAMED PATIENT PROGRAM (NPP): PRELIMINARY RESULTS FROM A RETROSPECTIVE STUDY. J Clin Oncol 31, 2013 (suppl; abstr e16078)
62. E. Bria, S. Pilotto, M. Bonomi, M. Milella, F. Massari, A. T. Fojo, I. Sperduti, D. Giannarelli, G. Tortora. TARGETED AGENTS (TA) FOR ADVANCED SOLID TUMORS (AST): WHAT IS THE LIKELIHOOD OF BEING HELPED OR HARMED (LHH)? ASSESSING THE CLINICAL IMPACT OF THERAPIES WITH FDA/EMEA APPROVAL. J Clin Oncol 31, 2013 (suppl; abstr e17555)
63. A.P. Fraccon, C. Barile, F. Pasini, C. Sacco, T. Sava, F. Valduga, U. Basso, E. Vattemi, G. Rosti, E. Durante, M. Nicodemo, G. Lo Re, R. Cengarle, P. Bertocchi, D. Bernardi, D. Sartori, D. Donati, C. Pegoraro, F. Bassan, F. Zustovich, F. Gaion, L. Salvagno, F. Massari, I. Martellucci, C. Modonesi, M. Giusto, A. Bearz, R. Segati. TARGET THERAPIES (TT) FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE REAL WORLD. RESULTS OF AN ITALIAN SURVEY. Anticancer Research 33: 2322-23
64. M. Santoni, C. Porta, C.N. Sternberg, U. Basso, U. De Giorgi, G. Carteni, F. Massari, R. Iacovelli, G. Procopio, S. Cascinu. EFFICACY AND SAFETY OF FIRST-LINE SUNITINIB IN PATIENTS WITH LATE RECURRENCE OF CLEAR CELL RENAL CELL CARCINOMA >5 YEARS AFTER SURGERY: RESULTS FROM Later STUDY. European Journal of Cancer Vol. 11, 2013 No. 2 (abs. 2767).
65. F. Pasini, A.P. Fraccon, A. Inno, U. Basso, F. Massari, S. Macrini, F. Valcamoico, G. Lo Re, E. Vattemi, E. Durante, M. Sorarù, A. Bearz, D. Sartori, P. Bertocchi, L. Salvagno, M. Giusto, R. Segati, M. Medici, G. Crepaldi, C. Barile. TARGETED THERAPIES (TT) FOR METASTATIC RENAL CELL CARCINOMA IN THE REAL WORLD SETTING: AN ITALIAN MULTICENTRIC SURVEY OF 1120 PTS. Suppl. Tumori Vol. 14, 2013 n.1, abstract G15
66. L. Burattini, M. Santoni, C. Porta, G. Procopio, L. Cerbone, M. Maruzzo, U. De Giorgi, M. Rizzo, V. Ballatore, F. Massari, R. Iacovelli, C. Masini, M. Milella, G. Di Lorenzo, F. Atzori, M. Pagano, R. De Vivo, R. Berardi, D. Santini, S. Cascinu. CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF PATIENTS WITH LATE-RELAPSING (>5 YARS) AFTER CURATIVE SURGERY: RESULTS FROM Later STUDY. Suppl. Tumori Vol. 14, 2013 n.1, abstract G12
67. M. Santoni, C. Porta, G. Procopio, L. Cerbone, U. Basso, U. De Giorgi, M. Rizzo, C. Ortega, F. Massari, R. Iacovelli, R. Sabbatini, M. Milella, G. Di Lorenzo, F. Atzori, M. Pagano, R. De Vivo, R. Berardi, D. Santini, S. Cascinu. EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS IN PATIENTS WITH LATE RECURRENCE (>5 YEARS) OF CLERA CELL RENAL CELL CARCINOMA: RESULTS FROM Later STUDY. Suppl. Tumori Vol. 14, 2013 n.1, abstract G13
68. F. Atzori, M. Marongiu, M. Santoni, L. De Rosa, G. Di Lorenzo, C. Masini, R. Iacovelli, F. Massari, L. Burattini, D. Raggi, F. Piera, E. Biasco, F. Notari, R. Sabbatini, M.T. Ionta, A. Necchi. POOLED ANALYSIS OF EFFICACY OF

SECOND-TO-THIRD LINE CHEMOTHERAPY NATIONWIDE FOR PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA (TCC). Suppl. Tumori Vol. 14, 2013 n.1, abstract G29

69. A. Modena, M. Santoni, F. Massari, A. Conti, R. Iacovelli, M. Rizzo, L. Burattini, C. Ciccarese, M. Pistelli, F. Maines, M. De Lisa, A. Savini, R. Berardi, G. Muzzonigro, E. Cortesi, S. Cascinu, G. Tortora. RISK OF TYROSINE KINASE INHIBITORS-RELATED FATIGUE IN CANCER PATIENTS: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS. Suppl. Tumori Vol. 14, 2013 n.1, abstract G4
70. R. Iacovelli, G. Carteni, M. Milella, M. Santoni, G. Di Lorenzo, C. Ortega, R. Sabbatini, R. Ricotta, C. Messina, V. Lorusso, F. Atzori, F. De Vincenzo, C. Sacco, F. Boccardo, F. Valduga, F. Massari, V. Baldazzi, S. Cinieri, A. Mosca, CN. Sternberg, G. Procopio. PROGRESSION FREE SURVIVAL BUT NOT OVERALL RESPONSE RATE (ORR) PREDICT BENEFIT OF SUBSEQUENT LINES OF THERAPY IN METASTATIC RENAL CELL CARCINOMA (mRCC). Suppl. Tumori Vol. 14, 2013 n.1, abstract G7
71. E. Lucchini, E. Bria, M. Frizziero, S. Cottini, L. Calvetti, I. Sperduti, F. Massari, V. Vaccaro, C. Bassi, P. Capelli, A. Scarpa, M. Milella, F. Cognetti, D. Melisi, G. Tortora. NEOADJUVANT FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC CANCER (LA-PDAC) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE: A FEASIBILITY ANALYSIS. Suppl. Tumori Vol. 14, 2013 n.1, abstract Q4
72. F. Massari, F. Maines, S. Pilotto, C. Porta, P. Carlini, A. Modena, C. Ciccarese, I. Sperduti, D. Giannarelli, G. Tortora, E. Bria. EXPECTED OVERALL SURVIVAL (OS) BENEFIT IN CASTRATION RESISTANT PROSTATE CANCER (CRPC). POTENTIAL IMPLICATIONS FOR CLINICAL TRIALS' DESIGN. Suppl. Tumori Vol. 14, 2013 n.1, abstract G16
73. A. Veccia, L. Frattino, F. Verderame, u. Basso, A. D'Angelo, M. Donini, F. Massari, G. Procopio, D. Gasparro, C. Messina, F. Zustovich, R. Iacovelli, A.P. Fraccon, G. Vicario, D.A. Santeufemia, R. Bortolus, F. Zustovich, G. Pappagallo, F. Maines, O. Caffo, E. Galligioni. ASSESSMENT OF CLINICAL OUTCOMES (CO) AND PREDICTIVE FACTORS (PRE) IN A COHORT OF CASTRATION RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS) TREATED WITH ABIRATERONE ACETATE (AA) IN A NAMED PATIENT PROGRAM (NPP). PRELIMINARY RESULTS FROM A MULTICENTER ITALIAN STUDY. Suppl. Tumori Vol. 14, 2013 n.1, abstract G2
74. S. Barni, L. Blasi, I. Vallini, M. Bonotto, O. Garrone, A. Brunello, A. Rizzi, M. Indelli, S. Gori, S. Saracchini, V. Fausti, A. Moretti, C. Saggia, G.F. Giaccon, M.C. Petrella, D. Andreis, R.R. Silva, F. Massari, G. Cotroneo, L. Porcu, E. Collovà. CHECKING OVERALL SURVIVAL IN METASTATIC BREAST CANCER PATIENTS: RESULTS OF A RETROSPECTIVE MULTICENTRE OBSERVATIONAL ITALIAN STUDY. Suppl. Tumori Vol. 14, 2013 n.1, abstract L5
75. J. Furlanetto, L. Carbognin, E. Bria, M. Brunelli, E. Manfrin, F. Massari, G. Tortora, E. Brunello, A. Nottegar, A.M. Molino, E. Fiorio, M. Chilosi, B. Jasani, M. Vergine, L. Marcolin, S. Beccari, G. Martignoni, F. Bonetti. HER-2/NEUGENE AMPLIFICATION IN THE CONTEXT OF A SCREENING DETECTED POPULATION OF 54,472 WOMEN ENROLLED IN THE 'BREAST CANCER SCREENING PROGRAM IN VERONA'. Suppl. Tumori Vol. 14, 2013 n.1, abstract L42
76. S. Pilotto, U. Peretti, M. Di Maio, F. Massari, I. Sperduti, D. Giannarelli, F. De Marinis, G. Tortora, E. Bria. BEYOND THE EPIDERMAL GROWTH FACTOR MUTATION: DO WE HAVE RELIABLE FACTORS TO PREDICT THE OUTCOME OF PATIENTS WITH LUNG ADENOCARCINOMA RECEIVING FIRST-LINE TYROSINE KINASE INHIBITORS? A SENSITIVITY AND META-REGRESSION ANALYSIS OF RANDOMIZED TRIALS. Suppl. Tumori Vol. 14, 2013 n.1, abstract H6
77. O. Caffo, C. Ortega, G. Di Lorenzo, F. La Russa, L. Burgio, G. Facchini, G. Messina, G. Spizzo, M. Aieta, G. Mansueto, M. Lodde, R. Iacovelli, A. D'Angelo, F. Morelli, G. Procopio, F. Massari, G. Pappagallo, F. Ruatta, F. Maines, E. Galligioni. DOCETAXEL (DOC) FOR TREATMENT OF YOUNG (<60 YEARS) CASTRATION RESISTANT PROSTATE CANCER (CRPC) PATIENTS. PRELIMINARY RESULTS OF AN ITALIAN MULTICENTER RETROSPECTIVE STUDY (CYCLOP STUDY) ON CLINICAL OUTCOMES (CO) AND PREDICTIVE FACTORS (PRE). Suppl. Tumori Vol. 14, 2013 n.1, abstract G31
78. S. Pilotto, U. Peretti, M. Di Maio, F. Massari, S. Kinspergher, R. Ferrara, I. Sperduti, D. Giannarelli, F. De Marinis, G. Tortora, E. Bria. SENSITIVITY AND META-REGRESSION ANALYSIS EXPLORING POTENTIAL OUTCOMES PREDICTORS IN RANDOMIZED TRIALS (RCTs) EVALUATING THE BENEFIT OF 1st-LINE

TYROSINEKINASE INHIBITORS (TKIs) FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT LUNG ADENOCARCINOMA. Poster [P1.10] – WCLC 2013

79. Marongiu M, Atzori F, Santoni M, Derosa L, Di Lorenzo G, Masini C, Iacovelli R, Massari F, Raggi D, Burattini L, Biasco E, Federico P, Sabbatini R, Notari F, Ionta MT, Necchi A. EFFICACY OF SECOND AND THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA: RESULTS OF A NATIONAL MULTICENTRE POOLED ANALYSIS. Abstract – European Urology Suppl. 12 (2013); 126
80. Santoni M, Porta C, Procopio G, Cerbone L, Basso U, De Giorgi U, Rizzo M, Ortega C, Massari F, Iacovelli R, Di Lorenzo G, Milella M, Sabbatini R, Atzori F, De Vivo R, Berardi R, Santini D, Cascinu S. DIFFERENCES IN TERMS OF PREGRESSION-FREE SURVIVAL (PFS) AND OVERAL SURVIVAL (OS) IN PATIENTS TREATED WITH FIRST-LINE SORAFENIB, SUNITINIB, AND PAZOPANIB FOR LATE RELAPSING (>5 YEARS) RENAL CELL CARCINOMA. J Clin Oncol 32, 2014 (suppl 4; abstr 421)
81. Basso U, Diminutto A, Morelli F, De Giorgi U, Perin A, Fraccon AP, Lo Re G, Rizzi A, Sava T, Valcamonico F, Zustovich F, Massari F, Maruzzo M, Zanardi E, Zattoni F, Zagonel V. DOSE CALCULATION AND TOLERABILITY OF ADJUVANT AUC 7 CARBOPLATIN IN 100 PATIENTS WITH STAGE I SEMINOMA. J Clin Oncol 32, 2014 (suppl 4; abstr 374)
82. Brunelli M, Massari F, Ciccarese C, Ferrero S, Gazzano G, Modena A, Bria E, Tortora G, Bosari S, Martignoni G. SUITABILITY OF CLEAR CELL RENAL CELL CARCINOMA TO HEAT SHOCK PROTEINS-INHIBITORS. J Clin Oncol 32, 2014 (suppl 4; abstr 480)
83. Iacovelli R, Massari F, Albiges L, Escudier E. PROGNOSTIC VALUE OF FLARE-UP PHENOMENON AFTER DISCONTINUATION OF SUNITINIB (SU) OR PAZOPANIB (PA) IN METASTATIC RENAL CELL CARCINOMA (mRCC). J Clin Oncol 32, 2014 (suppl 4; abstr 448)
84. Veccia A, Ortega C, Di Lorenzo G, La Russa F, Burgio SL, Facchini G, Messina C, Sacco C, Spizzo G, Aieta M, Lodde M, Mansueto G, Zucali PA, D'Angelo A, Iacovelli R, Massari F, Morelli F, Procopio G, Ruatta F, Caffo O, CYCLOP Study Group. CLINICAL OUTCOMES OF PATIENTS (PTS) AGE 60 OR YOUNGER TREATED WITH DOCETAXEL (DOC) FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC): RESULTS OF AN ITALIAN MULTICENTER RETROSPECTIVE STUDY (CYCLOP STUDY). J Clin Oncol 32, 2014 (suppl 4; abstr 214)
85. Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Santini D, Procopio G, Massari F, Gasparro D, Verderame F, Sacco C, Messina C, Iacovelli R, Zustovich F, Vicario G, Fraccon AP, Contedduca V, Maines F, De Giorgi U. SAFETY AND CLINICAL OUTCOME OF A COHORT OF PATIENTS (PTS) WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) TREATED WITH ABIRATERONE ACETATE (AA) IN A NAMED PATIENT PROGRAM (NPP): UPDATED RESULTS OF A RESTROSPECTIVE STUDY FROM AN ITALIAN COOPERATIVE GROUP. J Clin Oncol 32, 2014 (suppl 4; abstr 253)
86. Bracarda S, Procopio G, Alesini D, Grillone F, Massari F, Zaniboni A, Mattioli R, Buti S, Garanzini E, Sisani M, Hamzaj A, Altavilla A, De Angelis V. ENZALUTAMIDE ACTIVITY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY RESPONDING TO ANTIANDROGEN WITHDRAWAL SYNDROME (AWS): A PRELIMINARY REPORT. J Clin Oncol 32, 2014 (suppl; abstr e16058)
87. Caffo O, Basso U, Facchini G, Gasparro D, Alesini D, Tucci M, Ortega C, Fratino L, Campadelli E, Lo Re G, Sabbatini R, Procopio G, Zucali PA, D'Angelo A, Donini M, Massari F, Ratta R, Sava T, Messina C, De Giorgi U. ACTIVITY OF SUBSEQUENT NEW DRUGS (NDS) IN POST-DOCETAXEL (DOC) FAILURE FOR METASTATIC CASTRATION- RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS): A MULTICENTER ITALIAN EXPERIENCE. J Clin Oncol 32:5s, 2014 (suppl; abstr 5089)
88. Felici A, Santini D, De Giorgi U, De Tursi M, Facchini G, Santoni M, Verzoni E, Derosa L, Di Lorenzo G, Badalamenti G, Marchetti P, Cortesi E, Maruzzo M, Massari F, Longo F, Noto L, Carles J, Guida FM, Sperduti I, Milella M. TREATMENT AND OUTCOME(S) OF A LARGE COHORT OF ITALIAN PATIENTS (PTS) WITH POOR-RISK METASTATIC RENAL CELL CARCINOMA (PRCC). J Clin Oncol 32, 2014 (suppl; abstr e15568)

89. Matias M, Albiges L, Lassau N, Benatsou B, Ablard C, Massari F, Escudier B. EFFICACY OF AXITINIB IN RENAL CELL CARCINOMA: REAL-WORLD EXPERIENCE AT GUSTAVE ROUSSY (IGR). J Clin Oncol 32, 2014 (suppl; abstr e15593)
90. Santini D, Santoni M, De Giorgi U, Iacobelli S, Procopio G, Facchini G, Galli L, Di Lorenzo G, Badalamenti G, Guida FM, Felici A, Marchetti P, Iacovelli R, Basso U, Adamo V, Longo F, Massari F, Carles J, Tonini G, Milella M. A PROPOSED NEW MODEL FOR PROGNOSTIC STRATIFICATION OF POOR- RISK PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE ERA OF TARGETED THERAPY. J Clin Oncol 32, 2014 (suppl; abstr e15588)
91. Santoni M, Conti A, Porta C, Cerbone L, Procopio G, Basso U, De Giorgi U, Rizzo M, Ortega C, Massari F, Iacovelli R, Masini C, Milella M, Di Lorenzo G, Pagano M, Buti S, Falconi M, Burattini L, Santini D, Cascinu S. PROGNOSTIC FACTORS IN PATIENTS WITH PANCREATIC METASTASES FROM RENAL CELL CARCINOMA (PM-RCC): ROOM FOR THINKING ABOUT THE ROLE OF SURGERY? J Clin Oncol 32, 2014 (suppl; abstr e15563)
92. Massari F, Ciccarese C, Knuutila S, La Russa F, Bimbatti D, Modena A, Zampini C, Porcaro AB, Sava T, Artibani W, Martignoni G, Brunelli M, Tortora G. LOSS OF CHROMOSOMES 9P AND 14Q: RE-PROFILING METASTATIC TISSUE FOR RE-TARGETING PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Annals of Oncology, Volume 25, Supplement 4, 2014 (Abs. 820P)
93. Burattini L, Santoni M, Porta C, Sternberg CN, Procopio G, Basso U, De Giorgi U, Rizzo M, Ortega C, Massari F, Masini C, Milella M, Di Lorenzo G, Cerbone L, Conti A, Buti S, Partelli S, Falconi M, Santini D, Cascinu S. RENAL METASTASES TO PANCREAS: DO NOT OPERATE ALL AND ALWAYS? Annals of Oncology, Volume 25, Supplement 4, 2014 (Abs. 827P)
94. Guida FM, Santoni M, De Giorgi U, De Tursi M, Procopio G, Pignata S, Galli L, Di Lorenzo G, Badalamenti G, Felici A, Marchetti P, Iacovelli R, Longo F, Maruzzo M, Massari F, Suarez C, Aieta M, Cascinu S, Milella M, Santini D. POOR RISK METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS ARE NOT A HOMOGENEOUS GROUP: A NEW STRATIFICATING MODEL IN THE ERA OF TARGETED THERAPY. Annals of Oncology, Volume 25, Supplement 4, 2014 (Abs. 837P)
95. Guida FM, Santoni M, De Giorgi U, De Tursi M, Procopio G, Pignata S, Galli L, Di Lorenzo G, Badalamenti G, Felici A, Marchetti P, Iacovelli R, Longo F, Maruzzo M, Massari F, Luzzi Fedeli S, Cognetti F, Aieta M, Cascinu S, Milella M, Santini D. A PROPOSED NEW MODEL FOR PROGNOSTIC STRATIFICATION OF POOR RISK PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC) IN THE ERA OF TARGETED THERAPY. Suppl. Tumori Vol. 15, 2014 n.1, abstract H8.
96. Altavilla A, Procopio G, Alesini D, Grillone F, Massari F, Zaniboni A, Mattioli R, Buti S, Garanzini E, Sisani M, Hamzaj A, Marrocolo F, De Angelis V, Bracarda S. ENZALUTAMIDE ACTIVITY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY RESPONDING TO ANTIANDROGEN WITHDRAWAL SYNDROME (AWS): A PRELIMINARY REPORT. Suppl. Tumori Vol. 15, 2014 n.1, abstract H16.
97. Massari F, Ciccarese C, Modena A, Bimbatti D, Zampini C, Knuutila S, La Russa F, Sava T, Porcaro AB, Artibani W, Martignoni G, Brunelli M, Tortora G. LOSS OF CHROMOSOMES 9p AND 14q: RE-PROFILING METASTATIC TISSUE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Suppl. Tumori Vol. 15, 2014 n.1, abstract H18.
98. Burattini L, Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Milella M, Buti S, Cerbone L, Montirone R, Falconi M, Santini D, Cascinu S. NATURAL HISTORY OF RENAL METASTASES TO THE PANCREAS: DO NOT OPERATE ALL AND ALWAYS? Suppl. Tumori Vol. 15, 2014 n.1, abstract H23.
99. Bimbatti D, Massari F, Ciccarese C, Modena A, Artibani W, Martignoni G, Brunelli M, Tortora G. SCORING PD-1 IN PATIENTS AFFECTED BY CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA. Suppl. Tumori Vol. 15, 2014 n.1, abstract H27.

100. Ciccarese C, Massari F, Modena A, Fiorini C, Martignoni G, Brunelli M, Tortora G. VISUALIZATION OF ACTIVE MTOR PATHWAYS: METHODS TO BE USED TO STRATIFY PATIENTS FOR LIKELY RESPONSE TO AN MTOR INHIBITOR. Suppl. Tumori Vol. 15, 2014 n.1, abstract H34.
101. Modena A, Massari F, Ciccarese C, Porcaro AB, Sava T, Artibani W, Martignoni G, Brunelli M, Tortora G. EXPRESSION OF CATHEPSIN K IN A PARTICULAR SUBTYPE OF CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA AND PERITUMORAL STROMAL AND ITS POTENTIAL THERAPEUTICAL IMPLICATIONS IN PATIENTS WITH BONE METASTASES. Suppl. Tumori Vol. 15, 2014 n.1, abstract H40.
102. Maruzzo M, Basso U, Diminutto A, De Giorgi U, Fratino L, Lo Re G, D'Angelo A, Donini m, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Maines F, Zagonel V, Caffo O. PRIMARY RESISTANCE TO ABIRATERONE ACETATE (AA) AFTER DOCETAXEL TREATMENT IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A MULTICENTER RETROSPECTIVE ANALYSIS. J Clin Oncol 33, 2015 (suppl 7; abstr 206)
103. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, Di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Biasco E, Ricotta R, Porta C, Vincenzi B, Marchetti P, Cascinu S, Tonini G. COMPLETE REMISSION (CR) DURING TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (mRCC) WITH TYROSINE KINASE INHIBITORS (TKIs). J Clin Oncol 33, 2015 (suppl; abstr e15594)
104. De Giorgi U, Maruzzo M, Santoni M, Massari F, Wheeler MJ, Scarpi E, Lolli C, Sotte V, Crabb SJ, Cascinu S, Basso U, Schepisi G. SYSTEMIC IMMUNE-INFLAMMATION INDEX (SII) AS PROGNOSTIC/PREDICTIVE FACTOR IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (mRCC) TREATED WITH SUNITINIB. J Clin Oncol 33, 2015 (suppl; abstr e15595)
105. De Giorgi U, Crabb SJ, Jones RJ, Caffo O, Elliott T, Fabbri P, Derosa L, Massari F, Numico G, Conteduca V, Zarif S, Hanna C, Maines F, Joyce H, Scarpi E, Amadori D. HIGH NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) PERSISTENCE DURING ENZALUTAMIDE TO PREDICT POOR CLINICAL OUTCOME IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC). J Clin Oncol 33, 2015 (suppl; abstr e16059)
106. Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Maines F, De Giorgi U. VISCERAL DISEASE SITE TO PREDICT CLINICAL OUTCOME OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PATIENTS (PTS) TREATED WITH ABIRATERONE ACETATE (AA): RESULTS OF THE ITALIAN COMPASSIONATE USE NAMED PATIENT PROGRAM (NPP). J Clin Oncol 33, 2015 (suppl; abstr e16045)
107. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, Di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Biasco E, Ricotta R, Porta C, Vincenzi B, Marchetti P, Cascinu S, Tonini G. COMPLETE REMISSION (CR) DURING TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (mRCC) WITH TYROSINE KINASE INHIBITORS (TKIs). Abstract number: 2603 - European Cancer Congress 2015
108. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, Di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Biasco E, Ricotta R, Porta C, Vincenzi B, Marchetti P, Cascinu S, Tonini G. COMPLETE REMISSION (CR) DURING TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (mRCC) WITH TYROSINE KINASE INHIBITORS (TKIs). Annals of Oncology, Volume 26, Supplement 6, 2015 (Abs. F14)
109. Caffo O, Maines F, De Giorgi U, Fratino L, Lo Re G, Zagonel V, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Contedca V, Vecchia A, Galligione E. SAFETY AND CLINICAL OUTCOMES OF ABIRATERONE ACETATE (AA) AFTER DOCETAXEL (DOC) IN OCTOGENARIANS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). Annals of Oncology, Volume 26, Supplement 6, 2015 (Abs. F28)
110. Massari F, Ciccarese C, Brunelli M, Bimbatti D, Fantinel E, Eccher A, Modena A, Martignoni G, Tortora G. DE NOVO RENAL CELL NEOPLASIA AFTER KIDNEY TRANSPLANTATION, ACCORDING TO THE INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY (ISUP 2013) VANCOUVER CLASSIFICATION. Annals of Oncology, Volume 26, Supplement 6, 2015 (Abs. F37)

111. Ciccarese C, Massari F, Brunelli M, Fantinel E, Bimbatti D, Eccher A, Modena A, Martignoni G, Tortora G. AUTOPHAGY AND TRANSPLANTATION: ORGAN INJURY AND CANCEROGENESIS BY MOLECULAR EXPRESSION OF LC3B. *Annals of Oncology*, Volume 26, Supplement 6, 2015 (Abs. F38)
112. Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, Zarif S, Jones RJ, Caffo O, Elliott T, De Giorgi U. ASSOCIATION BETWEEN EARLY PSA INCREASE AND CLINICAL OUTCOME IN PATIENTS TREATED WITH ENZALUTAMIDE FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER. *J Clin Oncol* 34, 2016 (suppl 2S; abstr 231)
113. Lutrino SE, Fontanella C, Caffo O, Massari F, Atzori F, Maggi C, Calvani N, Sacco C, Vecchia A, Modena A, Cugudda S, Verzoni E, Calio C, Ermacora P, Maines F, Tortora G, Procopio G, Ferrara P, Fasola G, Cinieri S. PROGNOSTIC ROLE OF BODY MASS INDEX (BMI) IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) RECEIVING CHEMOTHERAPY: PRELIMINARY RESULTS FROM A RETROSPECTIVE ITALIAN MULTICENTER STUDY. *J Clin Oncol* 34, 2016 (suppl 2S; abstr 342)
114. Lolli C, Maruzzo M, Derosa L, Sava T, Santoni M, Massari F, Wheeler MJ, Aieta M, Scarpi E, La Russa F, Crabb SJ, Cascinu S, Galli L, Basso U, De Giorgi U. SYSTEMIC IMMUNE-INFLAMMATION INDEX TO PREDICT THE CLINICAL OUTCOME IN PATIENTS WITH METASTATIC RENAL CELL CANCER TREATED WITH SUNITINIB. *J Clin Oncol* 34, 2016 (suppl 2S; abstr 547)
115. Basso U, Maruzzo M, Fraccon AP, Sava T, Massari F, Sacco C, Valcamonico F, Maines F, Lo Re G, Donati D, Baier S, Durante E, Soraru' M, Nicodemo M, Bearz A, Sartori D, Fiduccia P, Zustovich F, Pasini F, Zagonel V. DO PATHOLOGICAL PARAMETERS OF PRIMARY TUMOR CORRELATE WITH OVERALL SURVIVAL (OS) OF METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (ccRCC)? *J Clin Oncol* 34, 2016 (suppl 2S; abstr 549)
116. Iacovelli R, Derosa L, Massari F, Verri E, Galli L, Ciccarese C, Cossu Rocca M, Cianci C, Bimbatti D, Aurilio G, Antonuzzo A, Fantinel E, Cullura D, Ricci S, Modena A, Falcone A, Tortora G, Nole F. IMPACT OF DOSE REDUCTION ON SURVIVAL IN PATIENTS STARTING SUNITINIB (SU) OR PAZOPANIB (PA) AS FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMA (mRCC). *J Clin Oncol* 34, 2016 (suppl 2S; abstr 553)
117. Tucci M, Lutrino SE, Di Maio M, Procopio G, Massari F, Calvani N, Fontanella C, Atzori F, Barni S, Calio C, Vignani F, Accettura C, Quaranta A, Mazzoni E, D'amico M, Scavelli C, Chettri MC, Ferrara P, Cinieri S. PRO-BMI STUDY: PROGNOSTIC ROLE OF BODY MASS INDEX (BMI) IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) PATIENTS RECEIVING CHEMOTHERAPY. *J Clin Oncol* 34, 2016 (suppl; abstr e16543)
118. Lutrino ES, Tucci M, Caffo O, Di Maio M, Procopio G, Scagliotti C, Massari F, Milano A, Atzori F, Barni S, Gambino A, Fontanella C, Scavelli C, Cinieri S. PROGNOSTIC ROLE OF BODY MASS INDEX (BMI) IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) RECEIVING CHEMOTHERAPY: PRO-BMI STUDY. *Annals of Oncology*, Volume 27, Supplement 4, 2016 (Abs. C17)
119. Farnesi A, Mazzarri S, Galli L, Boni G, Cianci C, Biasco E, Sbrana A, Monari F, Dionisi V, Graziani T, Fanti S, Massari F, Ardizzoni A, Borsatti E, Bortulus R, Gobitti C, Fratino L, Volterrani D, Ricci S, Falcone A. FIRST ITALIAN MULTICENTRE EXPERIENCE IN USING Ra-223 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC). *Annals of Oncology*, Volume 27, Supplement 4, 2016 (Abs. C21)
120. Grilli D, Gelsomino F, Massari F, Angelelli B, Tognetto M, Restuccia S, Puggioli C, Ardizzoni A. THE IMPACT OF THE CLINICAL PHARMACIST (CP) IN REPORTING SUSPECTED ADVERSE DRUG REACTIONS (ADRs): THE EXPERIENCE OF THE MEDICAL ONCOLOGY UNIT AT THE S. ORSOLA-MALPIGHI UNIVERSITY HOSPITAL. *Annals of Oncology*, Volume 27, Supplement 4, 2016 (Abs. S28)
121. Bimbatti D, Sava T, Massari F, Ciccarese C, Fantinel E, Dalla Volta A, Artibani W, Tortora G, Iacovelli R. CHANGES IN TUMOR BURDEN AND IMDC CLASS AFTER ACTIVE SURVEILLANCE (AS) FOR METASTATIC RENAL CELL CARCINOMA (mRCC). *J Clin Oncol* 35, 2017 (suppl 6S; abstract 435)
122. Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, Massari F, Fraccon AP, Mucciarini C, Sava T, Santoni M, Pegoraro MC, Durante E, Nicodemo M, Perin A, Bearz A, Pasini F, Gatti C, Zamarchi R, Zagonel

- V, CTC in mRCC Investigator Group. PROGNOSTIC ROLE OF CIRCULATING TUMOR CELLS-CTCS IN METASTATIC RENAL CELL CARCINOMA. J Clin Oncol 35, 2017 (suppl; abstr 4568)
123. Procopio G, Prisciandaro M, Iacovelli R, Mancini M, Fornarini G, Facchini G, Carteni G, Napolitano M, Sternberg C.N., Caserta C, Bregni M, Massari F, Buti S, Biasco E, De Giorgi U, Zustovich F, Ratta R, Ortega C, Tortora G, Verzoni E. SAFETY AND EFFICACY OF CABOZANTINIB FOR METASTATIC RENAL CELL CARCINOMA (mRCC): REAL WORLD DATA FROM AN ITALIAN EXPANDED ACCESS PROGRAM (EAP). Annals of Oncology, Volume 28, Supplement 5, 2017 (Abs. 901P)
 124. Ciccarese C, Iacovelli R, Massari F, Brunelli M, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. ADDRESSING THE BEST TREATMENT FOR NON-CLEAR CELL RENAL CELL CARCINOMA (nccRCC): A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS COMPARING VEGFR-TKIs VERSUS mTORi TARGETED THERAPIES. Annals of Oncology, Volume 28, Supplement 6, 2017 (Abs. B5)
 125. Bersanelli M, Castrignan P, Gambale E, Cortellini A, Tiseo M, Natoli C, Ficorella C, Panni S, Rossetti S, Papa A, Mazzoni F, Facchini G, De Giorgi U, Procopio G, Atzori F, Sava T, De Luca E, Maestri A, Massari F, Buti S. INFLUENZA VACCINE INDICATION DURING ANTICANCER THERAPY WITH IMMUNE CHECKPOINT INHIBITORS: A TRANSVERSAL CHALLENGE FOR PATIENT'S COUNSELLING – PRELIMINARY ANALYSIS OF THE INVIDIA STUDY. Annals of Oncology, Volume 28, Supplement 6, 2017 (Abs. 58P)
 126. Ciccarese C, Iacovelli R, Brunelli M, Massari F, Mosillo C, Bimbatti D1, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W and Tortora G. NON-CLEAR CELL RENAL CELL CARCINOMA: A META-ANALYSIS OF CLINICAL TRIALS COMPARING VEGFR-TKIS VERSUS MTORI. ANTICANCER RESEARCH 38: 2463-2596 (2018)
 127. De Luca E, Di Nunno V, Buttigliero C, Tucci M, Vignani F, Zichi C, Ardizzoni A, Massari F, Di Maio M. IMMUNE-CHECKPOINT INHIBITORS IN PREVIOUSLY TREATED PATIENTS WITH UROTHELIAL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Annals of Oncology, Volume 29, Supplement 8, 2018 (Abs. 960P)
 128. Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Verzoni E, Procopio G. SAFETY AND EFFICACY OF CABOZANTINIB FOR METASTATIC NON-CLEAR RENAL CELL CARCINOMA: REAL WORLD DATA FROM AN ITALIAN MANAGED ACCESS PROGRAM. Tumori Journal, Volume 104, Number 4S, November 2018 (Abs G03)
 129. Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Zichi C, Ardizzoni A, Di Maio M, Massari F. IMMUNE-CHECKPOINT INHIBITORS IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Tumori Journal, Volume 104, Number 4S, November 2018 (Abs G21)
 130. Mollica V, Di Nunno V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. PROGNOSTIC IMPACT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Clin Oncol 37, 2019 (suppl 7S; abstr 572)
 131. Loriot Y, Sternberg CN, Castellano Gauna D, Dumez H, Huddart R, Vianna KM, Alonso Gordo T, Skoneczna IA, Fay A, Sacco CPS, Nole F, Massari F, Brasiuniene B, Maroto P, Oosting SF, Fear S, Di Nucci F, De Ducla S, Choy E. SAFETY AND EFFICACY OF ATEZOLIZUMAB (ATEZO) IN PATIENTS (PTS) WITH AUTOIMMUNE DISEASE (AID): SUBGROUP ANALYSIS OF THE SAUL STUDY IN LOCALLY ADVANCED/METASTATIC URINARY TRACT CARCINOMA. Annals of Oncology, Volume 30, Supplement 5, 2019 (Abs. 922P)
 132. Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Modonesi C, Santini D, Procopio G, De Giorgi UFF. TIME TO CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND THE RISK OF DEVELOPING IMMUNE DISORDERS. Annals of Oncology, Volume 30, Supplement 5, 2019 (Abs. 861P)
 133. Di Nunno V, Mollica V, Sciavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. IMPROVING IMDC PROGNOSTIC PREDICTION THROUGH EVALUATION OF PRIMARY SITE OF METASTASIS. Tumori Journal, Volume 105, Number 46, October 2018 (Abs E09)
 134. Conteduca V, Procopio G, Maines F, Scarpi E, Galli L, Sepe P, Fratino L, Chiuri V.E., Zanardi E, Massari F, Modenesi C, Cirsano MC, Toma I, Casadei C, Sbrana A, Kinspergher S, Santoni M, Santini D, Caffo O, De Giorgi U. AUTOIMMUNE DISEASE AND RESPONSE TO THERAPY WITH ABIRATERONE AND ENZALUTAMIDE IN

- CASTRATION RESISTANT PROSTATE CANCER (CRPC) PATIENTS. Tumori Journal, Volume 105, Number 46, October 2018 (Abs E11)
135. Mollica V, Di Nunno V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. IMPROVING IMDC PROGNOSTIC PREDICTION THROUGH EVALUATION OF PRIMARY SITE OF METASTASES IN METASTATIC RENAL CELL CARCINOMA. European Urology Supplements, Vol. 18, Issue 11, e3541–e3543
 136. Di Nunno V, Mollica V, Santoni M, Conti A, Rodolfo R, Battelli N, Massari F. SYSTEMIC TREATMENT FOR METASTATIC HORMONE SENSITIVE PROSTATE CANCER: A COMPREHENSIVE META-ANALYSIS EVALUATING EFFICACY, SAFETY AND SPECIFIC SUB-GROUPS. European Urology Supplements, Vol. 18, Issue 11, e3495–e3496
 137. Di Nunno V, Massari F, Guida A, Costa Silva CA, Derosa L, Mollica V, Colomb Ea, Escudier B, Albiges L. IMPROVING IMDC CRITERIA IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA THROUGH THE ADDITION OF INITIAL METASTATIC SITE IN BONE, BRAIN, AND LIVER. J Clin Oncol 38, 2020 (suppl 6; abstr 754)
 138. de Velasco G, Ruiz-Granados A, Reig O, Massari F, Climent Duran MA, Verzoni E, Graham J, Llarena R, De Tursi M, Donskov F, Iglesias C, Pandha HS, Garcia del Muro X, Procopio G, Oudard S, Castellano D, Albiges L. OUTCOMES OF SYSTEMIC THERAPY IN RELAPSED RENAL CELL CARCINOMA (RCC) TREATED WITH ADJUVANT SUNITINIB (AS). J Clin Oncol 38, 2020 (suppl 6; abstr 701)
 139. Basso U, Procopio G, Fornarini G, Massari F, Bearz A, Fratino L, Milella M, Bassanelli M, Sacco C, Bimbatti D, Verzoni E, Rizzo M, Porta C. SAFETY AND EFFICACY OF TIVOZANIB IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA: A MULTICENTER COMPASSIONATE USE STUDY. J Clin Oncol 38, 2020 (suppl 6; abstr 632)
 140. Iacovelli R, Atzori F, Basso U, Bersanelli M, Bonomi L, Bracarda S, Buttigliero C, Fantinel E, Calabro F, Chiuri VE, Di Lorenzo G, Fornarini G, Massari F, Naglieri E, Ortega C, Procopio G, Milella M, Santoni M, Vitale MG, Zucali PA. PHASE II STUDY OF AVELUMAB PLUS INTERMITTENT AXITINIB IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (TIDE-A STUDY). J Clin Oncol 38, 2020 (suppl 6; abstr TPS762)
 141. Rebuzzi SE, Buti S, Galli L, Procopio G, De Giorgi U, Baldessari C, Massari F, Santini D, Cavo A, Banna GL, Sorarù M, Cortellini A, Messina M, Martelli V, Damassi A, Sbrana A, Apollonio G, Casadei C, Signori A, Fornarini G. BASELINE AND EARLY CHANGE OF NEUTROPHIL TO LYMPHOCYTE RATIO (bNLR and ΔNLR) AS PROGNOSTIC FACTORS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH NIVOLUMAB: PRELIMINARY RESULTS OF THE MEET-URO 15 (I-BIO-REC) STUDY. J Clin Oncol 38, 2020 (suppl 6; abstr 752)
 142. Rebuzzi SE, Buti S, Sbrana A, Procopio G, De Giorgi U, Vitale MG, Massari F, Santini D, Cavo A, Banna GL, Sorarù M, Cortellini A, Messina M, Martelli V, Mollica V, Stellato M, Lipari H, Catalano F, Signori A, Fornarini G. BASELINE LYMPHOCYTE TO MONOCYTE RATIO (LMR) AND SYSTEMIC INFLAMMATION INDEX (SII) AS PROGNOSTIC FACTORS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH NIVOLUMAB: PRELIMINARY RESULTS OF THE MEET-URO 15 (I-BIO-REC) STUDY. J Clin Oncol 38, 2020 (suppl 6; abstr 751)
 143. Dall'Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. IMMORTAL TIME BIAS IN THE ASSOCIATION BETWEEN TOXICITY AND RESPONSE FOR IMMUNE CHECKPOINT INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Clin Oncol 38: 2020 (suppl; abstr e15080)
 144. Rebuzzi SE, Buti S, Maruzzo M, De Giorgi U, Sbrana A, Zucali PA, Fantinel E, Procopio G, Merler S, Fratino L, Baldessari C, Ricotta R, Massari F, Banna GL, Soraru' M, Santoni M, Cortellini A, Bersanelli M, Signori A, Fornarini G. BASELINE AND EARLY CHANGE OF NEUTROPHIL TO LYMPHOCYTE RATIO (BNLR AND ΔNLR) AS PROGNOSTIC FACTORS IN METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH NIVOLUMAB: FINAL RESULTS OF THE MEET-URO 15 (I-BIO-REC) STUDY. J Clin Oncol 38: 2020 (suppl; abstr e17081)
 145. Rebuzzi SE, Sternberg CN, Banna GL, Ermacora P, Morelli F, Nolè F, Marandino L, Panni S, Massari F, Hamzaj A, Milesi L, Santini D, De Tursi M, Scartozzi M, Astolfi C, Fornarini G. NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AND SYSTEMIC INFLAMMATION INDEX (SII) AS PROGNOSTIC FACTORS IN ADVANCED URINARY TRACT CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB: SUBANALYSIS OF THE ITALIAN POPULATION OF THE SAUL STUDY. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274
 146. Mollica V, Rizzo A, Ricci AD, Maggio I, Dall'Olio FG, Ardizzoni A, Massari F. QUALITY OF LIFE ASSESSMENT IN RENAL CELL CARCINOMA PHASE II AND III CLINICAL TRIALS PUBLISHED BETWEEN 2010 AND 2020. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274
 147. Ricci AD, Rizzo A, Mollica V, Ardizzoni A, Massari F. PLATINUM-BASED ADJUVANT CHEMOTHERAPY IN UPPER TRACT UROTHELIAL CARCINOMAS (UTUCS): A CHANGE OF PARADIGM? A META-ANALYSIS OF AGGREGATE DATA. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274
 148. Mollica V, Rizzo A, Santoni M, Marchetti A, Rosellini M, Massari F. IMPACT OF CLINICOPATHOLOGICAL FEATURES ON SURVIVAL IN PATIENTS TREATED WITH IMMUNE-BASED COMBINATIONS FOR METASTATIC UROTHELIAL CARCINOMA: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS. J Clin Oncol 39, 2021 (suppl 15; abstr e16534)

149. Macrini S, Guida A, Mosillo C, Caserta C, Calandrella ML, Sirgiovanni G, Sabbatini R, Galli L, Di Girolamo S, Massari F, Berruti A, Zucali PA, Mecozzi A, Hamzaj A, Aschelter AM, Gernone A, Burattini L, Cortesi E, Baldazzi V, Bracarda S. PATTERNS OF PROGRESSION OF PATIENTS WITH HIGH-VOLUME METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TREATED WITH EARLY DOCETAXEL CHEMOTHERAPY: THE LONGITUDE OBSERVATIONAL STUDY. J Clin Oncol 40, 2022 (suppl 6; abstr 107)
150. Ciccarese C, Bimbatti D, Atzori F, Bonato A, Scagliarini S, Pellegrini I, Bracarda S, De Giorgi U, Masini C, Santoni M, Massari F, Buti S, Damassi A, Zampiva I, Strusi A, Sparagna I, Rebutti SE, Tortora G, Iacovelli R. EARLY PRIMARY TUMOR RESPONSE IN METASTATIC RCC PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS-BASED COMBINATIONS. J Clin Oncol 40, 2022 (suppl 6; abstr 349)
151. Molina-Cerrillo J, Ortego I, Pinto A, Alonso-Gordoa T, Massari F, Aurilio G, Buti S, Santoni M, Grande E. DOES TIMING OF IMMUNE CHECKPOINT INHIBITORS (ICIs) ADMINISTRATION IN FIRST LINE METASTATIC RENAL CELL CARCINOMA (mRCC) HAVE IMPACT IN SURVIVAL OUTCOMES? J Clin Oncol 40, 2022 (suppl 16; abstr e16512)
152. Rebutti SE, Signori A, Banna GL, Buti S, Rescigno P, Gemelli M, Panni S, Massari F, Sorarù M, Santoni M, Cortellini, Prati V, Soto Parra HJ, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Fornarini G. THE PROGNOSTIC ROLE OF NEPHRECTOMY IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (mRCC) TREATED WITH IMMUNOTHERAPY ACCORDING TO THE NOVEL PROGNOSTIC MEET-URO SCORE: SUBANALYSIS OF THE MEET-URO 15 STUDY. J Clin Oncol 40, 2022 (suppl 16; abstr 4535)

Full papers:

1. C. Zamagni, R.M. Wirtz, P. De Iaco, M. Rosati, E. Veltrup, F. Rosati, E. Capizzi, N. Cacciari, C. Alboni, A. Bernardi, F. Massari, S. Quercia, A. D'Errico Grigioni, M. Dietel, J. Sehouli, C. Denkert and A.A. Martoni. OESTROGEN RECEPTOR 1 mRNA IS A PROGNOSTIC FACTOR IN OVARIAN CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY: DETERMINATION BY ARRAY AND KINETIC PCR IN FRESH TISSUE BIOPSIES. *Endocrine-Related Cancer* 2009, 16, pag 1241 - 1249.
2. G.L. Banna, M. Di Maio, A. Follador, E. Collovà, J. Menis, S. Novello, E. Bria, on behalf of ISA Co-Authors°. ITALIAN SURVEY ON ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER (ISA). *Lung Cancer* 73 (2011); 78-88. (°) F. Massari.
3. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M, Tortora G, Bria E. ADJUVANT CHEMOTHERAPY FOR RESECTED NON-SMALL-CELL LUNG CANCER: FUTURE PERSPECTIVES FOR CLINICAL RESEARCH. *J Exp Clin Cancer Res*. 2011 Dec 29;30(1):115.
4. Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Calì A, Eccher A, Parolini C, Iannucci A, Gilioli E, Pedron S, Massari F, Tortora G, Borze I, Knuutila S, Gobbo S, Santo A, Tondulli L, Calabrò F, Martignoni G, Chilosi M. TRUE 3q CHROMOSOMAL AMPLIFICATION IN SQUAMOUS CELL LUNG CARCINOMA BY FISH AND aCGH MOLECULAR ANALYSIS: IMPACT ON TARGETED DRUGS. *PLoS One*. 2012;7(12):e49689. doi: 10.1371/journal.pone.0049689. Epub 2012 Dec 6.
5. Brunello E, Brunelli M, Bogina G, Calì A, Manfrin E, Nottegar A, Vergine M, Molino A, Bria E, Massari F, Tortora G, Cingarlini S, Pedron S, Chilosi M, Zamboni G, Miller K, Martignoni G, Bonetti F. FGFR-1 AMPLIFICATION IN METASTATIC LYMPH-NODAL AND HAEMATOGENOUS LOBULAR BREAST CARCINOMA. *J Exp Clin Cancer Res*. 2012 Dec 27;31(1):103. doi: 10.1186/1756-9966-31-103.
6. Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G. CASTRATION RESISTANT PROSTATE CANCER (CRPC): STATE OF THE ART, PERSPECTIVES AND NEW CHALLENGES. *Anticancer Agents Med Chem*. 2013, 13, 872-886
7. Bria E, Bonomi M, Pilotto S, Massari F, Novello S, Levra MG, Tortora G, Scagliotti G. CLINICAL META-ANALYSES OF TARGETED THERAPIES IN ADENOCARCINOMA. *Target Oncol*. 2013 Mar;8(1):35-45.
8. Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E. PROFILING NON-SMALL CELL LUNG CANCER PATIENTS FOR TREATMENT WITH CRIZOTINIB ACCORDING TO ALK ABNORMALITIES: TRANSLATING SCIENCE INTO MEDICINE. *Expert Opin. On Pharmacother*. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9.
9. Iacovelli R, Carteni G, Stemberg C, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri E, Berruti A, Cerbone L, Procopio. CLINICAL OUTCOMES IN PATIENTS RECEIVING THREE LINES OF TATGETD THERAPY FOR METASTATIC RENAL CELL CARCINOMA: RESULTS FROM A LARGE PATIENT COHORT. *Eur J Cancer*. 2013, 49, 2134-2142
10. Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. CHEMOTHERAPY IN METASTATIC RENAL CELL CARCINOMA TODAY? A SYSTEMATIC REVIEW. *Anticancer Drugs*. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1.
11. Massari F, Bria E, Maines F, Milella M, Giannarelli D, Cognetti F, Pappagallo G, Tortora G, Porta C. ADJUVANT TREATMENT FOR RESECTED RENAL CELL CARCINOMA: ARE ALL STRATEGIES EQUALLY NEGATIVE? POTENTIAL IMPLICATIONS FOR TRIAL DESIGN WITH TARGETED AGENTS. *Clinical Genitourinary Cancer*, Vol. 11, No. 4, 471-6, 2013
12. Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G. ANGIOGENIC AND SIGNALLING PROTEINS CORRELATE WITH SENSITIVITY TO SEQUENTIAL TREATMENT IN RENAL CELL CANCER. *Br J Cancer*. 2013 Aug 6;109(3):686-93. doi: 10.1038/bjc.2013.360. Epub 2013 Jul 9.

13. Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. LUNG ADENOCARCINOMA PATIENT REFRACTORY TO GEFITINIB AND RESPONSIVE TO CRIZOTINIB, WITH CONCURRENT RARE MUTATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (L861Q) AND INCREASED ALK/MET/ROS1 GENE COPY NUMBER. *J Thorac Oncol*. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.
14. Brunelli M, Manfrin E, Bria E, Massari F, Tortora G, Brunello E, Carbognin L, Nottage A, Furlanetto J, Molino A, Fiorio E, Chilosi M, Jasani B, Vergine M, Marcolini L, Filippini D, Scarpa A, Martignoni G, Bonetti F. HER2/neu GENE DETERMINATION IN WOMAN SCREENED FOR BREAST CARCINOMA: HOW SCREENING PROGRAMS REDUCE THE SKYROCKETING COST OF TARGETED THERAPY. *Anticancer Research* 2013 Sept; 33(9): 3705-10
15. Santoni M, Massari F, Amantini C, Nabissi, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. EMERGING ROLE OF TUMOR-ASSOCIATED MACROPHAGES AS THERAPEUTIC TARGETS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. *Cancer Immunol Immunother*. 2013 Dec;62(12):1757-68. doi: 10.1007/s00262-013-1487-6.
16. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. HETEROGENEOUS DRUG TARGET EXPRESSION AS POSSIBLE BASIS FOR DIFFERENT CLINICAL AND RADIOLOGICAL RESPONSE TO THE TREATMENT OF PRIMARY AND METASTATIC RENAL CELL CARCINOMA: SUGGESTION FROM BENCH TO BESIDES. *Cancer Metastasis Rev*. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5.
17. Pilotto S, Bonomi M, Massari F, Milella M, Ciuffreda L, Brunelli M, Fassan M, Chilosi M, Scarpa A, Tortora G, Bria E. ANTI-ANGIOGENIC DRUGS AND BIOMARKERS IN NON-SMALL-CELL LUNG CANCER: A 'HARD DAYS NIGHT'. *Curr Pharm Des*. 2014;20(24):3958-72.
18. Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. PREDICTORS OF OUTCOME FOR PATIENTS WITH LUNG ADENOCARCINOMA CARRYING THE EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION RECEIVING 1st-LINE TYROSINE KINASE INHIBITORS: SENSITIVITY AND META-REGRESSION ANALYSIS OF RANDOMIZED TRIALS. *Critical Reviews in Oncology/Hematology* 2014, 90: 135–145
19. Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Tremantino L, Procopio G, Tortora G, Cascinu S. TREATMENT-RELATED FATIGUE WITH SORAFENIB, SUNITINIB AND PAZOPANIB IN PATIENTS WITH ADVANCED SOLID TUMORS: AN UP-TO-DATE REVIEW AND META-ANALYSIS OF CLINICAL TRIALS. *Int J Cancer*. 2015 Jan 1;136(1):1-10.
20. De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, D'Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco P, Filippi AR and Alongi F. PROSTATE CANCER AS A PARADIGM OF MULTIDISCIPLINARY APPROACH? HIGHLIGHTS FROM THE ITALIAN YOUNG RADIATION ONCOLOGIST MEETING. *Tumori*. 2013 Nov-Dec;99(6):637-49. doi: 10.1700/1390.15450.
21. Maines F, Pilotto S, Milella M, Massari F, Vaccaro V, Felici A, Bria E, Tortora G. "TARGETING" RENAL CELL CARCINOMA PATIENTS WITH "TARGETED" AGENTS: ARE WE THERE YET? *World Journal of Clinical Urology* 2014, March 24; 3(1): 9-19
22. Massari F, Ciccarese C, Modena A, Maines F, Segala D, Luchini C, Marcolini L, Cavicchioli F, Cavalleri S, Bria E, Brunelli M, Martignoni G, Artibani W, and Tortora G. ADENOCARCINOMA OF THE PARAURETHRAL GLANDS: A CASE REPORT. *Histol Histopathol*. 2014 Oct;29(10):1295-303.
23. Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G and Cascinu S. CXC AND CC CHEMOKINES AS ANGIOGENIC MODULATORS IN NON-HAEMATOLOGICAL TUMORS. *Biomed Res Int*. 2014;2014:768758. Epub 2014 May 29.
24. Santoni M, Massari F, Cascinu S. PROPHYLACTIC USE OF mTOR INHIBITORS AND OTHER IMMUNOSUPPRESSIVE AGENTS IN HEART TRANSPLANT PATIENTS. *Cell Mol Immunol*. 2015 Jan;12(1):122-4.

25. Bria E, Furlanetto J, Carbognin L, Brunelli M, Calio C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, G Tortora. HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: HEAT SHOCK PROTEIN 90 OVEREXPRESSION, KI67 PROLIFERATIVE INDEX AND TOPOISOMERASE II-<ALPHA> CO-AMPLIFICATION AS PREDICTORS OF PATHOLOGICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH TRASTUZUMAB AND DOCETAXEL. Clin Breast Cancer. 2015 Feb;15(1):16-23.
26. Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Calio A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. QUANTITATIVE SCORE MODULATION OF HSP90 AND HSP27 IN CLEAR CELL RENAL CELL CARCINOMA. Pathology (October 2014) 46(6), pp. 523–526
27. Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. SAFETY AND CLINICAL OUTCOMES OF PATIENTS TREATED WITH ABIRATERONE ACETATE AFTER DOCETAXEL: RESULTS OF THE ITALIAN NAMED PATIENT PROGRAMME. BJU Int. 2015 May;115(5):764-71. doi: 10.1111/bju.12857.
28. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. SUNITINIB, PAZOPANIB OR SORAFENIB FOR THE TREATMENT OF PATIENTS WITH LATE-RELAPSING (>5 YEARS) METASTATIC RENAL CELL CARCINOMA. J Urol. 2015 Jan;193(1):41-7.
29. Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. PROGRESSION-FREE SURVIVAL AS PRIMARY ENDPOINT IN RANDOMIZED CLINICAL TRIALS OF TARGETED AGENTS FOR ADVANCED RENAL CELL CARCINOMA. CORRELATION WITH OVERALL SURVIVAL, BENCHMARKING AND POWER ANALYSIS. Crit Rev Oncol Hematol. Crit Rev Oncol Hematol. 2015 Jan;93(1):50-59.
30. Iacovelli R, Farcomeni A, Sternberg CN, Carteni G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Procopio G. PROGNOSTIC FACTORS IN PATIENTS RECEIVING THIRD-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092.
31. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Vecchia A, Conteduca V, Maines, Galligioni E. LINICAL OUTCOMES OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENTS ADMINISTERED AS THIRD OR FOURTH LINE FOLLOWING FAILURE OF DOCETAXEL AND OTHER SECOND-LINE TREATMENT: RESULTS OF AN ITALIAN MULTICENTRE STUDY. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014.
32. Massari F, Maines F, Bria E, Galligioni E, Caffo O, Tortora G. 2-WEEKLY DOCETAXEL: ISSUES FOR CLINICAL PRACTICE. Cancer Biol Ther. 2015 Jan 2;16(1):17-8.
33. Iacovelli R, Massari F, Albiges L, Lorient Y, Massard C, Fizazi K, Bernard E. EVIDENCE AND CLINICAL RELEVANCE OF TUMOR FLARE IN PATIENTS WHO DISCONTINUED TYROSINE KINASE INHIBITORS FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA. Eur Urol. 2015 Jul;68(1):154-60. doi: 10.1016/j.eururo.2014.10.034.
34. Bianconi M, Santoni M, Massari F, Faloppi L, Del Prete M, Giampieri R, Ciccarese C, Modena A, Tortora G, Scartozzi M, Cascinu S. SELECTED NEWS FROM THE 2014 GENITOURINARY CANCERS SYMPOSIUM: TRANSLATING NOVEL STRATEGIES INTO CLINICAL PRACTICE? Future Oncol. 2014 Nov;10(14):2103-6. doi: 10.2217/fon.14.185

35. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. SURGICAL RESECTION DOES NOT IMPROVE SURVIVAL IN PATIENTS WITH RENAL METASTASES TO THE PANCREAS IN THE ERA OF TYROSINE KINASE INHIBITORS. *Ann Surg Oncol*. 2015 Jun;22(6):2094-100. doi: 10.1245/s10434-014-4256-7.
36. Fiorini C, Massari F, Pedron S, Sanavio S, Ciccarese C, Porcaro AB, Artibani W, Bertoldo F, Zampini C, Sava T, Ficial M, Calì A, Chilosi M, D'Amuri A, Sanguedolce F, Tortora G, Scarpa A, Delahunt B, Porta C, Martignoni G and Matteo Brunelli M. METHODS TO IDENTIFY MOLECULAR EXPRESSION OF MTOR PATHWAY: A RATIONALE APPROACH TO STRATIFY PATIENTS AFFECTED BY CLEAR CELL RENAL CELL CARCINOMA FOR MORE LIKELY RESPONSE TO MTOR INHIBITORS. *Am J Cancer Res*. 2014 Nov 19;4(6):907-15
37. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. PROGNOSTIC SIGNIFICANCE OF HOST IMMUNE STATUS IN PATIENTS WITH LATE RELAPSING RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPY. *Target Oncol*. 2015 Jan 6. [Epub ahead of print]
38. Massari F, Ciccarese C, Bimbatti D, Fantinel E, Modena A, Simbolo M, Brunelli M, Artibani W, Martignoni G, Scarpa A, Tortora G. COMPLETE REMISSION WITH SUNITINIB IN A POOR RISK PATIENT WITH METASTATIC RENAL CELL CARCINOMA: THE FINE BALANCE BETWEEN TOXICITY AND EFFICACY. *Anticancer Drugs*. 2015 Apr;26(4):469-73. doi: 10.1097/CAD.0000000000000208.
39. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 BLOCKADE THERAPY IN RENAL CELL CARCINOMA: CURRENT STUDIES AND FUTURE PROMISES. *Cancer Treat Rev*. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013.
40. Buti S, Ciccarese C, Zanoni D, Santoni M, Modena A, Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, Cascinu S, Ardizzoni A, Tortora G, Massari F. PROGNOSTIC FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER: WHERE DO WE STAND? *Future Oncol*. 2015 Jan;11(1):107-19. doi: 10.2217/fon.14.172.
41. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. THE ROUTE TO PERSONALIZED MEDICINE IN BLADDER CANCER: WHERE DO WE STAND? *Target Oncol*. 2015 Sep;10(3):325-36.
42. Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C and Montironi R. BLADDER CANCER: MOLECULAR DETERMINANTS OF PERSONALIZED THERAPY. *Curr Drug Targets*. 2015;16(2):115-24.
43. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Motironi R, Bracarda S, Tonini G, Cascinu S, Santini D. BONE METASTASES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ARE THEY ALWAYS ASSOCIATED WITH POOR PROGNOSIS? *J Exp Clin Cancer Res*. 2015 Feb 5;34:10. doi: 10.1186/s13046-015-0122-0.
44. Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. INVESTIGATIONAL THERAPIES TARGETING SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 FOR THE TREATMENT OF CANCER. *Expert Opin Investig Drugs*. 2015 Jun;24(6):809-24. doi: 10.1517/13543784.2015.1020370.
45. Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D'Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Vecchia A, Galligioni E. CLINICAL OUTCOMES IN A CONTEMPORARY SERIES OF "YOUNG" PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WHO WERE 60 YEARS AND YOUNGER. *Urol Oncol*. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016.

46. Santoni M, Conti A, Piva F, Massari F, Ciccarese C, Burattini L, Cheng L, Lopez-Beltran A, Scarpelli M, Santini D, Tortora G, Cascinu S, Montironi R. ROLE OF STAT3 PATHWAY IN GENITOURINARY TUMORS. *Future Sci. OA* 2015, FSO 15
47. Ciccarese C, Modena A, Tortora G, Massari F. KIDNEY CANCER AND 2014: IS INNOVATION REALLY OVER? *Future Oncol.* 2015 May;11(9):1437-49.
48. Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. PRESENT AND FUTURE OF PERSONALIZED MEDICINE IN ADULT GENITOURINARY TUMORS. *Future Oncol.* 2015 May;11(9):1381-8.
49. Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S, Tortora G. EMERGING CONCEPTS ON DRUG RESISTANCE IN BLADDER CANCER: IMPLICATIONS FOR FUTURE STRATEGIES. *Crit Rev Oncol Hematol.* 2015 May 15. pii: S1040-8428(15)00094-3. doi: 10.1016/j.critrevonc.2015.05.005. [Epub ahead of print]
50. Ciccarese C, Massari F, Santoni M, Heng DY, Sotte V, Brunelli M, Conti A, Cheng L, Lopez-Beltran A, Scarpelli M, Cascinu S, Tortora G, Montironi R. NEW MOLECULAR TARGETS IN NON CLEAR RENAL CELL CARCINOMA: AN OVERVIEW OF ONGOING CLINICAL TRIALS. *Cancer Treat Rev.* 2015 Jul;41(7):614-22. doi: 10.1016/j.ctrv.2015.05.006.
51. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zamboni V, Sperduti I, Artibani W, Cheng L, Martignoni G, Tortora G, Brunelli M. PROGNOSTIC VALUE OF BETA-TUBULIN-3 AND c-MYC IN MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. *PLoS One.* 2015 Jun 5;10(6):e0127908. doi: 10.1371/journal.pone.0127908.
52. Massari F, Santoni M, Ciccarese C, Santini D. THE IMMUNOCHECKPOINTS IN MODERN ONCOLOGY: THE NEXT 15 YEARS. *Expert Opin. Biol. Ther.* (2015) 15(7):917-921.
53. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. RISK OF PRURITUS IN CANCER PATIENTS TREATED WITH BIOLOGICAL THERAPIES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS. *Crit Rev Oncol Hematol.* 2015 Jun 9. doi: 10.1016/j.critrevonc.2015.05.007. [Epub ahead of print]
54. Ortolani S, Ciccarese C, Cingarlini S, Tortora G, Massari F. SUPPRESSION OF mTOR PATHWAY IN SOLID TUMORS: LESSONS LEARNED FROM CLINICAL EXPERIENCE IN RENAL CELL CARCINOMA AND NEUROENDOCRINE TUMORS AND NEW PERSPECTIVES. *Future Oncol.* 2015 Jun;11(12):1809-1828.
55. Ciccarese C, Ferrara R, Fantinel E, Zecchetto C, Simionato F, Grego E, Ortolani S, Caccese M, Bimbatti D, Cingarlini S, Brunelli M, Andreini A, Tortora G, Massari F. ACQUIRED HEMOPHAGOCYTIC SYNDROME IN A PATIENT WITH SYNOVIAL SARCOMA: A CASE REPORT. *Future Science OA* 2015, FSO29, DOI: 10.4155/FSO.15.27
56. Ciccarese C, Massari F, Tortora G. ACQUIRED HEMOPHAGOCYTIC SYNDROME: COMMENT TO THE CASE REPORT. *Future Science OA* 2015, FSO31, DOI:10.4155/FSO.15.29
57. Modena A, Ciccarese C, Fantinel E, Bimbatti D, Tortora G, Massari F. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: TARGETING THE MECHANISMS OF RESISTANCE TO ABIRATERONE ACETATE AND ENZALUTAMIDE. *Expert Rev Anticancer Ther.* 2015 Jul 1:1-12. [Epub ahead of print]
58. Santoni M, Massari F, Iacovelli R, Ciccarese C, Verri E, Burattini L, Montironi R, Nolè F, Tortora G, Cascinu S. INSIDE THE 2015 ASCO GENITOURINARY CANCERS SYMPOSIUM. *Future Oncol.* 2015;11(13):1859-1862.
59. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. BAP1, PBRM1 AND SETD2 IN CLEAR-CELL RENAL CELL CARCINOMA: MOLECULAR DIAGNOSTICS AND POSSIBLE TARGETS FOR PERSONALIZED THERAPIES. *Expert Rev Mol Diagn.* 2015 Jul 11:1-10. [Epub ahead of print]

60. Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. METABOLIC ALTERATIONS IN RENAL CELL CARCINOMA. *Cancer Treatment Reviews* 41 (2015) 767–776
61. Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group^o. Ann Oncol. 2015 Jul 27. pii: mdv315. [Epub ahead of print] (*) F. Massari.
62. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G. BONE METASTASES AFFECT PROGNOSIS BUT NOT EFFECTIVENESS OF THIRD-LINE TARGETED THERAPIES IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. *Can Urol Assoc J* 2015;9(7-8):263-7.
63. Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, Iacovelli R, Berardi R, Santini D, Montironi R. THE ORIGIN OF PROSTATE METASTASES: EMERGING INSIGHTS. *Cancer Metastasis Rev.* 2015 Sep 12. [Epub ahead of print]
64. Maines F, Caffo O, De Giorgi U, Fratino L, Lo Re G, Zagonel V, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Basso U, Fraccon AP, Vicario G, Conteduca V, Galligioni E. SAFETY AND CLINICAL OUTCOMES OF ABIRATERONE ACETATE AFTER DOCETAXEL IN OCTOGENARIANS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS OF THE ITALIAN COMPASSIONATE USE NAMED PATIENT PROGRAMME. *Clin Genitourin Cancer.* 2015 Aug 6. pii: S1558-7673(15)00192-5. doi: 10.1016/j.clgc.2015.07.019. [Epub ahead of print]
65. Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. IMPACT OF VISCERAL METASTASES ON OUTCOME TO ABIRATERONE AFTER DOCETAXEL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS. *Future Oncol.* 2015 Oct 5. [Epub ahead of print]
66. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G. COMPUTATIONAL ANALYSIS OF THE MUTATIONS IN BAP1, PBRM1 AND SETD2 GENES REVEALS THE IMPAIRED MOLECULAR PROCESSES IN RENAL CELL CARCINOMA. *Oncotarget.* 2015 Oct 7. doi: 10.18632/oncotarget.5147. [Epub ahead of print]
67. Ciccarese C, Santoni M, Massari F, Modena A, Piva P, Conti4 A, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora T, Montironi R. METABOLIC ALTERATIONS IN RENAL AND PROSTATE CANCER. *Current Drug Metabolism* 2015. [Epub ahead of print]
68. Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. REPROFILING METASTATIC SAMPLES FOR CHROMOSOME 9p AND 14q ABERRATIONS AS A STRATEGY TO OVERCOME TUMOR HETEROGENEITY IN CLEAR-CELL RENAL CELL CARCINOMA. *Appl Immunohistochem Mol Morphol.* 2015 Oct 27. [Epub ahead of print]
69. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montironi R, Tortora G, Massari F. NEW TOXICITY PROFILE FOR NOVEL IMMUNOTHERAPY AGENTS: FOCUS ON IMMUNE-CHECKPOINT INHIBITORS. *Expert Opin Drug Metab Toxicol.* 2015 Nov 13. [Epub ahead of print]
70. Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosì M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. MAGNITUDE OF PD-1, PD-L1 AND T LYMPHOCYTE EXPRESSION ON TISSUE FROM CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA: AN EXPLORATORY ANALYSIS. *Target Oncol.* 2015 Nov 6. [Epub ahead of print]
71. Massari F, Ciccarese C, Santoni M, Lopez-Beltran A, Scarpelli M, Montironi R, Cheng L. TARGETING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) PATHWAY IN RENAL CELL CARCINOMA. *Expert Rev Anticancer Ther.* 2015 Nov 14:1-3. [Epub ahead of print]

72. Massari F, Modena, Ciccarese C, Pilotto S, Maines F, Bracarda S, Sperduti I, Giannarelli D, Carlini P, Santini D, Tortora G, Porta C, Bria E. ADDRESSING THE EXPECTED SURVIVAL BENEFIT FOR CLINICAL TRIAL DESIGN IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: SENSITIVITY ANALYSIS OF RANDOMIZED TRIALS. *Critical Reviews in Oncology/Hematology* 2015 Nov. [Epub ahead of print]
73. Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. EMERGING IMMUNOTARGETS IN METASTATIC RENAL CELL CARCINOMA. *Curr Drug Targets*. 2015 Dec 8. [Epub ahead of print]
74. Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. AN OVERVIEW OF EMERGING IMMUNOTARGETS OF GENITOURINARY TUMORS. *Curr Drug Targets*. 2015 Dec 9. [Epub ahead of print]
75. Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 AND PROSTATE CANCER: THE WATERSHED FOR TREATMENT SELECTION? *Cancer Treatment Reviews* 2015, Vol. 43, p27–35. DOI: <http://dx.doi.org/10.1016/j.ctrv.2015.12.003>
76. Ciccarese C, Massari F, Tortora G. CABOZANTINIB IN ADVANCED RENAL CELL CARCINOMA: IS IT A METEOR? *Eur Urol*. 2015 Dec 24. pii: S0302-2838(15)01239-7. doi: 10.1016/j.eururo.2015.12.030. [Epub ahead of print]
77. Diminutto A, Basso U, Maruzzo M, Morelli F, De Giorgi U, Perin A, Fraccon AP, Lo Re G, Rizzi A, Sava T, Fornarini G, Valcamonica F, Zustovich F, Massari F, Zanardi E, Roma A, Zattoni F, Zagonel V. ADJUVANT CARBOPLATIN TREATMENT IN 115 PATIENTS WITH STAGE I SEMINOMA: RETROSPECTIVE MULTICENTER SURVEY. *Clin Genitourin Cancer*. 2015 Dec 17. pii: S1558-7673(15)00339-0. doi: 10.1016/j.clgc.2015.12.009. [Epub ahead of print]
78. Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. CLINICAL OUTCOMES IN OCTOGENARIANS TREATED WITH DOCETAXEL AS FIRST-LINE CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER. *Future Oncol*. 2016 Jan 18. [Epub ahead of print]
79. Ciccarese C, Santoni M, Massari F. CHEMOHORMONAL THERAPY IN HORMONE-SENSITIVE PROSTATE CANCER. *N Engl J Med*. 2016 Jan 21;374(3):286-287.
80. Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. EMERGING IMMUNOTARGETS IN BLADDER CANCER. *Curr Drug Targets*. 2016 Jan 31. [Epub ahead of print]
81. Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting MET AND VEGFR AXIS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 'GAME OVER'? *Target Oncol*. 2016 Feb 5. [Epub ahead of print]
82. Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. EMERGING IMMUNOTARGETS AND IMMUNOTHERAPIES IN PROSTATE CANCER. *Curr Drug Targets*. 2016 Feb 17. [Epub ahead of print]
83. Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. METABOLIC PHENOTYPE OF BLADDER CANCER. *Cancer Treat Rev*. 2016 Mar 8;45:46-57. doi: 10.1016/j.ctrv.2016.03.005. [Epub ahead of print]
84. Ciccarese C, Massari F, Tortora G. 2015 and human cancer: back to overall survival. *Future Oncol*. 2016 [Epub ahead of print]
85. Conteduca V, Crabb SJ, Scarpi E, Hanna C, Maines F, Joyce H, Fabbri P, Derosa L, Massari F, Lolli C, Zarif S, Jones RJ, Caffo O, Elliott T, De Giorgi U. ASSOCIATION BETWEEN EARLY PSA INCREASE AND CLINICAL OUTCOME IN PATIENTS TREATED WITH ENZALUTAMIDE FOR METASTATIC CASTRATION RESISTANT PROSTATE

86. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. RISK OF RECURRENCE AND CONDITIONAL SURVIVAL IN COMPLETE RESPONDERS TREATED WITH TKIs PLUS OR LESS LOCOREGIONAL THERAPIES FOR METASTATIC RENAL CELL CARCINOMA. *Oncotarget*. 2016 Mar 23. doi: 10.18632/oncotarget.8302. [Epub ahead of print]
87. Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M. EDITORIAL: EMERGING IMMUNOTARGETS IN GENITOURINARY TUMORS. *Curr Drug Targets*. 2016;17(7):748-9.
88. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Ciccarese C, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. IMMUNOTARGETING AND PERSONALIZED THERAPIES IN GENITOURINARY CANCERS. *Future Oncol*. 2016 Apr 26. [Epub ahead of print]
89. Minardi D, Mazzucchelli R, Scarpelli M, Massari F, Ciccarese C, Lopez-Beltran A, Cheng L, Montironi R. PROSTATE CANCER GLANDS WITH CRIBRIFORM ARCHITECTURE AND WITH GLOMERULOID FEATURES SHOULD BE CONSIDERED AS GLEASON PATTERN 4 AND NOT PATTERN 3. *Future Oncol*. 2016 Mar 26. [Epub ahead of print]
90. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G, Massari F. IMMUNE CHECKPOINT INHIBITORS AND PROSTATE CANCER: A NEW FRONTIER? *Oncology Reviews* 2016; volume 10:293
91. Schepisi G, Santoni M, Massari F, Gurioli G, Salvi S, Conteduca V, Montironi R, De Giorgi U. UROTHELIAL CANCER: INFLAMMATORY MEDIATORS AND IMPLICATIONS FOR IMMUNOTHERAPY. *BioDrugs*. 2016 May 13. [Epub ahead of print]
92. Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F. THE SAFETY AND EFFICACY OF ENZALUTAMIDE IN THE TREATMENT OF ADVANCED PROSTATE CANCER. *Expert Rev Anticancer Ther*. 2016 May 21. [Epub ahead of print]
93. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. INSIDE THE 2016 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM: PART 1 - KIDNEY CANCER. *Future Oncol*. 2016 Jun 17. [Epub ahead of print]
94. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. INSIDE THE 2016 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM: PART 2 - PROSTATE AND BLADDER CANCER. *Future Oncol*. 2016 Jun 17. [Epub ahead of print]
95. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Raspollini MR, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. GENITOURINARY CANCERS: MOLECULAR DETERMINANTS FOR PERSONALIZED THERAPIES. *Urologia*. 2016 Jun 23;0. doi: 10.5301/uro.5000187. [Epub ahead of print]
96. Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G. INVESTIGATING BRCA MUTATIONS: A BREAKTHROUGH IN PRECISION MEDICINE OF CASTRATION-RESISTANT PROSTATE CANCER. *Target Oncol*. 2016 Jul 11. [Epub ahead of print]
97. Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheeler M, Berardi R, Galli L, De Giorgi U. SYSTEMIC IMMUNE-INFLAMMATION INDEX PREDICTS THE CLINICAL OUTCOME IN PATIENTS WITH METASTATIC RENAL CELL CANCER TREATED WITH SUNITINIB. *Oncotarget*. 2016 Jul 9. doi: 10.18632/oncotarget.10515. [Epub ahead of print]
98. Conteduca V, Crabb SJ, Jones RJ, Caffo O, Elliott T, Scarpi E, Fabbri P, Derosa L, Massari F, Numico G, Zarif S, Hanna C, Maines F, Joyce H, Lolli C, De Giorgi U. PERSISTENT NEUTROPHIL TO LYMPHOCYTE RATIO >3 DURING TREATMENT WITH ENZALUTAMIDE AND CLINICAL OUTCOME IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER. *PLoS One*. 2016 Jul 19;11(7):e0158952. doi: 10.1371/journal.pone.0158952.

99. Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. THE PROSPECT OF PRECISION THERAPY FOR RENAL CELL CARCINOMA. *Cancer Treat Rev*. 2016 Jul 12;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. [Epub ahead of print]
100. Ciccarese C, Di Nunno V, Montironi R, Fiorentino M, Brunelli M, Tortora G, Ardizzoni A, Massari F. THE ROLE OF PRECISION MEDICINE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA. *Expert Review of Precision Medicine and Drug Development* 2016, VOL. 1, N. 4, 369–377.
101. Montironi R, Gasparrini S, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montorsi F, Scarpelli M. RE: KARIM A. TOUIJER, JAMES A. EASTHAM. THE SENTINEL LYMPH NODE CONCEPT AND NOVEL APPROACHES IN DETECTING LYMPH NODE METASTASIS IN PROSTATE CANCER. *Eur Urol*. 2016 Aug 24. pii: S0302-2838(16)30503-6. doi: 10.1016/j.eururo.2016.08.036.
102. Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. WIDE SPETCRUM MUTATIONAL ANALYSIS OF METASTATIC RENAL CELL CANCER: A RETROSPECTIVE NEXT GENERATION SEQUENCING APPROACH. *Oncotarget*. 2016 Oct 10. doi: 10.18632/oncotarget.12551. [Epub ahead of print]
103. Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, Bianchi E, Massari F, Vecchia A, Chiuri VE, Facchini G, De Giorgi U. SYSTEMIC IMMUNE-INFLAMMATION INDEX PREDICTS THE CLINICAL OUTCOME IN PATIENTS WITH mCRPC TREATED WITH ABIRATERONE. *Front Pharmacol*. 2016 Oct 13;7:376. eCollection 2016.
104. Gasparrini S, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Lopez-Beltran A, Cheng L, Montironi R. PROSTATE CANCER GRADING IN 2016. *Minerva Urol Nefrol*. 2016 Nov 4. [Epub ahead of print]
105. Ciccarese C, Tortora G, Montironi R, Massari F. IS THERE STILL AN OPEN WINDOW IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER IMMUNOTHERAPY HORIZON? *Transl Cancer Res* 2016. doi: 10.21037/tcr.2016.11.05
106. Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Calìò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M. CATHEPSIN K EXPRESSION IN CASTRATION-RESISTANT PROSTATE CARCINOMA: A THERAPEUTICAL TARGET FOR PATIENTS AT RISK FOR BONE METASTASES. *Int J Biol Markers*. 2017 Jan 12;0. doi: 10.5301/jbm.5000246. [Epub ahead of print]
107. Cimadamore A, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. ACTIVITY OF CHEMOKINES IN PROSTATE AND RENAL TUMORS AND THEIR POTENTIAL ROLE AS FUTURE THERAPEUTIC TARGETS. *Future Oncol*. 2017 Feb 2. doi: 10.2217/fon-2016-0481. [Epub ahead of print]
108. Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G. PROSTATE CANCER HETEROGENEITY: DISCOVERING NOVEL MOLECULAR TARGETS FOR THERAPY. *Cancer Treat Rev*. 2017 Feb 11;54:68-73. doi: 10.1016/j.ctrv.2017.02.001. [Epub ahead of print]
109. Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. TP53 AND ITS POTENTIAL THERAPEUTIC ROLE AS A TARGET IN BLADDER CANCER. *Expert Opin Ther Targets*. 2017 Apr;21(4):401-414. doi: 10.1080/14728222.2017.1297798.
110. Montironi R, Lopez-Beltran A, Cheng L, Gasparrini S, Montironi MA, Massari F, Scarpelli M, Montorsi F. Re: Kenneth A. Iczkowski's Letter to the Editor re: RE: RODOLFO MONTIRONI, SILVIA GASPARRINI, ROBERTA MAZZUCHELLI, ET AL'S LETTER TO THE EDITOR RE: KARIM A. TOUIJER, JAMES A. EASTHAM. THE SENTINEL LYMPH NODE CONCEPT AND NOVEL APPROACHES IN DETECTING LYMPH NODE METASTASIS IN PROSTATE CANCER. *EUR UROL* 2016;70:738-9: SENTINEL LYMPH NODES IN ADIPOSE TISSUE SURROUNDING THE PROSTATE GLAND AND SEMINAL VESICLES AS OBSERVED IN VIRTUAL WHOLE-MOUNT HISTOLOGIC SLIDES. *EUR UROL* 2017;71:E73-5. *Eur Urol*. 2017 Mar 11. pii: S0302-2838(17)30127-6. doi: 10.1016/j.eururo.2017.02.032. [Epub ahead of print]
111. Ciccarese C, Montironi R, Iacovelli R, Massari F. LOCALIZED PROSTATE CANCER GENOTYPING: ANOTHER STEP

112. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R. THE ROLE OF DRUG-DRUG INTERACTIONS IN PROSTATE CANCER TREATMENT: FOCUS ON ABIRATERONE ACETATE/PREDNISONE AND ENZALUTAMIDE. *Cancer Treat Rev.* 22017; 55:71-82. doi: 10.1016/j.ctrv.2017.03.001. [Epub ahead of print]
113. Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Vecchia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U. LONG-TERM CLINICAL IMPACT OF PSA SURGE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE. *Prostate* 2017; 9999:1–8. <https://doi.org/10.1002/pros.23357>
114. Bianconi M, Faloppi L, Lopez-Beltran A, Cheng L, Cimadamore A, Gasparrini S, Massari F, Scarpelli M, Montironi R. Immunotherapy in genitourinary cancers: where are we going? *Expert Review of Precision Medicine and Drug Development* 2017
115. Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S. PATHOGENESIS, CLINICAL MANIFESTATIONS AND MANAGEMENT OF IMMUNE CHECKPOINT INHIBITORS TOXICITY. *Tumori.* 2017 May 8:0. doi: 10.5301/tj.5000625. [Epub ahead of print]
116. Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. MIRNA EXPRESSION IN BLADDER CANCER AND THEIR POTENTIAL ROLE IN CLINICAL PRACTICE. *Curr Drug Metab.* 2017 May 18. doi: 10.2174/1389200218666170518164507. [Epub ahead of print]
117. Montironi R, Cheng L, Moch H, Lopez-Beltran A, Scarpelli M, Massari F, Fiorentino M, Ciccicarese C, Koch M, Kaimakliotis HZ, Wang L, Pili R, Mann SA. TARGETING THE PROGRAMMED CELL DEATH-1 PATHWAY IN GENITOURINARY TUMORS: CURRENT PROGRESS AND FUTURE PERSPECTIVES. *Curr Drug Metab.* 2017 May 18. doi: 10.2174/1389200218666170518162500. [Epub ahead of print]
118. Giunchi F, Ciccicarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. URINARY BIOMARKERS FOR PROSTATE CANCER. *Curr Drug Metab.* 2017 May 18. doi: 10.2174/1389200218666170518161140. [Epub ahead of print]
119. Ciccicarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. CIRCULATING TUMOR CELLS: A RELIABLE BIOMARKER FOR PROSTATE CANCER TREATMENT ASSESSMENT? *Curr Drug Metab.* 2017 May 18. doi: 10.2174/1389200218666170518163549. [Epub ahead of print]
120. Cubelli M, Di Nunno V, Rihawi K, Massari F. IMMUNE CHECKPOINT INHIBITORS FOR METASTATIC BLADDER CANCER. *Transl Cancer Res* 2017;6(Suppl 4):S720-S732. doi: 10.21037/tcr.2017.05.36
121. Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. CLINICAL OUTCOME OF PATIENTS WHO REDUCED SUNITINIB OR PAZOPANIB DURING FIRST-LINE TREATMENT FOR ADVANCED KIDNEY CANCER. *Urol Oncol.* 2017 May 29. pii: S1078-1439(17)30217-X. doi: 10.1016/j.urolonc.2017.05.007. [Epub ahead of print]
122. Montironi R, Gasparrini S, Lopez-Beltran A, Cheng L, Massari F, Montorsi F, Scarpelli M. RE: UMBERTO LEONE ROBERTI MAGGIORE, SIMONE FERRERO, MASSIMO CANDIANI, ET AL. BLADDER ENDOMETRIOSIS: A SYSTEMATIC REVIEW OF PATHOGENESIS, DIAGNOSIS, TREATMENT, IMPACT ON FERTILITY, AND RISK OF MALIGNANT TRANSFORMATION. *EUR UROL* 2017;71:790-807. *Eur Urol.* 2017 May 30. pii: S0302-2838(17)30457-8. doi: 10.1016/j.eururo.2017.05.029. [Epub ahead of print]
123. Ciccicarese C, Di Nunno V, Iacovelli R, Massari F. FUTURE PERSPECTIVES FOR PERSONALIZED IMMUNOTHERAPY IN RENAL CELL CARCINOMA. *Exp. Op. Biol. Ther.* 2017 <https://doi.org/10.1080/14712598.2017.1339030>
124. Ciccicarese C, Iacovelli R, Bria E, Modena A, Massari F, Brunelli M, Fantinel E, Bimbatti D, Zamboni GA, Artibani W, Tortora G. THE INCIDENCE AND RELATIVE RISK OF PULMONARY TOXICITY IN PATIENTS TREATED WITH

ANTI-PD1/PD-L1 THERAPY FOR SOLID TUMORS: A META-ANALYSIS OF CURRENT STUDIES. *Immunotherapy* 2017, 9(7), 579–587.

125. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. PATHOLOGY AND MOLECULAR UPDATES IN TUMORS OF THE PROSTATE: TOWARDS A PERSONALIZED APPROACH. *Expert Rev Mol Diagn.* 2017 Jun 9. doi: 10.1080/14737159.2017.1341314. [Epub ahead of print]
126. Di Nunno V, Cubelli M, Massari F. THE ROLE OF THE MET/AXL PATHWAY AS A NEW TARGET FOR MULTIKINASE INHIBITORS IN RENAL CELL CARCINOMA. *Expert Review of Precision Medicine and Drug Development* 2017
127. Massari F, Ciccarese C, Hes O, Michal M, Calì A, Fiorentino M, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M. THE TUMOR ENTITY DENOMINATED "CLEAR CELL-PAPILLARY RENAL CELL CARCINOMA" ACCORDING TO THE WHO 2016 NEW CLASSIFICATION, HAVE THE CLINICAL CHARACTERS OF A RENAL CELL ADENOMA AS DOES HARBOR A BENIGN OUTCOME. *Pathol Oncol Res.* 2017 Jul 10. doi: 10.1007/s12253-017-0271-x. [Epub ahead of print]
128. Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. ADDRESSING THE BEST TREATMENT FOR NON-CLEAR CELL RENAL CELL CARCINOMA: A META-ANALYSIS OF RANDOMISED CLINICAL TRIALS COMPARING VEGFR-TKIS VERSUS MTORI-TARGETED THERAPIES. *European Journal of Cancer* 83 (2017) 237e246
129. Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. CONTEMPORARY GRADING OF PROSTATE CANCER: 2017 UPDATE FOR PATHOLOGISTS AND CLINICIANS. *Asian Journal of Andrology* (2017) 19, 1–5
130. Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G and Tonini G. OUTCOME OF OLIGOPROGRESSING METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH LOCOREGIONAL THERAPY: A MULTICENTER RETROSPECTIVE 3 ANALYSIS. *Oncotarget* 2017
131. Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. EPIGENETIC MODIFICATIONS AND MODULATORS IN PROSTATE CANCER. *Critical Reviews in Oncogenesis* 2017, 21(5-6): 395–406.
132. Montironi R, Gasparrini S, Cimadamore A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Moch H, Montorsi F, Scarpelli M. VARIANTS AND VARIATIONS IN EPITHELIAL RENAL CELL TUMORS IN ADULTS: THE PATHOLOGIST'S POINT OF VIEW. *European Urology Supplements* 2017 article in press.
133. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent JJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators° (Massari F). RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER PLATINUM-BASED THERAPY (RANGE): A RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL. *Lancet.* 2017 Sep 12. pii: S0140-6736(17)32365-6. doi: 10.1016/S0140-6736(17)32365-6. [Epub ahead of print]
134. Montironi R, Gasparrini S, Cimadamore A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Moch H, Montorsi F, Scarpelli M. MORPHOLOGIC VARIANTS OF EPITHELIAL AND NEUROENDOCRINE TUMORS OF THE PROSTATE. THE PATHOLOGIST'S POINT OF VIEW. *European Urology Supplements* 2017 article in press.
135. Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DY. ADJUVANT THERAPY IN RENAL CELL CARCINOMA. *Cancer Treatment Reviews* 2017; 60:152–157

136. Vau N, Volavsek M, Blanca A, Montironi R, Raspollini MR, Massari F, Cheng L, Scarpelli M, Lopez-Beltran A. PROSPECTS FOR PRECISION THERAPY OF BLADDER UROTHELIAL CARCINOMA. *Expert Review of Precision Medicine and Drug Development*, 2017
137. Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. WHOLE SLIDE IMAGING OF LARGE FORMAT HISTOLOGY IN PROSTATE PATHOLOGY: POTENTIAL FOR INFORMATION FUSION. *Arch Pathol Lab Med*. 2017 Nov;141(11):1460-1461.
138. Massari F, Di Nunno V, Ardizzoni A. RE: ROBERT J. MOTZER, ALAIN RAVAUD, JEAN-JACQUES PATARD, ET AL. ADJUVANT SUNITINIB FOR HIGH-RISK RENAL CELL CARCINOMA AFTER NEPHRECTOMY: SUBGROUP ANALYSES AND UPDATED OVERALL SURVIVAL RESULTS. *Eur Urol*. 2017 In press.
139. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. MOLECULAR TESTING FOR BRAF MUTATIONS TO INFORM MELANOMA TREATMENT DECISIONS: A MOVE TOWARD PRECISION MEDICINE. *Mod Pathol*. 2017 Nov 17. doi: 10.1038/modpathol.2017.104. [Epub ahead of print]
140. Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A. CIRCULATING TUMOR CELLS IN GENITOURINARY TUMORS. *Ther Adv Urol* 2017.
141. Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C. LIVER METASTASES FROM PROSTATE CANCER AT 11C-CHOLINE PET/CT: A MULTICENTER, RETROSPECTIVE ANALYSIS. *Eur J Nucl Med Mol Imaging*. 2017
142. Massari F, Di Nunno V. ATEZOLIZUMAB FOR PLATINUM-TREATED METASTATIC UROTHELIAL CARCINOMA. *The Lancet* 2017.
143. Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. IMMUNE CHECKPOINT INHIBITORS FOR METASTATIC BLADDER CANCER. *Cancer Treat Rev*. 2018 Jan 31;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. [Epub ahead of print]
144. Massari F, Di Nunno V. Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. *Eur Urol* 2018;73:462–8. *Eur Urol*. 2018 In press. DOI of original article: <https://doi.org/10.1016/j.eururo.2017.11.023>
145. Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. PROSTATE CANCER WITH CRIBRIFORM MORPHOLOGY: DIAGNOSIS, AGGRESSIVENESS, MOLECULAR PATHOLOGY AND POSSIBLE RELATIONSHIPS WITH INTRADUCTAL CARCINOMA. *Expert Review of Anticancer Therapy* 2018
146. Di Nunno V, Santoni M, Massari F. RE: MICHAEL B. ATKINS, ELIZABETH R. PLIMACK, IGOR PUZANOV, ET AL. AXITINIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CANCER: A NON-RANDOMISED, OPEN-LABEL, DOSE-FINDING, AND DOSE-EXPANSION PHASE 1B TRIAL. *LANCET ONCOL* 2018;19:405–15. *Eur Urol* 2018 In Press.
147. Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Lodi Rizzini E, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F. ²²³RA-CHLORIDE THERAPY IN MEN WITH HORMONE-REFRACTORY PROSTATE CANCER AND SKELETAL METASTASES: REAL-WORLD EXPERIENCE. *Tumori Journal* 2018.
148. Mosillo C, Ciccarese C, Bimbatti D, Fantinel E, Dalla Volta A, Bisogno I, Zampiva I, Santoni M, Massari F, Brunelli M, Montironi R, Tortora G, Iacovelli R. RENAL CELL CARCINOMA IN ONE YEAR: GOING INSIDE THE NEWS OF 2017 – A REPORT OF THE MAIN ADVANCES IN RCC CANCER RESEARCH. *Cancer Treatment Reviews* 2018;67:29–33
149. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F,

- Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. SAFETY AND EFFICACY OF CABOZANTINIB IN METASTATIC RENAL-CELL CARCINOMA: REAL-WORLD DATA FROM AN ITALIAN MANAGED ACCESS PROGRAM. *Clin Genitourin Cancer*. 2018 Apr 19. pii: S1558-7673(18)30084-3. doi: 10.1016/j.clgc.2018.03.014. [Epub ahead of print]
150. Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C. IS IT POSSIBLE TO IMPROVE PROGNOSTIC CLASSIFICATION IN PATIENTS AFFECTED BY METASTATIC RENAL CELL CARCINOMA WITH AN INTERMEDIATE OR POOR PROGNOSIS? *Clin Genitourin Cancer*. 2018 May 7. pii: S1558-7673(18)30151-4. doi: 10.1016/j.clgc.2018.04.007. [Epub ahead of print]
151. Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. THE OUTCOME TO AXITINIB OR EVEROLIMUS AFTER SUNITINIB IN METASTATIC RENAL CELL CARCINOMA. *ANTICANCER DRUGS*. 2018 May 25. doi: 10.1097/CAD.0000000000000632. [Epub ahead of print]
152. Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. CLINICAL MANAGEMENT OF A PITUITARY GLAND METASTASIS FROM CLEAR CELL RENAL CELL CARCINOMA. *Anticancer Drugs*. 2018 May 25. doi: 10.1097/CAD.0000000000000644. [Epub ahead of print]
153. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. TIVOZANIB FOR THE TREATMENT OF RENAL CELL CARCINOMA. *Expert Opin Pharmacother*. 2018 May 31;1-5. doi: 10.1080/14656566.2018.1480722. [Epub ahead of print]
154. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. IMMUNOTHERAPY IN RENAL CELL CARCINOMA: LATEST EVIDENCE AND CLINICAL IMPLICATIONS. *Drugs in Context* 2018; 7: 212528. DOI: 10.7573/dic.212528
155. Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R. ADJUVANT AND NEOADJUVANT APPROACHES FOR UROTHELIAL CANCER: UPDATED INDICATIONS AND CONTROVERSIES. *Cancer Treat Rev*. 2018 Jun 5;68:80-85. doi: 10.1016/j.ctrv.2018.06.002. [Epub ahead of print]
156. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. BIOMARKERS OF AGGRESSIVENESS IN GENITOURINARY TUMORS WITH EMPHASIS ON KIDNEY, BLADDER AND PROSTATE CANCER. *Expert Rev Mol Diagn*. 2018 Jun 18. doi: 10.1080/14737159.2018.1490179. [Epub ahead of print]
157. Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F. A CASE OF COMPLETE RESPONSE TO NIVOLUMAB AFTER LONG-TERM PROGRESSION-FREE SURVIVAL WITH TYROSINE KINASE INHIBITOR. *Anticancer Drugs*. 2018 Jun 18. doi: 10.1097/CAD.0000000000000663. [Epub ahead of print]
158. Di Nunno V, Santoni M, Cimadamore A, Battelli N, Massari F. RE: GLADELL P. PANER, WALTER M. STADLER, DONNA E. HANSEL, RODOLFO MONTIRONI, DANIEL W. LIN, MAHUL B. AMIN. UPDATES IN THE EIGHTH EDITION OF THE TUMOR-NODE-METASTASIS STAGING CLASSIFICATION FOR UROLOGIC CANCERS. *EUR UROL* 2018;73:560-9: TUMOUR, NODE, AND METASTASIS STAGING SYSTEM FOR UROLOGICAL MALIGNANCIES: ARE WE READY FOR THE NEXT STEP? *Eur Urol*. 2018 Jul 12. pii: S0302-2838(18)30478-0. doi: 10.1016/j.eururo.2018.06.050. [Epub ahead of print]
159. Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Gatto L, Zichi C, Ardizzoni A, Di Maio M, Massari F. IMMUNE-CHECKPOINT INHIBITORS IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Critical Reviews in Oncology/Hematology* 2018, DOI: <https://doi.org/10.1016/j.critrevonc.2018.07.004>. [Epub ahead of print]

160. Massari F, Santoni M, Di Nunno V, Cimadamore A, Battelli N, Scarpelli M, Cheng M, Lopez-Beltran A, Cheng L, Montironi R. QUICK STEPS TOWARD PRECISION MEDICINE IN RENAL CELL CARCINOMA. Expert Review of Precision Medicine and Drug Development 2018 [Epub ahead of print]
161. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. BIOLOGICAL ISSUES WITH CABOZANTINIB IN BONE METASTATIC RENAL CELL CARCINOMA AND CASTRATION-RESISTANT PROSTATE CANCER. Future Oncology 2018, [Epub ahead of print]
162. Massari F, Di Nunno V, Santoni M. RE: ARNAUD MÉJEAN, ALAIN RAVAUD, SIMON THEZENAS, ET AL. SUNITINIB ALONE OR AFTER NEPHRECTOMY IN METASTATIC RENAL-CELL CARCINOMA. N ENGL J MED 2018;379:417–27 - CARMENA TRIAL: IS THIS THE END OF CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS WITH CLEAR-CELL RENAL CELL CARCINOMA? European Urology Oncology 2018
163. Di Nunno V, Santoni M, Massari F. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration resistant prostate cancer? Lancet Oncology 2018, e437
164. Di Nunno V, Santoni M, Massari F. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival? European Urology Oncology 2018
165. Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Mennitto A, Verzoni E, Procopio G. SAFETY AND EFFICACY OF CABOZANTINIB FOR METASTATIC NONCLEAR RENAL CELL CARCINOMA: REAL-WORLD DATA FROM AN ITALIAN MANAGED ACCESS PROGRAM. Am J Clin Oncol. 2018. doi: 10.1097/COC.0000000000000478. [Epub ahead of print]
166. Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Contedua V, Verzoni E, Rossetti S, Vecchia A, Kinspergher S, Caffo O. ENZALUTAMIDE AFTER CHEMOTHERAPY IN ADVANCED CASTRATION-RESISTANT PROSTATE CANCER: THE ITALIAN NAMED PATIENT PROGRAM. Future Oncol. 2018. doi: 10.2217/fon-2018-0113. [Epub ahead of print]
167. Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. RECENT ADVANCES IN LIQUID BIOPSY IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER. Front. Oncol. 2018. doi: 10.3389/fonc.2018.00397
168. Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. PREDICTIVE ROLE OF CHANGES IN THE TUMOR BURDEN AND INTERNATIONAL METASTATIC RENAL CELL CARCINOMA DATABASE CONSORTIUM CLASS DURING ACTIVE SURVEILLANCE FOR METASTATIC RENAL CELL CARCINOMA. Urol Oncol. 2018 Oct 6. pii: S1078-1439(18)30338-7. doi: 10.1016/j.urolonc.2018.08.018. [Epub ahead of print]
169. Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. SHOULD CARMENA REALLY CHANGE OUR ATTITUDE TOWARDS CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA? A SYSTEMATIC REVIEW AND META-ANALYSIS EVALUATING CYTOREDUCTIVE NEPHRECTOMY IN THE ERA OF TARGETED THERAPY. Targeted Oncology 2018
170. Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, Luca E, Sorarù M, Mucciari C, Atzori F, Banna GL, Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, Tursi M, Maio MD, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S. INFLUENZA VACCINE INDICATION DURING THERAPY WITH IMMUNE CHECKPOINT INHIBITORS: A TRANSVERSAL CHALLENGE. THE INVIDIA STUDY. Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.
171. Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, Pietrantonio F, Spada f, Valente M, Di Maio M, Torri V. GENDER INFLUENCE ON PROFESSIONAL SATISFACTION AND GENDER ISSUE PERCEPTION

- AMONG YOUNG ONCOLOGISTS. A SURVEY OF THE YOUNG ONCOLOGISTS WORKING GROUP OF THE ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY (AIOM). *ESMO Open* 2018;3:e000389. doi:10.1136/esmoopen-2018-000389
172. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. THE IDENTIFICATION OF IMMUNOLOGICAL BIOMARKERS IN KIDNEY CANCERS. *Front. Oncol.* 2018 doi: 10.3389/fonc.2018.00456
 173. Santoni M, Montironi R, Battelli N, Massari F. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. *Eur Urol.* In press. <https://doi.org/10.1016/j.eururo.2018.08.011>: *Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma*. *Eur Urol.* 2018 Oct 31. pii: S0302-2838(18)30819-4. doi: 10.1016/j.eururo.2018.10.031. [Epub ahead of print]
 174. Di Nunno V, Gatto L, Fragomeno B, Cubelli M, Nobili E, Romano I, Santoni M, Pisconti M, Montironi R, Massari F. COMBINATION IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMA. ARE WE LEAVING SOMETHING BACK? *Future Oncol.* 2018 [Epub ahead of print]
 175. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS GENES IN COLORECTAL CARCINOMA: PATHOGENESIS, TESTING GUIDELINES AND TREATMENT IMPLICATIONS. *J Clin Pathol.* 2018 Nov 13. pii: jclinpath-2018-205471. doi: 10.1136/jclinpath-2018-205471. [Epub ahead of print]
 176. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. NEW PROSTATE CANCER TARGETS FOR DIAGNOSIS, IMAGING, AND THERAPY: FOCUS ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN. *Front. Oncol.* 2018; 8:653. doi: 10.3389/fonc.2018.00653
 177. Dalbeni A, Ciccicarese C, Bevilacqua M, Benati M, Caimmi C, Cerrito L, Famà F, Iacovelli R, Mantovani A, Massari F, Meneguzzi A, Minuz P, Montagnana M, Orsolini G, Rossini M, Tortora G, Viapiana O, Fava C. EFFECTS OF ANTIANGIOGENETIC DRUGS ON MICROCIRCULATION AND MACROCIRCULATION IN PATIENTS WITH ADVANCED-STAGE RENAL CANCER. *Cancers* 2019, 11(1), 30; <https://doi.org/10.3390/cancers11010030>
 178. Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. MOLECULAR MECHANISMS RELATED TO HORMONE INHIBITION RESISTANCE IN PROSTATE CANCER. *Cells* 2019, 8, 43; doi:10.3390/cells8010043
 179. Massari F, Di Nunno V. CHECKMATE 214 PATIENT-REPORTED OUTCOMES: LISTENING TO OUR PATIENTS. *Lancet Oncology* 2019
 180. Di Nunno V, Frega G, Gatto L, Brandi G, Massari F. HYPOTHYROIDISM IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING CABOZANTINIB: AN UNASSESSED ISSUE. *Future Oncology* 2019
 181. Massari F, Di Nunno V, Santoni M, Gatto L, Mollica V, Porta C. RE: BIMAL BHINDI, E. JASON ABEL, LAURENCE ALBIGES, ET AL. SYSTEMATIC REVIEW OF THE ROLE OF CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA AND BEYOND: AN INDIVIDUALIZED APPROACH TO METASTATIC RENAL CELL CARCINOMA. *EUR UROL* 2019;75:111–28 *CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: THIS IS NOT THE END*. *Eur Urol Oncol* (2019), <https://doi.org/10.1016/j.euo.2019.01.005>
 182. Massari F, Di Nunno V, Mollica V, Graham J, Gatto L, Heng D. ADJUVANT TYROSINE KINASE INHIBITORS IN TREATMENT OF RENAL CELL CARCINOMA: A META-ANALYSIS OF AVAILABLE CLINICAL TRIALS. *Clinical Genitourinary Cancer* 2019
 183. Cimadamore C, Gasparri S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. EMERGING MOLECULAR TECHNOLOGIES IN RENAL CELL CARCINOMA: LIQUID BIOPSY. *Cancers* 2019, 11, 196; doi:10.3390/cancers11020196

184. Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizoni A, Tortora G. CABOZANTINIB-RELATED CARDIOTOXICITY: A PROSPECTIVE ANALYSIS IN A "REAL WORLD" COHORT OF METASTATIC RENAL CELL CARCINOMA PATIENTS. *Br J Clin Pharmacol*. 2019 Feb 10. doi: 10.1111/bcp.13895. [Epub ahead of print]
185. Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. GENITOURINARY TUMORS: UPDATE ON MOLECULAR BIOMARKERS FOR DIAGNOSIS, PROGNOSIS AND PREDICTION OF RESPONSE TO THERAPY. *Curr Drug Metab*. 2019 Feb 25. doi:10.2174/1389200220666190225124352. [Epub ahead of print]
186. Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, Battelli N, Massari F. ADJUVANT THERAPY IN RENAL CELL CARCINOMA—IS PHARMACOGENOMICS ASSESSMENT ANOTHER ELEMENT TO SELECT OUR PATIENTS? *Annals of Translational Medicine* 2019.
187. Di Nunno V, Santoni M, Gatto L, Mollica V, Massari F. RE: CHRISTOPHER C. PARKER, NICHOLAS D. JAMES, CHRISTOPHER D. BRAWLEY, ET AL. RADIOTHERAPY TO THE PRIMARY TUMOUR FOR NEWLY DIAGNOSED, METASTATIC PROSTATE CANCER (STAMPEDE): A RANDOMISED CONTROLLED PHASE 3 TRIAL. *LANCET* 2018;392:2353–66. *METASTATIC HORMONE-NAÏVE PROSTATE CANCER: A MULTIMODAL APPROACH FOR A HETEROGENEOUS DISEASE*. *European Urology Oncology* 2019
188. Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. MICROBIOME AND CANCERS, WITH FOCUS ON GENITOURINARY TUMORS. *Front. Oncol*. 9:178. doi: 10.3389/fonc.2019.00178
189. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. THE HUMAN MICROBIOTA AND PROSTATE CANCER: FRIEND OR FOE? *Cancers* 2019, 11, 459; doi:10.3390/cancers11040459
190. Santoni M, Maiorani G, Faloppi L, Di Nunno V, Gatto L, Massari F, Battelli N. OPTIMIZING RENAL FUNCTION AND OUTCOME OF PATIENTS WITH CT2 RENAL CELL CARCINOMA. *Annals of Translational Medicine* 2019.
191. Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. THE EFFECT OF A TREATMENT DELAY ON OUTCOME IN METASTATIC RENAL CELL CARCINOMA. *Urol Oncol*. 2019 Mar 29. pii: S1078-1439(19)30098-5. doi: 10.1016/j.urolonc.2019.03.005. [Epub ahead of print]
192. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. NOVEL THERAPEUTIC APPROACHES AND TARGETS CURRENTLY UNDER EVALUATION FOR RENAL CELL CARCINOMA: WAITING FOR THE REVOLUTION. *Clin Drug Investig*. 2019 Apr 1. doi: 10.1007/s40261-019-00773-w. [Epub ahead of print]
193. Di Nunno V, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. PROGNOSTIC IMPACT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Immunotherapy* 2019; 11(7): 631-643
194. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA: RECENT FINDINGS AND FUTURE CHALLENGES. *Front. Oncol*. 9:228. doi: 10.3389/fonc.2019.00228
195. Mollica V, Di Nunno V, Massari F. PEMBROLIZUMAB PLUS AXITINIB: A NEW TREATMENT OPTION FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. *Chin Clin Oncol* 2019
196. Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. BAP1 IN SOLID TUMORS. *Future Oncology* 2019

197. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. RESISTANCE TO SYSTEMIC AGENTS IN RENAL CELL CARCINOMA PREDICT AND OVERCOME GENOMIC STRATEGIES ADOPTED BY TUMOR. *Cancers* 2019
198. Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. ANOTHER ONE IN THE CHAMBER: CABOZANTINIB FOR PATIENTS WITH METASTATIC NON CLEAR CELL RENAL CELL CARCINOMA. *Ann Transl Med* 2019. doi: 10.21037/atm.2019.06.06
199. Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Calì A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F. A META-ANALYSIS EVALUATING CLINICAL OUTCOMES OF PATIENTS WITH RENAL CELL CARCINOMA HARBORING CHROMOSOME 9P LOSS. *Mol Diagn Ther.* 2019 Jul 22. doi: 10.1007/s40291-019-00414-0. [Epub ahead of print]
200. Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. NEW HORMONAL AGENTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: META-ANALYSIS OF EFFICACY AND SAFETY OUTCOMES. *Clinical Genitourinary Cancer* 2019 <https://doi.org/10.1016/j.clgc.2019.07.001>
201. Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S. TOWARD A GENOME-BASED TREATMENT LANDSCAPE FOR RENAL CELL CARCINOMA. *Critical Reviews in Oncology / Hematology* 142 (2019) 141–152
202. Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R. KEY ROLE OF OBESITY IN GENITOURINARY TUMORS WITH EMPHASIS ON UROTHELIAL AND PROSTATE CANCERS. *Cancers* 2019, 11, 1225; doi:10.3390/cancers11091225
203. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. MOLECULAR CHARACTERIZATION AND DIAGNOSTIC CRITERIA OF RENAL CELL CARCINOMA WITH EMPHASIS ON LIQUID BIOPSIES. *Expert Rev Mol Diagn.* 2019 Sep 9. doi: 10.1080/14737159.2019.1665510. [Epub ahead of print]
204. Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. PROSTATE CANCER PATHOLOGY: WHAT HAS CHANGED IN THE LAST 5 YEARS. *Urologia Journal* 2019
205. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. LIQUID BIOPSY IN THE CLINICAL MANAGEMENT OF BLADDER CANCER: CURRENT STATUS AND FUTURE DEVELOPMENTS. *Expert Rev Mol Diagn.* 2019 Oct 12. doi: 10.1080/14737159.2019.1680284. [Epub ahead of print]
206. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F. AN EVALUATION OF CURRENT PROSTATE CANCER DIAGNOSTIC APPROACHES WITH EMPHASIS ON LIQUID BIOPSIES AND PROSTATE CANCER. *Expert Rev Mol Diagn.* 2019 Oct 22. doi: 10.1080/14737159.2019.1684265. [Epub ahead of print]
207. Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. LIQUID BIOPSIES IN RENAL CELL CARCINOMA WITH FOCUS ON EPIGENOME ANALYSIS. *Ann Transl Med.* 2019 Sep;7(Suppl 6):S194. doi: 10.21037/atm.2019.07.30
208. Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. IMMUNOTHERAPY IN RENAL CELL CARCINOMA FROM POVERTY TO THE SPOILED OF CHOICE. *Immunotherapy.* 2019 Oct 30. doi: 10.2217/imt-2019-0115. [Epub ahead of print]
209. Dall'Olio FG, Di Nunno V, Massari F. IMMORTAL TIME BIAS QUESTION IN THE ASSOCIATION BETWEEN TOXICITY AND OUTCOME OF IMMUNE CHECKPOINT INHIBITORS. *J Clin Oncol.* 2019 Nov 1;JCO1901728. doi: 10.1200/JCO.19.01728. [Epub ahead of print]

210. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent JJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators^o (^oMassari F). RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER PLATINUM-BASED THERAPY (RANGE): OVERALL SURVIVAL AND UPDATED RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL. *Lancet Oncol*. 2019 Nov 18. pii: S1470-2045(19)30668-0. doi: 10.1016/S1470-2045(19)30668-0. [Epub ahead of print]
211. Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Improving IMDC PROGNOSTIC PREDICTION THROUGH EVALUATION OF INITIAL SITE OF METASTASIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. *Clin Genitourin Cancer*. 2019 Aug 20. pii: S1558-7673(19)30256-3. doi: 10.1016/j.clgc.2019.08.007. [Epub ahead of print]
212. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. CURRENT AND EMERGING BLADDER CANCER BIOMARKERS WITH AN EMPHASIS ON URINE BIOMARKERS. *Expert Rev Mol Diagn*. 2019 Dec 4. doi: 10.1080/14737159.2020.1699791. [Epub ahead of print]
213. Santoni M, Conti A, Massari F, di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. TARGETED THERAPY FOR SOLID TUMORS AND RISK OF HYPERTENSION: A META-ANALYSIS OF 68077 PATIENTS FROM 93 PHASE III STUDIES. *Expert Rev Cardiovasc Ther*. 2019 Dec 12. doi: 10.1080/14779072.2019.1704626. [Epub ahead of print]
214. Santoni M, Heng DY, Bracarda s, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A , Cheng L , Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A , Montironi R, Battelli N. REAL-WORLD DATA ON CABOZANTINIB IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: FOCUS ON SEQUENCES AND PROGNOSTIC FACTORS. *Cancers* 2020, 12, 84; doi:10.3390/cancers12010084
215. Di Nuno V, Mollica V, Massari F. N-MYC A KEY GENE PROMOTING A WORST PROSTATE CANCER PROGRESSION. *Transl Cancer Res* 2019;8(8):E15-E17. doi: 10.21037/tcr.2019.12.63
216. Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. GERMLINE AND SOMATIC MUTATIONS IN PROSTATE CANCER: FOCUS ON DEFECTIVE DNA REPAIR, PARP INHIBITORS AND IMMUNOTHERAPY. *Future Oncology* 2020 Epub ahead of print]
217. Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, Battelli N, Ardizzoni A, Massari F. SYSTEMIC TREATMENT FOR METASTATIC HORMONE SENSITIVE PROSTATE CANCER: A COMPREHENSIVE META-ANALYSIS EVALUATING EFFICACY AND SAFETY IN SPECIFIC SUB-GROUPS OF PATIENTS. *Clin Drug Investig*. 2020 Jan 28. doi: 10.1007/s40261-020-00888-5. [Epub ahead of print]
218. Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. IMMUNOTHERAPY FOR UROTHELIAL CANCER: FROM THE DIAGNOSTIC PATHOLOGIST'S POINT OF VIEW. *Expert Opin Biol Ther*. 2020 Feb 21. doi: 10.1080/14712598.2020.1733965. [Epub ahead of print]
219. Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, Fiorentino M. SIMILARITIES AND DIFFERENCES BETWEEN CLEAR CELL TUBULO-PAPILLARY AND CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA: A COMPARATIVE PHENOTYPICAL AND MUTATIONAL ANALYSIS. *Diagnostics* 2020

220. Aurilio G, Santoni M, Cimdamore A, Massari F, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Nol  F, Montironi R. RENAL CELL CARCINOMA: GENOMIC LANDSCAPE AND CLINICAL IMPLICATIONS. *Exp Rev prec med drug dev* 2020. <https://doi.org/10.1080/23808993.2020.1733407>
221. Bersanelli M, Buti S, Banna GL, Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, Tursi M, Marino PD, Rossetti S, Rossi E, Tomao S, Luca E, Sorar  M, Mucciarini C, Atzori F, Torre L, Vitale MG, Martelli V, Sepe P, Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Maio MD, Verzoni E, Procopio G, Giannarelli D. IMPACT OF INFLUENZA SYNDROME AND FLU VACCINE ON SURVIVAL OF CANCER PATIENTS DURING IMMUNOTHERAPY IN THE INVIDIA STUDY. *Immunotherapy* 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180.
222. Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, Huang K, Massari F, Lu X, Cimdamore A, Lopez-Beltran A, Cheng L. EPIGENETIC MODULATIONS AND LINEAGE PLASTICITY IN ADVANCED PROSTATE CANCER. *Ann Oncol.* 2020 Feb 13. pii: S0923-7534(20)36034-8. doi: 10.1016/j.annonc.2020.02.002. [Epub ahead of print]
223. Mollica V, Santoni M, Di Nunno V, Cimdamore A, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. IMMUNOTHERAPY AND RADIATION THERAPY IN RENAL CELL CARCINOMA. *Curr Drug Targets.* 2020 Mar 11. doi: 10.2174/1389450121666200311121540. [Epub ahead of print]
224. Cimdamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. PD1 and PD-L1 INHIBITORS FOR THE TREATMENT OF KIDNEY CANCER: THE ROLE OF PD-L1 ASSAY. *Curr Drug Targets.* 2020 Mar 24. doi: 10.2174/1389450121666200324151056. [Epub ahead of print]
225. Di Nunno V, Mollica V, Massari F. CABAZITAXEL IN METASTATIC PROSTATE CANCER. *N Engl J Med.* 2020 Mar 26;382(13):1286. doi: 10.1056/NEJMc2000990.
226. Montironi R, Cimdamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. MORPHOLOGIC, MOLECULAR AND CLINICAL FEATURES OF AGGRESSIVE VARIANT PROSTATE CANCER. *Cells* 2020, 9, 1073; doi:10.3390/cells9051073
227. Lamberti G, Brizzi MP, Pusceddu S, Gelsomino F, Di Meglio G, Massari F, Badalamenti G, Riccardi F, Ibrahim t, Ciccarese C, Buti 1S, Carnaghi C, Prinzi N, Panzuto F, Campana D. PERIOPERATIVE CHEMOTHERAPY IN POORLY DIFFERENTIATED NEUROENDOCRINE NEOPLASIA OF THE BLADDER: A MULTICENTER ANALYSIS. *J. Clin. Med.* 2020, 9, 1351; doi:10.3390/jcm9051351.
228. Massari F, Mollica V, Salvagni S, Tognetto M, Ardizzoni A. ONCOLOGY CLINICAL TRIALS IN THE TIME OF COVID-19: HOW A PANDEMIC CAN REVOLUTIONIZE PATIENTS' CARE. *Future Oncology* 2020
229. Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. ANTI-PROGRAMMED CELL DEATH-1 AND ANTI-PROGRAMMED CELL DEATH LIGAND-1 IMMUNE-RELATED LIVER DISEASES: FROM CLINICAL PIVOTAL STUDIES TO REAL-LIFE EXPERIENCE. *Expert Opinion on Biological Therapy* 2020, DOI: 10.1080/14712598.2020.1762562
230. Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M. MANAGEMENT OF OLIGOMETASTATIC AND OLIGOPROGRESSIVE RENAL CELL CARCINOMA: STATE OF THE ART AND FUTURE DIRECTIONS. *Expert Rev Anticancer Ther.* 2020; 1-11. doi:10.1080/14737140.2020.1770601
231. Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, Fiorentino M, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. CURRENT STRATEGIES AND NOVEL THERAPEUTIC APPROACHES FOR METASTATIC UROTHELIAL CARCINOMA. *Cancers* 2020, 12, 1449; doi:10.3390/cancers12061449
232. Franceschini T, Capizzi E, Massari F, Schiavina R, Fiorentino M, Giunchi F. IMMUNOHISTOCHEMICAL OVER-EXPRESSION OF HER2 DOES NOT ALWAYS MATCH WITH GENE AMPLIFICATION IN INVASIVE BLADDER CANCER. *Pathology - Research and Practice* 216 (2020) 153012

233. Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A. PD-L1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER. [published online ahead of print, 2020 Jun 9]. *Curr Drug Targets*. 2020; doi:10.2174/1389450121666200609142219
234. Mollica V, Rizzo A, Massari F. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2020.04.038>: Cytoreductive Nephrectomy: To Whom and When? *European Urology Oncology* 2020 <https://doi.org/10.1016/j.euo.2020.05.011>
235. Caffo O, Zagonel V, Baldessari C, Berruti A, Bortolus R, Buti S, Ceresoli GL, Donini M, Ermacora P, Fornarini G, Fratino L, Masini C, Massari F, Mosca A, Mucciari C, Procopio G, Tucci M, Verri E, Zucali P, Buttigliero C. ON THE RELATIONSHIP BETWEEN ANDROGEN-DEPRIVATION THERAPY FOR PROSTATE CANCER AND RISK OF INFECTION BY SARS-COV-2. [published online ahead of print, 2020 Jun 17]. *Ann Oncol*. 2020;S0923-7534(20)39892-6. doi:10.1016/j.annonc.2020.06.005
236. Cimadamore A, Aurilio G, Nolè F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. UPDATE ON CIRCULATING TUMOR CELLS IN GENITOURINARY TUMORS WITH FOCUS ON PROSTATE CANCER. *Cells*. 2020;9(6):E1495. doi:10.3390/cells9061495
237. Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. NEW FRONTIERS IN PROSTATE CANCER TREATMENT: ARE WE READY FOR DRUG COMBINATIONS WITH NOVEL AGENTS? *Cells*. 2020;9(6):E1522. doi:10.3390/cells9061522
238. Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. MODULATION IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN RECEPTOR (AR)-TARGETED THERAPY. *J Clin Med*. 2020;9(6):E1950. doi:10.3390/jcm9061950
239. Rizzo A, Mollica V, Massari F. RE: HANBING SONG, BOBAK SEDDIGHZADEH, MATTHEW R. COOPERBERG, FRANKLIN W. HUANG. EXPRESSION OF ACE2 AND TMPRSS2, THE SARS-COV-2 RECEPTOR AND CO-RECEPTOR, IN PROSTATE EPITHELIAL CELLS. *EUR UROL*. IN PRESS DOI: 10.1016/J.EURURO.2020.04.065. *Eur Urol*. 2020;S0302-2838(20)30463-2. doi:10.1016/j.eururo.2020.06.034
240. Massari F, Mollica V. RE: PLATINUM-BASED CHEMOTHERAPY IN METASTATIC PROSTATE CANCER WITH DNA REPAIR GENE ALTERATIONS. *Eur Urol*. 2020;S0302-2838(20)30442-5. doi:10.1016/j.eururo.2020.06.013
241. Mollica V, Rizzo A, Massari F. RE: TONI K. CHOUERI, DANIEL Y.C. HENG, JAE LYUN LEE, ET AL. EFFICACY OF SAVOLITINIB VS SUNITINIB IN PATIENTS WITH MET-DRIVEN PAPILLARY RENAL CELL CARCINOMA: THE SAVOIR PHASE 3 RANDOMIZED CLINICAL TRIAL. *JAMA ONCOL*. IN PRESS. [HTTPS://DOI.ORG/10.1001/JAMAONCOL.2020.2218](https://doi.org/10.1001/JAMAONCOL.2020.2218): SAVOIR: FROM OWN GOAL TO WINNING GOAL? *European Urology Oncology* 2020
242. Mollica V, Rizzo A, Massari F. THE PIVOTAL ROLE OF TMPRSS2 IN CORONAVIRUS DISEASE 2019 AND PROSTATE CANCER. *Future Oncol*. 2020;10.2217/fon-2020-0571. doi:10.2217/fon-2020-0571
243. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. CABOZANTINIB AFTER A PREVIOUS IMMUNE CHECKPOINT INHIBITOR IN METASTATIC RENAL CELL CARCINOMA: A RETROSPECTIVE MULTI-INSTITUTIONAL ANALYSIS. *Target Oncol*. 2020;10.1007/s11523-020-00732-y. doi:10.1007/s11523-020-00732-y
244. Massari F, Di Nunno V, Guida A, Costa Silva CA, Derosa L, Mollica V, Colomba E, Brandi G, Albiges L. ADDITION OF PRIMARY METASTATIC SITE ON BONE, BRAIN, AND LIVER TO IMDC CRITERIA IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: A VALIDATION STUDY. *Clin Genitourin Cancer*. 2020;S1558-7673(20)30142-7. doi:10.1016/j.clgc.2020.06.003

245. Maggio I, Mollica V, Del Governatore M, Giunchi F, Massucci M, Manuzzi L, Caira A, Fiorentino M, Brandi G, Massari F. GALLBLADDER METASTASIS FROM CLEAR CELL RENAL CELL CARCINOMA: A RARE SITE OF PRESENTATION OF METASTATIC DISEASE. *Journal of Case Reports* 2020;10(3):148-151
246. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. COMBINATION THERAPY IN ADVANCED UROTHELIAL CANCER: THE ROLE OF PARP, HER-2 AND MTOR INHIBITORS. *Expert Rev Anticancer Ther.* 2020 Aug 6. doi: 10.1080/14737140.2020.1807334. Epub ahead of print.
247. Massari F, Mollica V, Rizzo A, Cosmai L, Rizzo M, Porta C. SAFETY EVALUATION OF IMMUNE-BASED COMBINATIONS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Expert Opin Drug Saf.* 2020; doi:10.1080/14740338.2020.1811226
248. Rizzo A, Mollica V, Cimadamore A, Santoni A, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. IS THERE A ROLE FOR IMMUNOTHERAPY IN PROSTATE CANCER? *Cells* 2020, 9, 2051
249. Lorient Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Gordo TA, Skoneczna I, Fay AP, Nolè F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. SAFETY AND EFFICACY OF ATEZOLIZUMAB IN PATIENTS WITH AUTOIMMUNE DISEASE: SUBGROUP ANALYSIS OF THE SAUL STUDY IN LOCALLY ADVANCED/METASTATIC URINARY TRACT CARCINOMA. *Eur J Cancer.* 2020 Sep 6;138:202-211. doi: 10.1016/j.ejca.2020.07.023. Epub ahead of print. PMID: 32905959.
250. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. DESIGNING NOVEL IMMUNOCOMBINATIONS IN METASTATIC RENAL CELL CARCINOMA. *Immunotherapy* 2020. doi: 10.2217/imt-2020-0144
251. Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. RE: ALFONSO GÓMEZ DE LIAÑO LISTA, NICK VAN DIJK, GUILLERMO DE VELASCO ORIA DE RUEDA, ET AL. CLINICAL OUTCOME AFTER PROGRESSING TO FRONTLINE AND SECONDLINE ANTI-PD-1/PD-L1 IN ADVANCED UROTHELIAL CANCER. *EUR UROL* 2020;77:269–76. *European Urology* 79 (2021); E17-E19.
252. Brandi G, Deserti M, Palloni A, Turchetti D, Zuntini R, Pedica F, Frega G, De Lorenzo S, Abbati F, Rizzo A, Di Marco M, Massari F, Tavolari S. INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS. *Cancer Genet.* 2020 Oct 11: S2210-7762(20)30276-3. doi: 10.1016/j.cancergen.2020.10.001. Epub ahead of print.
253. Rizzo A, Mollica V, Massari F. RE: NIZAR M. TANNIR, SABINA SIGNORETTI, TONI K. CHOUERI, ET AL. EFFICACY AND SAFETY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS SUNITINIB IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED SARCOMATOID RENAL CELL CARCINOMA. *CLIN CANCER RES. IN PRESS.* [HTTPS://DOI.ORG/10.1158/1078-0432.CCR-20-2063](https://doi.org/10.1158/1078-0432.CCR-20-2063). *Eur Urol Oncol.* 3(2020); 804-805.. doi: 10.1016/j.euo.2020.10.005.
254. Rizzo A, Mollica V, Massari F. RE: MAHA HUSSAIN, JOAQUIN MATEO, KARIM FIZAZI, ET AL. SURVIVAL WITH OLAPARIB IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. *N ENGL J MED. IN PRESS.* [HTTPS://DOI.ORG/10.1056/NEJMOA2022485](https://doi.org/10.1056/NEJMOA2022485). *Eur Urol Oncol* 3 (2020); 806 <https://doi.org/10.1016/j.euo.2020.10.004>
255. Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, Scarpelli M, Santoni M, Cimadamore A, Cheng L. INTRADUCTAL CARCINOMA OF THE PROSTATE: PATHOGENESIS AND MOLECULAR PERSPECTIVES. *Eur Urol Focus* 2020 <https://doi.org/10.1016/j.euf.2020.10.007> Epub ahead of print.
256. Dall'Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. IMMORTAL TIME BIAS IN THE ASSOCIATION BETWEEN TOXICITY AND RESPONSE FOR IMMUNE CHECKPOINT INHIBITORS: A META-ANALYSIS. *Immunotherapy* 2020 doi: 10.2217/imt-2020-0179 Epub ahead of print
257. Santoni M, Piva F, Porta C, Bracarda S, Heng DY, Matrana MR, Grande E, Mollica V, Aurilio G, Rizzo M, Giulietti M, Montironi R, Massari F. ARTIFICIAL NEURAL NETWORKS AS A WAY TO PREDICT FUTURE KIDNEY CANCER

- INCIDENCE IN THE UNITED STATES. Clin Genitourin Cancer. 2020 Nov 10:S1558-7673(20)30250-0. doi: 10.1016/j.clgc.2020.10.008. Epub ahead of print.
258. De Giglio A, Scorsetti M, Franceschini D, Massari F, Ardizzoni A. BILATERAL RADIATION RECALL PNEUMONITIS DURING IMMUNOTHERAPY FOR AN ADVANCED RENAL CELL CARCINOMA: A CHALLENGING CASE ENHANCES THE NEED FOR A MULTIDISCIPLINARY APPROACH. Eur J Cancer. 2020 Dec 3;143:75-77. doi: 10.1016/j.ejca.2020.10.024. Epub ahead of print.
 259. Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. PROGNOSTIC AND PREDICTIVE FACTORS TO NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: A SINGLE CENTER STUDY. Anticancer Drugs. 2020 Dec 7. doi: 10.1097/CAD.0000000000001017. Epub ahead of print.
 260. Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. ANDROGEN RECEPTOR SIGNALING PATHWAY IN PROSTATE CANCER: FROM GENETICS TO CLINICAL APPLICATIONS. Cells. 2020 Dec 10;9(12):E2653. doi: 10.3390/cells9122653.
 261. Mollica V, Rizzo A, Massari F. AVELUMAB MAINTENANCE FOR UROTHELIAL CARCINOMA. N Engl J Med. 2020 Dec 17;383(25):2482. doi: 10.1056/NEJMc2032018.
 262. Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF BLADDER CANCER. Cancers (Basel). 2021 Jan 3;13(1):E131. doi: 10.3390/cancers13010131.
 263. Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A. DUAL TMPRSS2:ERG FUSION IN A PATIENT WITH LUNG AND PROSTATE CANCERS. Diagnostics (Basel). 2020 Dec 20;10(12):E1109. doi: 10.3390/diagnostics10121109
 264. Massucci M, Mollica V, Rizzo A, Ventrella L, Maggio I, Manuzzi L, Gatto L, Brandi G, Massari F. ENCEPHALIC LEUKOCYTOCLASTIC VASCULITIS DURING TREATMENT WITH SUNITINIB FOR RENAL CELL CARCINOMA: A CASE REPORT. Medicines 2021, 8, 5. <https://doi.org/10.3390/medicines8010005>
 265. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Carteni G, Grande 1E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. BODY MASS INDEX IN PATIENTS TREATED WITH CABOZANTINIB FOR ADVANCED RENAL CELL CARCINOMA: A NEW PROGNOSTIC FACTOR? Diagnostics 2021, 11, 138. <https://doi.org/10.3390/diagnostics11010138>
 266. Rizzo A, Mollica V, Massari F. EXPRESSION OF PROGRAMMED CELL DEATH LIGAND 1 AS A PREDICTIVE BIOMARKER IN METASTATIC UROTHELIAL CARCINOMA PATIENTS TREATED WITH FIRST-LINE IMMUNE CHECKPOINT INHIBITORS VERSUS CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS. Eur Urol Focus. 2021 Jan 27:S2405-4569(21)00004-3. doi: 10.1016/j.euf.2021.01.003. Epub ahead of print.
 267. Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, Fiorentino M, Massari F. RENAL TUMORS WITH ONCOCYTIC AND PAPILLARY FEATURES: A PHENOTYPIC AND GENOTYPIC STUDY. Diagnostics (Basel). 2021 Jan 28;11(2):184. doi: 10.3390/diagnostics11020184.
 268. Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimadamore A, Scarpelli M, Bonucci C, Andriani E, Errani C, Santoni M, Montironi R, Massari F. BONE TARGETING AGENTS IN PATIENTS WITH METASTATIC PROSTATE CANCER: STATE OF THE ART. Cancers (Basel). 2021 Feb 1;13(3):546. doi: 10.3390/cancers13030546.
 269. de Velasco G, Ruiz-Granados Á, Reig O, Massari F, Climent Duran MA, Verzoni E, Graham J, Llaena R, De Tursi M, Donskov F, Iglesias C, Pandha HS, Del Muro XG, Procopio G, Oudard S, Castellano D, Albiges L. OUTCOMES OF SYSTEMIC TARGETED THERAPY IN RECURRENT RCC RENAL CELL CARCINOMA TREATED WITH ADJUVANT SUNITINIB. BJU Int. 2021 Feb 6. doi: 10.1111/bju.15356.

270. Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. RE: HUMAN CHIMERIC ANTIGEN RECEPTOR MACROPHAGES FOR CANCER IMMUNOTHERAPY. *Eur Urol*. 2021 Feb 3:S0302-2838(21)00064-6. doi: 10.1016/j.eururo.2021.01.025. Epub ahead of print.
271. Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, Fiorentino M, Giunchi F, Massari F. BROAD SPECTRUM MUTATIONAL ANALYSIS OF CHROMOPHOBE RENAL CELL CARCINOMA USING NEXT-GENERATION SEQUENCING. *Pathol Res Pract*. 2021 Feb 1;219:153350. doi: 10.1016/j.prp.2021.153350. Epub ahead of print.
272. Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. TREATING PROSTATE CANCER BY ANTIBODY-DRUG CONJUGATES. *Int J Mol Sci*. 2021 Feb 4;22(4):1551. doi: 10.3390/ijms22041551
273. Massari F, Rizzo A, Mollica V, Santoni M. A BRAND-NEW CAR FOR MACROPHAGES: IS IT TIME TO FIRE UP THE ENGINES OF A NEW ERA FOR THE TREATMENT OF RENAL CELL CARCINOMA? *Future Oncol*. 2021 Feb 16. doi: 10.2217/fo-2021-0089. Epub ahead of print.
274. Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. AN UPDATE ON INVESTIGATIONAL THERAPIES THAT TARGET STAT3 FOR THE TREATMENT OF CANCER. *Expert Opin Investig Drugs*. 2021 Feb 18. doi: 10.1080/13543784.2021.1891222. Epub ahead of print.
275. Ciccicarese F, Piccinino A, Brocchi S, Balacchi C, Dall'Olio FG, Massari F, Rihawi K, Paccapelo A, Ardizzoni A, Golfieri R. EXPECTED AND NON-EXPECTED IMMUNE-RELATED ADVERSE EVENTS DETECTABLE BY CT. *Eur J Radiol*. 2021 Feb 25;138:109617. doi: 10.1016/j.ejrad.2021.109617. Epub ahead of print.
276. Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. IMPACT OF CLINICOPATHOLOGICAL FEATURES ON SURVIVAL IN PATIENTS TREATED WITH FIRST-LINE IMMUNE CHECKPOINT INHIBITORS PLUS TYROSINE KINASE INHIBITORS FOR RENAL CELL CARCINOMA: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS. *Eur Urol Focus*. 2021 Mar 10:S2405-4569(21)00058-4. doi: 10.1016/j.euf.2021.03.001. Epub ahead of print.
277. Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F. IMPACT OF HER2 ASSESSMENT BY CISH IN UROTHELIAL CARCINOMA: A RETROSPECTIVE SINGLE-CENTER EXPERIENCE. *Pathol Res Pract*. 2021 Mar 18; 220:153410. doi: 10.1016/j.prp.2021.153410. Epub ahead of print.
278. Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. DETERMINANTS OF TREATMENT FOR FIRST-LINE IMMUNE-BASED COMBINATIONS IN METASTATIC RENAL CELL CARCINOMA: A CRITICAL OVERVIEW OF RECENT EVIDENCE. *Immunotherapy*. 2021 Apr 7. doi: 10.2217/imt-2020-0323. Epub ahead of print.
279. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordo T, Merchan JR, Winkquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutkus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. LENVATINIB PLUS PEMBROLIZUMAB OR EVEROLIMUS FOR ADVANCED RENAL CELL CARCINOMA. *N Engl J Med*. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
280. Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. TOWARDS A NEW WHO CLASSIFICATION OF RENAL CELL TUMOR: WHAT THE CLINICIAN NEEDS TO KNOW-A NARRATIVE REVIEW. *Transl Androl Urol*. 2021 Mar;10(3):1506-1520. doi: 10.21037/tau-20-1150.
281. Aurilio G, Cimadamore A, Lopez-Beltran A, Scarpelli M, Massari F, Verri E, Cheng L, Santoni M, Montironi R. NARRATIVE REVIEW: UPDATE ON IMMUNOTHERAPY AND PATHOLOGICAL FEATURES IN PATIENTS WITH BLADDER CANCER. *Transl Androl Urol*. 2021 Mar;10(3):1521-1529. doi: 10.21037/tau-20-1436.

282. Montironi R, Cheng L, Cimdamore A, Mazzucchelli R, Scarpelli M, Santoni M, Massari F, Lopez-Beltran A. NARRATIVE REVIEW OF PROSTATE CANCER GRADING SYSTEMS: WILL THE GLEASON SCORES BE REPLACED BY THE GRADE GROUPS? *Transl Androl Urol*. 2021 Mar;10(3):1530-1540. doi: 10.21037/tau-20-853.
283. Rizzo A, Mollica V, Cimdamore A, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F. TNM STAGING TOWARDS A PERSONALIZED APPROACH IN METASTATIC UROTHELIAL CARCINOMA: WHAT WILL THE FUTURE BE LIKE? A NARRATIVE REVIEW. *Transl Androl Urol*. 2021 Mar;10(3):1541-1552. doi: 10.21037/tau-20-1109.
284. Santoni M, Cimdamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R. NARRATIVE REVIEW: PREDICTING FUTURE MOLECULAR AND CLINICAL PROFILES OF PROSTATE CANCER IN THE UNITED STATES. *Transl Androl Urol*. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.
285. Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimdamore A, Montironi R, Massari F. ADJUVANT THERAPY IN RENAL CELL CARCINOMA: IS IT THE RIGHT STRATEGY TO INHIBIT VEGF? *Transl Androl Urol*. 2021 Mar;10(3):1581-1587. doi: 10.21037/tau-20-1125.
286. Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F. EXPLORING THE ASSOCIATION BETWEEN METASTATIC SITES AND ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A META-ANALYSIS OF PROSPECTIVE CLINICAL TRIALS. *Pathol Res Pract*. 2021 Apr 9;222:153440. doi: 10.1016/j.prp.2021.153440. Epub ahead of print.
287. Rizzo A, Mollica V, Dall'Olio FG, Ricci AD, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F. QUALITY OF LIFE ASSESSMENT IN RENAL CELL CARCINOMA PHASE II AND III CLINICAL TRIALS PUBLISHED BETWEEN 2010 AND 2020: A SYSTEMATIC REVIEW. *Future Oncol*. 2021 Apr 21. doi: 10.2217/fon-2021-0069. Epub ahead of print.
288. Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. COMPARATIVE EFFECTIVENESS OF FIRST-LINE IMMUNE CHECKPOINT INHIBITORS PLUS TYROSINE KINASE INHIBITORS ACCORDING TO IMDC RISK GROUPS IN METASTATIC RENAL CELL CARCINOMA: A META-ANALYSIS. *Immunotherapy*. 2021 Apr 28. doi: 10.2217/imt-2021-0005. Epub ahead of print.
289. Santoni M, Massari F, Montironi R, Battelli N. MANIPULATING MACROPHAGE POLARIZATION IN CANCER PATIENTS: FROM NANOPARTICLES TO HUMAN CHIMERIC ANTIGEN RECEPTOR MACROPHAGES. *Biochim Biophys Acta Rev Cancer*. 2021 Apr 28:188547. doi: 10.1016/j.bbcan.2021.188547. Epub ahead of print.
290. Cimdamore A, Rizzo A, Mollica V, Massari F, Lopez-Beltran A, Scarpelli M, Cheng L, Santoni M, Montironi R. AN UPDATE ON IMMUNOTHERAPY IN URO-ONCOLOGY. *Exp Rew of Prec Med and Drug Dev* 2021 <https://doi.org/10.1080/23808993.2021.1911638>
291. Rizzo A, Mollica V, Massari F. CONSIDERATIONS REGARDING A NETWORK META-ANALYSIS OF SYSTEMIC TREATMENTS FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER. *JAMA Oncol*. 2021 May 13. doi: 10.1001/jamaoncol.2021.0960. Epub ahead of print.
292. Rizzo A, Mollica V, Massari F. RE: THOMAS POWLES, JONATHAN E. ROSENBERG, GURU P. SONPAVDE, ET AL. ENFORTUMAB VEDOTIN IN PREVIOUSLY TREATED ADVANCED UROTHELIAL CARCINOMA. *N ENGL J MED* 2021;384:1125-35. *Eur Urol Oncol*. 2021 May 13:S2588-9311(21)00084-5. doi: 10.1016/j.euo.2021.04.010. Epub ahead of print.
293. Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. PEMBROLIZUMAB PLUS LENVATINIB OR AXITINIB COMPARED TO NIVOLUMAB PLUS IPILIMUMAB OR CABOZANTINIB IN ADVANCED RENAL CELL CARCINOMA: A NUMBER NEEDED TO TREAT ANALYSIS. *Expert Rev Pharmacoecon Outcomes Res*. 2021 Jun 1. doi: 10.1080/14737167.2021.1937130. Epub ahead of print.
294. Cimdamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R. CIRCULATING TUMOR DNA TESTING FOR HOMOLGY RECOMBINATION REPAIR GENES IN

- PROSTATE CANCER: FROM THE LAB TO THE CLINIC. *Int J Mol Sci.* 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
295. Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, Massari F, Fraccon AP, Mucciarini C, Sava T, Santoni M, Pegoraro C, Durante E, Nicodemo M, Perin A, Bearz A, Gatti C, Fiduccia P, Diminutto A, Barile C, De Giorgi U, Zamarchi R, Zagonel V. PROGNOSTIC ROLE OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC RENAL CELL CARCINOMA: A LARGE, MULTICENTER PROSPECTIVE TRIAL. *Oncologist.* 2021 Jun 2. doi: 10.1002/onco.13842. Epub ahead of print.
 296. Rizzo A, Mollica V, Massari F. ADJUVANT IMMUNOTHERAPY IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA. *Lancet Oncol.* 2021 Jun;22(6):e237. doi: 10.1016/S1470-2045(21)00202-3.
 297. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. THE MOLECULAR CHARACTERISTICS OF NON-CLEAR CELL RENAL CELL CARCINOMA: WHAT'S THE STORY MORNING GLORY? *Int J Mol. Sci.* 2021, 22, 6237. <https://doi.org/10.3390/ijms22126237>
 298. Rizzo A, Mollica V, Santoni M, Massari F. RISK OF SELECTED GASTROINTESTINAL TOXICITIES IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNO-TKI COMBINATIONS: A META-ANALYSIS. *Expert Rev Gastroenterol Hepatol.* 2021 Jun 25. doi: 10.1080/17474124.2021.1948328. Epub ahead of print.
 299. Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. LENVATINIB PLUS PEMBROLIZUMAB: THE NEXT FRONTIER FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA? *Expert Opin Investig Drugs.* 2021 Jun 25. doi: 10.1080/13543784.2021.1948532. Epub ahead of print.
 300. Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, Santoni M. IMMUNE-BASED COMBINATIONS FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA: A META-ANALYSIS OF RANDOMISED CLINICAL TRIALS. *Eur J Cancer.* 2021 Jul 12;154:120-127. doi: 10.1016/j.ejca.2021.06.015. Epub ahead of print.
 301. Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R. PROSTATE CANCER IN 2021: NOVELTIES IN PROGNOSTIC AND THERAPEUTIC BIOMARKER EVALUATION. *Cancers (Basel).* 2021 Jul 11;13(14):3471. doi: 10.3390/cancers13143471.
 302. Mollica V, Brocchi S, Dall'Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, Ardizzoni A. TUMOR GROWTH RATE DECLINE DESPITE PROGRESSIVE DISEASE MAY PREDICT IMPROVED NIVOLUMAB TREATMENT OUTCOME IN mRCC: WHEN RECIST IS NOT ENOUGH. *Cancers (Basel).* 2021 Jul 12;13(14):3492. doi: 10.3390/cancers13143492
 303. Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. CABOZANTINIB IN PRETREATED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID DIFFERENTIATION: A REAL-WORLD STUDY. *Target Oncol.* 2021 Aug 2. doi: 10.1007/s11523-021-00828-z.
 304. Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A META-ANALYSIS ON OVERALL SURVIVAL AND SAFETY OUTCOMES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH NOVEL HORMONAL AGENTS. *Anticancer Drugs.* 2021 Aug 11. doi: 10.1097/CAD.0000000000001168. Epub ahead of print.
 305. Ricci AD, Rizzo A, Mollica V, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. PLATINUM-BASED ADJUVANT CHEMOTHERAPY FOR UPPER TRACT UROTHELIAL CARCINOMA: A CHANGE OF PARADIGM? A META-ANALYSIS OF AGGREGATE DATA. *Anticancer Drugs.* 2021 Aug 11. doi: 10.1097/CAD.0000000000001200. Epub ahead of print.
 306. Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. AN UP-TO-DATE EVALUATION OF CABOZANTINIB FOR THE TREATMENT OF RENAL CELL CARCINOMA. *Expert Opin Pharmacother.* 2021 Aug 18:1-14. doi: 10.1080/14656566.2021.1959548. Epub ahead of print.

307. Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, Santoni M, Massari F. RISK OF CARDIOVASCULAR TOXICITIES AND HYPERTENSION IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH NOVEL HORMONAL AGENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Expert Opin Drug Metab Toxicol*. 2021 Aug 19. doi: 10.1080/17425255.2021.1970745. Epub ahead of print
308. Rizzo A, Mollica V, Massari F. RANDOMIZED CLINICAL TRIALS IN THE ERA OF PRECISION ONCOLOGY-THE ROLE OF END POINTS, INDUSTRY FUNDING, AND MEDICAL WRITING INTEGRITY. *JAMA Oncol*. 2021 Aug 26. doi: 10.1001/jamaoncol.2021.3335. Epub ahead of print.
309. Mollica V, Rizzo A, Massari F. ADJUVANT NIVOLUMAB IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA. *N Engl J Med*. 2021 Sep 2;385(10):956-957. doi: 10.1056/NEJMc2110897
310. Mollica V, Rizzo A, Massari F. RE: THOMAS POWLES, TIBOR CSŐSZI, MUSTAFA ÖZGÜROĞLU, ET AL. PEMBROLIZUMAB ALONE OR COMBINED WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (KEYNOTE-361): A RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL. *LANCET ONCOL*. IN PRESS. [HTTPS://DOI.ORG/10.1016/S1470-2045\(21\)00152-2](https://doi.org/10.1016/S1470-2045(21)00152-2): THE CONFLICT OF ADDING IMMUNOTHERAPY TO CHEMOTHERAPY IN METASTATIC UROTHELIAL CARCINOMA: A MATTER OF THE RIGHT TIMING? *Eur Urol Oncol*. 2021 Sep 14:S2588-9311(21)00151-6. doi: 10.1016/j.euo.2021.06.008. Epub ahead of print.
311. Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. MICROBIOTA AND PROSTATE CANCER. *Semin Cancer Biol*. 2021 Sep 15:S1044-579X(21)00230-3. doi: 10.1016/j.semcancer.2021.09.007. Epub ahead of print.
312. Basso U, Procopio G, Fornarini G, Massari F, Bearz A, Fratino L, Milella M, Bassanelli M, Ermacora P, Bimbatti D, Verzoni E, Rizzo M, Porta C. SAFETY AND EFFICACY OF TIVOZANIB IN FIRST-LINE MRCC: A MULTICENTER COMPASSIONATE-USE STUDY (Meet-Uro 16). *Oncology*. 2021 Sep 28;1-9. doi: 10.1159/000515951. Epub ahead of print.
313. Ricci C, Franceschini T, Giunchi F, Borsato M, Mollica V, Massari F, Fiorentino M. A PRELIMINARY STUDY INVESTIGATING THE DETECTION OF LYMPHOVASCULAR INVASION IN GERM CELL TUMORS OF THE TESTIS WITH DOUBLE STAINING FOR OCT4/CD34. *Pathol Res Pract*. 2021 Sep 29;227:153637. doi: 10.1016/j.prp.2021.153637. Epub ahead of print.
314. Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. METABOLOMIC PROFILING IN RENAL CELL CARCINOMA PATIENTS: NEWS AND VIEWS. *Cancers (Basel)*. 2021 Oct 18;13(20):5229. doi: 10.3390/cancers13205229.
315. Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, Bracarda S, Procopio G, Porta C. GU-CA-COVID: A CLINICAL AUDIT AMONG ITALIAN GENITOURINARY ONCOLOGISTS DURING THE FIRST COVID-19 OUTBREAK. *Ther Adv Urol*. 2021 Oct 22;13:17562872211054302. doi: 10.1177/17562872211054302
316. Rizzo A, Mollica V, Santoni M, Massari F. CANCER IMMUNOTHERAPY: CURRENT AND FUTURE PERSPECTIVES ON A THERAPEUTIC REVOLUTION. *J Clin Med*. 2021 Nov 11;10(22):5246. doi: 10.3390/jcm10225246
317. Ricci C, Franceschini T, Giunchi F, Grillini M, Ambrosi F, Massari F, Mollica V, Colecchia M, Fiorentino M. IMMUNOHISTOCHEMICAL EXPRESSION OF PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) IN THE UNINVOLVED BACKGROUND TESTIS, GERM CELL NEOPLASIA IN SITU, AND GERM CELL TUMORS OF THE TESTIS. *Am J Clin Pathol*. 2021 Dec 1;aqab200. doi: 10.1093/ajcp/aqab200. Epub ahead of print.
318. Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Blevé S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. CONCOMITANT PROTON PUMP INHIBITORS AND OUTCOME OF PATIENTS TREATED WITH NIVOLUMAB ALONE OR PLUS IPILIMUMAB FOR ADVANCED RENAL CELL CARCINOMA. *Target Oncol*. 2021 Dec 11. doi: 10.1007/s11523-021-00861-y. Epub ahead of print.

319. Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. FIRST-LINE PAZOPANIB IN PATIENTS WITH ADVANCED NON-CLEAR CELL RENAL CARCINOMA: AN ITALIAN CASE SERIES. *World J Clin Oncol*. 2021 Nov 24;12(11):1037-1046. doi: 10.5306/wjco.v12.i11.1037
320. Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. RISK OF TOXICITY WITH IMMUNOTHERAPY-TYROSINE KINASE INHIBITORS FOR METASTATIC RENAL CELL CARCINOMA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. *Future Oncol*. 2021 Dec 20. doi: 10.2217/fon-2021-0888. Epub ahead of print
321. Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. CURRENT ANDROGEN RECEPTOR ANTAGONISTS UNDER INVESTIGATION FOR RESISTANT PROSTATE CANCER. *Expert Rev Anticancer Ther*. 2021 Dec 20. doi: 10.1080/14737140.2022.2020651. Epub ahead of print.
322. Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. AN INSIGHT ON NOVEL MOLECULAR PATHWAYS IN METASTATIC PROSTATE CANCER: A FOCUS ON DDR, MSI AND AKT. *Int J Mol Sci*. 2021 Dec 16;22(24):13519. doi: 10.3390/ijms222413519.
323. Nuvola G, Rizzo A, Mollica V, Massari F. THE DILEMMA OF NEOADJUVANT AND ADJUVANT THERAPY IN UROTHELIAL CARCINOMA: WILL IMMUNOTHERAPY SOLVE THE PROBLEM? *Immunotherapy*. 2022 Jan 10. doi: 10.2217/imt-2021-0324. Epub ahead of print.
324. Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. PERIPHERAL NEUROPATHY AND HEADACHE IN CANCER PATIENTS TREATED WITH IMMUNOTHERAPY AND IMMUNO-ONCOLOGY COMBINATIONS: THE MOUSEION-02 STUDY. *Expert Opin Drug Metab Toxicol*. 2022 Jan 14. doi: 10.1080/17425255.2021.2029405. Epub ahead of print.
325. Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. THE IMPACT OF GENDER ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS: THE MOUSEION-01 STUDY. *Crit Rev Oncol Hematol*. 2022 Jan 11:103596. doi: 10.1016/j.critrevonc.2022.103596. Epub ahead of print.
326. Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. IMPACT OF CLINICOPATHOLOGICAL FEATURES ON IMMUNE-BASED COMBINATIONS FOR ADVANCED UROTHELIAL CARCINOMA: A META-ANALYSIS. *Future Oncol*. 2022 Jan 20. doi: 10.2217/fon-2021-0841. Epub ahead of print.
327. Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. CABOZANTINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA PRIMARY REFRACTORY TO FIRST-LINE IMMUNOCOMBINATIONS OR TYROSINE KINASE INHIBITORS. *Eur Urol Focus*. 2022 Feb 19:S2405-4569(22)00049-9. doi: 10.1016/j.euf.2022.02.004. Epub ahead of print.
328. Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, Fanti S, Massari F. PARP INHIBITORS AND RADIOMETABOLIC APPROACHES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: WHAT'S NOW, WHAT'S NEW, AND WHAT'S COMING? *Cancers (Basel)*. 2022 Feb 11;14(4):907. doi: 10.3390/cancers14040907.
329. Rizzo A, Mollica V, Santoni M, Palmiotti G, Massari F. PATHOLOGIC COMPLETE RESPONSE IN UROTHELIAL CARCINOMA PATIENTS RECEIVING NEOADJUVANT IMMUNE CHECKPOINT INHIBITORS: A META-ANALYSIS. *J Clin Med*. 2022 Feb 17;11(4):1038. doi: 10.3390/jcm11041038.
330. Ciccarese C, Iacovelli R, Buti S, Primi F, Astore S, Massari F, Ferrara MG, Palermo G, Foschi N, Iacovelli V, Rossi E, Schinzari G, Bove P, Bassi P, Bria E, Tortora G. CONCURRENT NIVOLUMAB AND METFORMIN IN DIABETIC CANCER PATIENTS: IS IT SAFE AND MORE ACTIVE? *Anticancer Res*. 2022 Mar;42(3):1487-1493. doi: 10.21873/anticancer.15620.

- 331.Rebuzzi SE, Cerbone L, Signori A, Santoni M, Murianni V, De Giorgi U, Procopio G, Porta C, Milella M, Basso U, Massari F, Maruzzo M, Iacovelli R, Battelli N, Carmisciano L, Banna GL, Buti S, Fornarini G. APPLICATION OF THE MEET-URO SCORE TO METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH SECOND- AND THIRD-LINE CABOZANTINIB. *Ther Adv Med Oncol.* 2022 Feb 26;14:17588359221079580. doi: 10.1177/17588359221079580.
- 332.Rizzo A, Mollica V, Massari F. CABOZANTINIB FOR TREATMENT OF BRAIN METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA. *JAMA Oncol.* 2022 Mar 3. doi: 10.1001/jamaoncol.2022.0049. Epub ahead of print
- 333.Medici F, Siepe G, Strigari L, Massari F, Buwenge M, Bisello S, Castellucci P, Fanti S, Cammelli S, Morganti AG. CARE-COMPLIANT STEREOTACTIC RADIOTHERAPY OF UROTHELIAL NODAL METASTASES: A CASE REPORT. *Mol Clin Oncol.* 2022 Apr;16(4):85. doi: 10.3892/mco.2022.2518. Epub 2022 Feb 18.
- 334.Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. IMMUNE CHECKPOINT INHIBITORS IN ADVANCED PROSTATE CANCER: CURRENT DATA AND FUTURE PERSPECTIVES. *Cancers (Basel).* 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245.
- 335.Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. NIVOLUMAB VERSUS CABOZANTINIB AS SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: A REAL-WORLD COMPARISON. *Clin Genitourin Cancer.* 2022 Feb 19:S1558-7673(22)00039-8. doi: 10.1016/j.clgc.2022.02.003. Epub ahead of print.
- 336.Mollica V, Nuvola G, Tassinari E, Nigro MC, Marchetti A, Rosellini M, Rizzo A, Errani C, Massari F. Bone TARGETING AGENTS IN PATIENTS WITH PROSTATE CANCER: GENERAL TOXICITIES AND OSTEONECROSIS OF THE JAW. *Curr Oncol.* 2022 Mar 5;29(3):1709-1722. doi: 10.3390/curroncol29030142.
- 337.Rizzo A, Mollica V, Santoni M, Massari F. ASSESSING PD-L1 STATUS IN MRCC TREATED WITH FIRST-LINE IMMUNE-BASED COMBINATIONS: A META-ANALYSIS. *Immunotherapy.* 2022 Apr 13. doi: 10.2217/imt-2021-0261. Epub ahead of print.
- 338.Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. DAROLUTAMIDE AND SURVIVAL IN METASTATIC, HORMONE-SENSITIVE PROSTATE CANCER. *N Engl J Med.* 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
- 339.Santoni M, Molina-Cerrillo J, Massari F, Montironi R, Grande E. RE: EFFECT OF IMMUNOTHERAPY TIME-OF-DAY INFUSION ON OVERALL SURVIVAL AMONG PATIENTS WITH ADVANCED MELANOMA IN THE USA (MEMOIR): A PROPENSITY SCORE-MATCHED ANALYSIS OF A SINGLE-CENTRE, LONGITUDINAL STUDY. *Eur Urol.* 2022 Mar 30:S0302-2838(22)01788-2. doi: 10.1016/j.eururo.2022.03.017. Epub ahead of print.
- 340.Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. INCIDENCE OF GRADE 3-4 ADVERSE EVENTS, DOSE REDUCTION AND TREATMENT DISCONTINUATION IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING PARP INHIBITORS: A META-ANALYSIS. *Expert Opin Drug Metab Toxicol.* 2022 Apr 29. doi: 10.1080/17425255.2022.2072727. Epub ahead of print.
- 341.Di Sciascio L, Ambrosi F, Franceschini T, Giunchi F, Franchini E, Massari F, Bianchi FM, Colecchia M, Fiorentino M, Ricci C. COULD DOUBLE STAIN FOR P53/CK20 BE A USEFUL DIAGNOSTIC TOOL FOR THE APPROPRIATE CLASSIFICATION OF FLAT UROTHELIAL LESIONS? *Pathol Res Pract.* 2022 May 6;234:153937. doi: 10.1016/j.prp.2022.153937. Epub ahead of print.
- 342.Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. APALUTAMIDE OR ENZALUTAMIDE IN CASTRATION-SENSITIVE PROSTATE CANCER: A NUMBER NEEDED TO TREAT ANALYSIS. *Tumori.* 2022 May 20:3008916221090323. doi: 10.1177/03008916221090323. Epub ahead of print.

343. Mollica V, Massari F, Rizzo A, Ferrara R, Menta AK, Adashek JJ. GENOMICS AND IMMUNOMICS IN THE TREATMENT OF UROTHELIAL CARCINOMA. *Curr Oncol*. 2022 May 12;29(5):3499-3518. doi: 10.3390/curroncol29050283.
344. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calio A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. VALIDATION OF A NOVEL THREE-DIMENSIONAL (3D FUSION) GROSS SAMPLING PROTOCOL FOR CLEAR CELL RENAL CELL CARCINOMA TO OVERCOME INTRATUMORAL HETEROGENEITY: THE MEET-URO 18 STUDY. *J Pers Med*. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.
345. Rizzo A, Santoni M, Mollica V, Ricci AD, Calabrò C, Cusmai A, Gadaleta-Caldarola G, Palmiotti G, Massari F. THE IMPACT OF CONCOMITANT PROTON PUMP INHIBITORS ON IMMUNOTHERAPY EFFICACY AMONG PATIENTS WITH UROTHELIAL CARCINOMA: A META-ANALYSIS. *J Pers Med*. 2022 May 20;12(5):842. doi: 10.3390/jpm12050842.
346. Raschi E, Fusaroli M, Massari F, Mollica V, Repaci A, Ardizzoni A, Poluzzi E, Pagotto U, Di Dalmazi G. THE CHANGING FACE OF DRUG-INDUCED ADRENAL INSUFFICIENCY IN THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM. *J Clin Endocrinol Metab*. 2022 Jun 15:dgac359. doi: 10.1210/clinem/dgac359. Epub ahead of print.
347. Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Morillo J, Myint ZW, Zabalza IO, Battelli N, Grande E. STATINS AND RENAL CELL CARCINOMA: ANTITUMOR ACTIVITY AND INFLUENCE ON CANCER RISK AND SURVIVAL. *Crit Rev Oncol Hematol*. 2022 Jun 16:103731. doi: 10.1016/j.critrevonc.2022.103731. Epub ahead of print.
348. Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F. TREATMENT OPTIONS FOR METASTATIC UROTHELIAL CARCINOMA AFTER FIRST-LINE CHEMOTHERAPY. *Cancer Manag Res*. 2022 Jun 13;14:1945-1960. doi: 10.2147/CMAR.S287904.
349. Marchese PV, Mollica V, De Biase D, Giunchi F, Tassinari E, Marchetti A, Rosellini M, Nuvola G, Maloberti T, Fiorentino M, Massari F. A HYPOTHESIS-GENERATING ANALYSIS ON THE ROLE OF TERT PROMOTER MUTATION IN ADVANCED UROTHELIAL CARCINOMA TREATED WITH IMMUNOTHERAPY. *Pathol Res Pract*. 2022 Jun 13;236:153983. doi: 10.1016/j.prp.2022.153983. Epub ahead of print.
350. Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta MG, Caserta C, Bimabatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. PRIMARY TUMOR SHRINKAGE AND THE EFFECT ON METASTATIC DISEASE AND OUTCOMES IN PATIENTS WITH ADVANCED KIDNEY CANCER WITH INTERMEDIATE OR POOR PROGNOSIS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB OR CABOZANTINIB. *Clin Genitourin Cancer*. 2022 Jun 9:S1558-7673(22)00131-8. doi: 10.1016/j.clgc.2022.06.006. Epub ahead of print.
351. Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. STATIN USE IMPROVES THE EFFICACY OF NIVOLUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA. *Eur J Cancer*. 2022 Jun 30;172:191-198. doi: 10.1016/j.ejca.2022.04.035. Epub ahead of print.

Book Chapters:

1. F. Massari, Translator, curator of the Italian version of "The Merck Manual" – Springer Editor, 18th edition 2006.
2. F. Massari, "ECM e Oncologia", in "Professione oncologo. Formazione e percorsi di crescita professionale continua", il Pensiero scientifico editore, novembre 2010, p. 187 ss.
3. F. Massari, "Cenni di terapia adiuvante", in "Camici invisibili" a cura di B. Buralli – D. Amoroso, Franco Angeli editore, 2011, p. 97 ss.
4. E. Bria, F. Massari, S. Pilotto, F. Maines, G. Tortora. "Neoplasie a sede primitiva ignota", in "La Medicina Oncologica", EDRA, edizione settembre 2013, cap. 18, pp. 691-707.
5. F. Massari, Translator, curator of the Italian version of "The Merck Manual" – Springer Editor, 19th edition (ISBN: 978-88-470-5497-4) 2011.
6. G. Di Lorenzo, G. Palmieri, A.R. Bianco, F. Massari, "Tumori Urologici", in "Core Curriculum Oncologia Clinica", MC Graw Hill Education, 2 edizione settembre 2015, cap. 14, pp.227-254 (ISBN: 978-88-386-3984-5)
7. E. Matano, F. Massari, E. Bria, "Emergenze in Oncologia", in "Core Curriculum Oncologia Clinica", MC Graw Hill Education, 2 edizione settembre 2015, cap. 21, pp.227-254 (ISBN: 978-88-386-3984-5)
8. M. Santoni, F. Massari, "mTOR Pathway in Renal Cell Carcinoma", in "Molecules to Medicine with mTOR", Academic Press, 2016, cap. 25, pp. 417-428 (DOI: 10.1016/B978-0-12-802733-2.00026-8)

COMPLETE LIST OF CERTIFICATES OF ATTENDANCE TO SCIENTIFIC CONFERENCES AND UPDATE MEETINGS.

- Infections in Oncology and Hematology. Bologna, June 21-23, 2004. (Italian)
- VI National Meeting of the Italian Association of Medical Oncology (AIOM). Bologna, September 21-24, 2004. (Italian)
- Gastric cancer. Bologna, November 22-24, 2004. (Italian)
- Strategies for the management of colorectal carcinoma. Bologna, December 14, 2004. (Italian)
- Treatment of lung metastases. Bologna, March 11, 2005. (Italian)
- Breast cancer in the older woman. Bologna, March 20-22, 2005.
- Adjuvant therapy of breast cancer: St. Gallen 2005. Bologna, April 5, 2005. (Italian)
- Meet the professor – Professor Aaron Goldhirsch - after St. Gallen 2005: what has changed in the treatment of breast cancer. Rimini, April 9, 2005. (Italian)
- Kidney cancer nowadays. Bologna, April 12, 2005. (Italian)
- Multidisciplinary international conference on gynecologic cancer. Bologna, June 8-10, 2005.
- Breast cancer therapy: from multidisciplinary approach to treatment planning; 5th educational interactive meeting. Bologna, June 11, 2005. (Italian)
- Targeted therapies in oncology. Bologna, June 20-22, 2005.
- Novel therapeutic approaches in the treatment of chest tumors. Bologna, September 13, 2005. (Italian)
- New trends in molecular imaging and nuclear medicine. Bologna, September 19-20, 2005.
- 81st National Meeting of the Italian Society of Gynecology and Obstetrics (SIGO). Bologna, September 21, 2005. (Italian)
- VII National Meeting of the Italian Association of Medical Oncology (AIOM). Naples, October 18-21, 2005. (Italian)
- Advanced course in senology after the screening era. Bologna, November 11, 2005.
- Current and future trends in bone metastatic disease. Bologna, November 15, 2005. (Italian)
- From bench to bedside: a comprehensive approach in the treatment of solid malignancies. Bologna, November 25, 2005. (Italian)
- Endocrine therapies for breast cancer: recent advances. Parma, December 1, 2005. (Italian)
- Melanoma: updates for improving clinical management. Bologna, January 24, 2006. (Italian)
- The road to a cure for HER2 positive breast cancer. Modena, February 24, 2006. (Italian)
- The treatment of colorectal carcinoma as of 2006. Bologna, March 24, 2006. (Italian)
- Multidisciplinary treatment of early breast cancer. Modena, March 27-28, 2006.
- Testicular germ cell tumors. Bologna, April 1, 2006. (Italian)
- Resectable breast cancer: guidelines, clinical judgement and medical treatment-oriented decision-making. Milan, May 15, 2006. (Italian)
- Medical Oncology National Forum. Adjuvant treatments. Bologna, May 25-26, 2006. (Italian)
- How to read and write a scientific paper: operative instructions. Rome, June 16-17, 2006. (Italian)
- Adjuvant therapy for breast cancer: treatment-oriented decision-making in the era of guidelines and recommendations; 6th educational interactive meeting. Bologna, June 23, 2006. (Italian)
- Training workshop aimed at professional development in Hemolymphopathology. Bologna, July 3-5, 2006. (Italian)
- A global approach to the treatment of advanced breast cancer from palliation to cure. Modena, September 21, 2006.
- Updates in Geriatric Oncology. Bologna, September 22, 2006. (Lecturer) (Italian)
- The development of cell therapy and regenerative medicine: research, biotechnologies, regulations and health. Bologna, September 29, 2006. (Italian)
- Advancements in hormonal therapy of breast cancer. Bologna, November 7, 2006. (Italian)
- VIII National Meeting of the Italian Association of Medical Oncology (AIOM). Milan, November 18-21, 2006. (Italian)
- Study Protocol ML20445 “SUN: Survey on the Lung Cancer Management”. Milan, November 21, 2006. (Italian)
- Therapeutic progress and perspectives in ovarian cancer. Bologna, December 1, 2006. (Italian)
- Combined treatments in gastrointestinal malignancies: clinical research and therapeutic perspectives. Bologna, December 5, 2006. (Italian)
- Treatment options and criteria for choosing the appropriate management of the advanced breast cancer patient. Modena, March 21, 2007. (Italian)
- Melanoma: research, diagnosis, treatment. Milano, May 11, 2007. (Italian)

- What clinical relevance of heart damage by drug therapy for breast cancer. Milan, May 25, 2007.
- Advances in Gynaecologic oncology. 19th National Meeting of the Italian Society of Gynecologic Oncology (SIOG). Milan, June 14, 2007. (Italian)
- Novel findings in the adjuvant hormonal therapy of breast cancer. 7th educational interactive workshop. Bologna, June 15, 2007. (Italian)
- 9th Milan Breast Cancer Conference. Milan, June 20-21, 2007. (Italian)
- III Educational Workshop of the Italian Association of Medical Oncology (AIOM) Young Investigators. Let's analyze and design a clinical trial together. Rome, June 22-23, 2007. (Italian)
- Progress in the management of breast cancer. Modena, September 13-15, 2007.
- 14th European Cancer Conference (ECCO 14). Barcelona, 23-27 Settembre 2007.
- State of the art and new perspective in recurrent ovarian, cervical and endometrial cancer. Bologna, October 3, 2007.
- IX National Meeting of the Italian Association of Medical Oncology (AIOM). Palermo, October 12-15, 2007. (Italian)
- Primary epithelial ovarian cancer. Modena, October 19, 2007.
- Postmenopausal breast cancer: clinical opinions by comparison. Bologna, October 25, 2007. (Italian)
- Certainties and uncertainties in Oncology: the role of taxanes in the light of evidence-based medicine. Bologna, October 26, 2007. (Italian)
- The management of the patient with metastatic renal cell carcinoma. Bologna, November 16, 2007. (Italian)
- Combined and translational treatments in gastroenteric malignancies. Bologna, November 29, 2007. (Italian)
- Therapeutic algorithm in lung cancer (NSCLC). Bologna, December 6-7, 2007. (Italian)
- Advances in the treatment of renal cell carcinoma. Berlin, February 28-29, 2008.
- How to assess the effect of targeted therapies: tests predictive of sensitivity, evaluation criteria and end-points. Bologna, March 6 – March 13 – April 17, 2008. (Italian)
- Special Care: specialists in renal cell carcinoma. Milan, May 22-23, 2008. (Italian)
- Breast cancer 2008. 8th educational interactive workshop. Bologna, June 13, 2008. (Italian)
- IV educational workshop of the Italian Association of Medical Oncology (AIOM) Young Investigators. From guidelines to clinical practice. Rome, June 20-21, 2008. (Italian)
- Renal Cell Carcinoma: the importance of a well-judged choice. Rome, September 26, 2008. (Italian)
- The surgical treatment of rare intraabdominal tumors and carcinomatoses. Bologna, October 2, 2008. (Italian)
- X National Meeting of the Italian Association of Medical Oncology (AIOM). Verona, October 11-14, 2008. (Italian)
- AIOM-sponsored inter-regional meeting (Emilia-Romagna, Marche, Umbria, Abruzzo). Targeted therapies: scientific evidence, clinical relevance and cost-effectiveness. Rimini, November 7, 2008. (Italian)
- Ariad investigator meeting. Prague, November 12, 2008.
- Sensible treatment strategy in the management of kidney cancer patient. Bologna, November 14, 2008. (Italian)
- Primary epithelial ovarian cancer. II Edition. Modena, 24 Novembre 2008.
- Multidisciplinary management in the context of targeted therapy for breast cancer. Bologna, November 27-28, 2008. (Italian)
- Novel findings in breast cancer: updates from San Antonio. Bologna, February 6, 2009. (Italian)
- Chemotherapy past to present: back to the future. Camogli, March 27-28, 2009. (Italian)
- Clinical share in kidney cancer. Experiences from theoretical and practical standpoints. Bologna, April 2, 2009. (Italian)
- UROcontest. Opinions in Uro-oncology: from guidelines to clinical practice. Rome, April 29, 2009. (Italian)
- Triple-negative breast cancer: a new disease entity or a new protocol entity? Milan, April 24, 2009. (Italian)
- The new treatment choice in ErbB2+ breast cancer. Bologna, May 15, 2009. (Italian)
- Breast cancer 2009. 9th educational interactive workshop. Bologna, June 12, 2009. (Lecturer) (Italian)
- V Educational Workshop of the Italian Association of Medical Oncology (AIOM) Young Investigators. Neo-adjuvant treatments in gastric, rectal and breast cancers: to whom, how, when and why. Rome, June 19-20, 2009. (Italian)
- Second Pavia International Symposium on Advanced Kidney Cancer. Pavia, June 26-27, 2009.
- AIOM (Young Investigators) - sponsored inter-regional meeting. 2009: news in Oncology. Perugia, July 10, 2009. (Italian).
- XI National Meeting of the Italian Association of Medical Oncology (AIOM). Milan, October 10-13, 2009.
- Renal cell carcinoma: pathology, diagnosis and treatment. Cleveland, November 3-4, 2009.

- The treatment of the patient with renal cell carcinoma. Bologna, November 13, 2009. (Lecturer) (Italian)
- Core Curriculum Uro-Oncology. Bertinoro (FC), November 26-28, 2009. (Italian)
- Therapeutic progresses and perspectives in ovarian cancer. Bologna, December 17, 2009.
- Nexpert. The approach to the patient with renal cell carcinoma: the optimization of the treatment. Milano, January 21-22, 2010. (Italian)
- Core Curriculum Uro-Oncology. Bertinoro (FC), March 11-13, 2010. (Italian)
- Sorafenib in the renal cell carcinoma: three years of experience. Leverkusen, May 3-5, 2010. (Lecturer).
- Renal cell carcinoma: new challenge in the biologic therapies era. Riva del Garda (VR), May 14-15, 2010. (Italian) (BEST ABSTRACT AWARD)
- XX National Congress of Italian Society of Oncologic Urology. Roma, June 23-25, 2010. (Italia) (Lecturer)
- 2010: News in Oncology. Perugia, 9-10 Luglio 2010. (Italian) (Lecturer)
- Ninth International Kidney Cancer Symposium. Chicago, October 1-2, 2010.
- Core Curriculum Uro-Oncology. Bertinoro (FC), March 11-13, 2010. (Italian) (Lecturer)
- XII National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, November 6-8, 2010.
- Prostate Cancer Follow up. Milano, November 23, 2010. (Lecturer)
- Renal cell carcinoma: new challenge in the biologic therapies era. Bologna, November 26, 2010. (Italian) (Lecturer)
- 2011 Genitourinary Cancers Symposium. Orlando (Florida), February 17-19, 2011.
- Renal Cell Carcinoma: identifying risk status, selecting therapy & limiting risk. Orlando (Florida), February 18, 2011.
- The treatment of metastatic kidney cancer in the era of biological therapies. Altavilla Vicentina (VI), February 25, 2011.
- 2nd Annual conference of renal cancer experts. Amburgo, April 8-9, 2011.
- Expert meeting "ToGOHERound". Mogliano Veneto (TV), April 14, 2011.
- National Aiom conference on the use of oral therapy in oncology. Verona, April 29-30, 2011.
- Multidisciplinary approach to renal cell carcinoma in the targeted therapies era. Mestre, May 13-14, 2011. (Lecturer)
- AIOM post ASCO review: updates and news from the annual meeting in Chicago. Bologna, June 18-19, 2011.
- XXI National Congress of Italian Society of Oncologic Urology. Napoli, June 22-24, 2011. (Italia) (Lecturer)
- Expert meeting. EXTRA Project. Verona, June 28, 2011.
- Third Pavia International Symposium on Advanced Kidney Cancer. Pavia, June 30 and July 1st, 2011. (Lecturer)
- 2011: News in Oncology. Perugia, July 1-2, 2011.
- Prostate Project - CIPOMO meets young oncologists. Bologna, September 2-3, 2011. (Lecturer)
- GSK Oncology: From translational research to patient. Verona, September 16-17, 2011.
- The 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO 2011). Stoccolma, September 23-27, 2011.
- New strategies for the treatment of urological tumor. Montecchio Maggiore (VI), September 29, 2011. (Lecturer)
- Protocol 212082PCR3001 – EAP – Abiraterone: investigator meeting. Milano, October 3, 2011.
- Workshop: doctor-patient relationship. Bertinoro, October 4, 2011. (LECTURER)
- Expert meeting Doc Team. Bologna, 11 Ottobre 2011. (LECTURER)
- Multidisciplinary approach to renal cell carcinoma in the targeted therapies era. Camogli, October 21-22, 2011. (Lecturer)
- Metastatic renal cell carcinoma: lo scenario attuale e futuro del trattamento. Padova, October 24, 2011. (Lecturer)
- Clinical research in Italy. Bologna, November 4, 2011.
- XIII National Meeting of the Italian Association of Medical Oncology (AIOM). Bologna, November 5-7, 2011. (LECTURER)
- Biomarkers in oncology clinical practice: problems and solutions in comparison oncologist and pathologist - II meeting. Reggio Emilia, November 11, 2011. (LECTURER)
- Metastatic renal cell carcinoma. Comparing reflections and experiences. Monselice (PD), November 24, 2011. (LECTURER)
- Pfizer Oncology RCC Academy. Vienna, November 25-26, 2011.
- Refresher course GCP (GOOD CLINICAL PRACTICE). Verona, January 18, 2012.
- Prostate Cancer. Integrated and multidisciplinary follow up. Verona, January 21, 2012. (LECTURER)
- 2012 Genitourinary Cancers Symposium. San Francisco (California), February 02-04, 2012.
- Refresher course BASIC LIFE SUPPORT – DEFIBRILLATION (BLS-D). Verona, March 13, 2012.

- SIOG National Congress. Innovation, cooperation, fertility in Gynecologic Oncology. Verona, March 20-21, 2012. (LECTURER)
- 3rd annual conference of renal cancer experts. Monaco, April 20-21, 2012.
- Therapy management with sunitinib in first line treatment of mRCC. Padova, April 23, 2012
- 1st Workshop SIUR Young. Critical issues in the multidisciplinary management of patients with prostate cancer. Bologna, April 27, 2012. (LECTURER)
- Kidney cancer on 360°: multidisciplinary approach. Sirmione (BS), May 11-12, 2012. (LECTURER)
- Editorial project mCRPC: State of Art and new challenges. Padova, May 15, 2012.
- A new age in the management of mCRPC patients. Sestri Levante (GE), May 24-25, 2012. (LECTURER)
- XXII National Congress of Italian Society of Oncologic Urology. Bologna, June 13-15, 2012. (Italia) (Lecturer)
- Mediterrean School of Oncology. New Perspectives in Metastatic Prostate Cancer. Roma, June 15, 2012. (Lecturer)
- Algorithms of treatment of first and second line mRCC: contributions Post ASCO. Mestre (VE), July 02, 2012
- 2012: News in Oncology. Perugia, July 6-7, 2012.
- ESMO 2012 Congress. Vienna, September 28 – October 02, 2012.
- 1st World top communications of the year in Genito-Urinary Oncology. Arezzo, October 18-19, 2012. (LECTURER)
- XIV National Meeting of the Italian Association of Medical Oncology (AIOM). Roma, October 27-29, 2012.
- Algorithms of treatment of first and second line mRCC: contributions Post ESMO. Mestre (VE), November 05, 2012
- The hidden side of the evidence. Scientific research and treatment decisions in oncology. Udine, November 07, 2012
- Young specialists compared: the urological cancers. Milano, November 09, 2012. (LECTURER)
- Current trends in the clinical approach to kidney and prostate cancer. Ferrara, November 16, 2012. (LECTURER)
- The scientific basis for the treatment of prostate cancer. Milano, November 30 – December 01, 2012. (LECTURER)
- Mediterrean School of Oncology. Highlights in the management of renal cell carcinoma. Roma, February 22, 2013. (LECTURER)
- Kidney Cancer Group Triveneto's meeting IV Edition. Venezia, March 15-16, 2013.
- RCC Academy and Renal Hotizons 2013. Berlin, March 22-23, 2013.
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Firenze, April 11-12, 2013. (LECTURER)
- Adenocarcinoma of the prostate: the radio-oncologist and therapeutic management between evidence and new perspectives. VI Congress AIRO Young. Rimini, May 18, 2013 (LECTURER)
- ASCO Annual Meeting '13. Chicago, May 31– June 04 2013
- XXIII National Congress of Italian Society of Oncologic Urology. Firenze, June 09-11, 2013. (LECTURER)
- Rare Tumors: between empiricism and evidence. Padua, June 21, 2013. (LECTURER)
- 2013: News in Oncology. Perugia, July 5-6, 2013. (LECTURER)
- Locally advanced and metastatic prostate cancer: current trends and future prospects. Dossobuono di Villafranca (VR), September 14, 2013. (LECTURER)
- XV National Meeting of the Italian Association of Medical Oncology (AIOM). Milan, October 11-13, 2013.
- 5 Congress of the Association for Research on Kidney Tumors. Chantilly, October 25-26, 2013.
- 2nd World top communications of the year in Genito-Urinary Oncology. Arezzo, November 07-08, 2013 (LECTURER).
- Young specialists compared: the urological cancers. Torino, November 12, 2013. (LECTURER)
- Changes in oncology. Verona, November 15, 2013. (LECTURER)
- The hidden side of the evidence. Scientific research and treatment decisions in oncology. Milan, November 22, 2013. (LECTURER)
- Customizing treatment strategy in prostate cancer. Naples, November 23, 2013. (LECTURER)
- Clinical diagnosis and therapy of TCCU. Verona, February 07, 2014 (LECTURER)
- Siuro Lab in uro-oncology: what training needs? ...Work in progress... Bologna, February 15, 2014 (LECTURER)
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Firenze, February 20-21, 2014. (LECTURER)
- 1st Young Specialist Renal Care. Verona, March 07-08, 2014 (LECTURER)
- Ninth European International Kidney Cancer Symposium. Dublin, April 25-26, 2014
- The treatment of Metastatic Renal Carcinoma. PERSONALISED MEDICINE: myth or opportunity? Trieste, May 09-10, 2014 (LECTURER)

- Youngs in Renal. Pacengo di Lazise, May 23-24, 2014. (LECTURER)
- A new age in the management of mCRPC patients: work in progress. Trento, June 12-13, 2014 (LECTURER)
- AIOM post ASCO review: updates and news from the Annual Meeting in Chicago. Bologna, June 13-14, 2014 (LECTURER)
- Diagnosis and treatment of metastatic castration-resistant prostate cancer: current strategies and new perspectives. Verona, June 16, 2014
- XXIV National Congress of Italian Society of Oncologic Urology. Bologna, June 22-24, 2014. (LECTURER)
- 2014: News in Oncology. Perugia, July 11-12, 2014. (LECTURER)
- 4th International Pavia Kidney Cancer Symposium. Pavia, September 11, 2014. (LECTURER)
- Macro-regional educational course AIOM Young - Think a translational research project. Verona, September 12-13, 2014. (LECTURER)
- News in Genitourinary Tumors. Milano, September 18, 2014 (LECTURER)
- Cardio-Oncology. Negrar (VR), September 19, 2014 (LECTURER)
- 39th ESMO Congress – ESMO 2014. Madrid, September 26-30, 2014.
- 3rd World top communications of the year in Genito-Urinary Oncology. Arezzo, October 09-10, 2014. (LECTURER)
- Food and nutrition in cancer patients. Padova, October 17, 2014. (LECTURER)
- XVI National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, October 24-26, 2014.
- Update on new treatments in patient with metastatic prostate cancer. Treviso, October 31, 2014. (LECTURER)
- XXIV AIRO National Meeting. Padova, November 08-11, 2014 (LECTURER)
- Nutrition, lifestyle and cancer. The word to the experts. Francavilla Fontana, November 28-29, 2014 (LECTURER)
- Treating and Caring for Patients with Renal Cell Carcinoma . Padova, December 04, 2014. (LECTURER)
- 2nd Young Specialist Renal Care. Verona, March 06-07, 2015. (LECTURER)
- Renal Horizons Summit 2015. Atene, March 13-14, 2015.
- CORE: Conference of Renal Cancer Experts in Pursuit of the Optimal. Venezia, March 20-21, 2015. (LECTURER)
- AIOM post ASCO GU review. UPDATES and NEWS from the Genitourinary Cancers Symposium in Orlando. Milan, March 27, 2015. (LECTURER)
- Le Jeunesse durer: neoplasm in young and related problems. Padova, April 15, 2015.
- mRCC: continuous care and multidisciplinary approach. Clinicians and mRCC's Patients. Riva del Garda (TN), May 08, 2015. (LECTURER)
- Medical therapy of advanced prostate cancer. Padova, May, 12 2015. (LECTURER)
- The young biomarkers day a SIF-AIOM joint symposium. Pisa, May 16, 2015. (LECTURER)
- The Prostate cancer: current trends and future prospects. Verona, May 23, 2015. (LECTURER)
- Focus on the patient mCRPC (metastatic castration resistant prostate cancer) post ADT (pre DOCETAXEL). Verona, July 1st, 2015 (LECTURER)
- 2015: News in Oncology. Perugia, July 10-11, 2015. (LECTURER)
- The supportive care and palliative care in oncology. Rome, 18-19 September 2015. (LECTURER)
- Update on the diagnosis and treatment of patients with prostate cancer. Vicenza, October 3, 2015. (LECTURER)
- XVII National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, October 23-25, 2015. (LECTURER)
- Tumor Immunology. Rome, November 11, 2015. (LECTURER)
- Updates on prostate cancer. Bologna, November 27, 2015. (LECTURER)
- Immunotherapy of cancer the fourth street. Fermo (AN), December 18, 2015. (LECTURER)
- Nutrition, lifestyle and cancer. Francavilla Fontana (BR), December 18-19, 2015. (LECTURER)
- AIOM post ASCO GU review. UPDATES and NEWS from the Genitourinary Cancers Symposium in San Francisco. Milan, January 22, 2016. (LECTURER)
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Rome, February 18-19, 2016. (LECTURER)
- GOIRC. Synergies between actors in the research against cancer. Florence, February 26, 2016. (LECTURER)
- Dial the puzzle in prostate cancer. Bologna, March 23, 2016. (LECTURER)
- 3rd Young Specialist Renal Care. Florence, April 08-09, 2016 (LECTURER)
- Eleventh European International Kidney Cancer Symposium. Barcellona, April 29-30, 2016
- Lights and Shadows in the imaging of prostate cancer. Bologna, June 23-24, 2016. (LECTURER)
- 2016: News in Oncology. Perugia, July 08-09, 2016. (LECTURER)
- Oncology match, meetings - fighting in oncology. Bari, September 23-24, 2016. (LECTURER)

- ESMO Congress 2016. Copenhagen, October 07-11, 2016.
- The time of immunotherapy in the treatment of kidney cancer. Modena, October 21, 2016 (LECTURER)
- XVIII National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, October 28-30, 2016. (LECTURER)
- New Perspectives in Urological Cancers Therapy. Bologna, November 03, 2016. (LECTURER)
- The future is already present: urogynecological therapeutic advances in oncology. Lecce, November 11, 2016. (LECTURER)
- 5th World top communications of the year in Genito-Urinary Oncology. Arezzo, November, 16-18 2016. (LECTURER)
- Focus on cancer and new therapies: prostate cancer. Lucca, November 22, 2016. (LECTURER)
- Nutrition, lifestyle and cancer. The word to the experts. Francavilla Fontana, November 25-26, 2016 (LECTURER)
- New Perspectives of medical therapy in prostate cancer. Bologna, December 02, 2016. (LECTURER)
- 4th Young Specialist Renal Care. Bologna, January 13-14, 2017 (LECTURER)
- Updates on the renal and prostate cancer. Maranello (MO), January 20-21, 2017 (LECTURER)
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Rome, February 02-03, 2017. (LECTURER)
- Watch different: the other face of the uro-oncology. Bologna, February 22, 2017. (LECTURER)
- AIOM post ASCO GU review. UPDATES and NEWS from the Genitourinary Cancers Symposium in Orlando. Milan, March 03, 2017. (LECTURER)
- XIII National Congress AIMN (Italian Association Nuclear Medicine). Rimini, March 02-05, 2017. (LECTURER)
- GOIRC. Sustainability in oncology in the clinical practice and in the research. Firenze, March 10, 2017. (LECTURER)
- Winter School. Renal cell carcinoma. Arezzo, March 17, 2017. (LECTURER)
- The real world value: experience on the elderly patient. Bologna, May 03, 2017. (LECTURER)
- Nivolution. Bologna, May 19, 2017. (LECTURER)
- 2017 Young AIOM Annual Meeting. Perugia, July 07-08, 2017. (LECTURER)
- Oncology match – Part II. Bari, September 22-23, 2017. (LECTURER)
- III Regional SIUT Meeting Emilia Romagna: therapies and technologies a comparison in urology. What do we communicate to our patients? Bologna, September 29, 2017. (LECTURER)
- IXX National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, October 27-29, 2017. (LECTURER)
- Nutrition, lifestyle and cancer. The word to the experts. Brindisi, November 24-25, 2017 (LECTURER)
- Targeted alpha therapy in clinical practice. Bologna, November 27, 2017 (LECTURER)
- Immunotherapy course in oncology. “Renal cell carcinoma and bladder cancer”. Negrar (VR), Novembre 29, 2017. (LECTURER)
- Treatment of genitourinary tumors: what new goals? Bologna, December 05, 2017. (LECTURER)
- NIBIT training course on immunobiotherapy of human tumors. Bologna, December 18, 2017. (LECTURER)
- CA.RE. 3.0 - Cabozantinib: new molecular targets, new therapeutic opportunities. Milan, January 26-27, 2018. (LECTURER)
- 2018 Genitourinary Cancers Symposium. San Francisco (California), February 08-10, 2018.
- AIOM post ASCO GU review. UPDATES and NEWS from the Genitourinary Cancers Symposium in San Francisco. Milan, March 02, 2018. (LECTURER)
- A New Treatment Scenario in Genito-Urinary Malignancies: from biomolecular issues to clinical decision making. Arezzo, March 08, 2018 (LECTURER)
- XXVIII National Congress of Italian Society of Oncologic Urology. Milan, April 12-14, 2018. (LECTURER)
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Rome, May 18-19, 2018. (LECTURER)
- 2018 ASCO Annual Meeting. Chicago, June 01-05, 2018.
- AIOM POST-ASCO Review: Updates and news from the Annual Meeting in Chicago. Milano, June 15-16, 2018 (LECTURER)
- Optimal management of the patient with prostate cancer. Milano, September 25-26, 2018. (LECTURER)
- 6th World top communications of the year in Genito-Urinary Oncology. Terni, September 27-28, 2018. (LECTURER)
- Prostate Cancer Unit MEETING 2018: a common goal. Bologna, September 28-29, 2018. (LECTURER)
- Updates on the treatment of uro-gynecological carcinomas. Taranto, October 27, 2018. (LECTURER)
- Genitourinary neoplasms between clinical practice and innovation. Brescia, November 09, 2018. (LECTURER)
- XX National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, November 16-18, 2018.

- 6th Pavia International Symposium on Advanced Kidney cancer – Pavia, November 30, 2018 (LECTURER)
- Anti-VEGF and TKI multitarget Cardiotoxicity – Negrar (VR), January 25, 2019 (LECTURER)
- Real World Evidence of innovative drugs in urological tumors. Bologna, January 30, 2019 (LECTURER)
- News for urothelial tumors. Reggio Emilia, March 12, 2019 (LECTURER)
- Prostate Cancer. From studie to clinical practice. Turin, March 16, 2019 (LECTURER)
- XIX National Congres of Italian Society of Oncologic Urology. Bologna, April 11-13, 2019. (LECTURER)
- HORIZON - Integrated management of the patient with prostate cancer: state of the art and future prospects. Bologna, April 15, 2019.
- SPECIAL. CA.RE. Specialists in renal cell carcinoma. Bologna, May 16-17, 2019. (LECTURER)
- Guidelines and professional responsibility in prostatic carcinoma: what changes? Reggio Emilia, May 22, 2019. (LECTURER)
- Workshop managing innovation in prostate cancer. Torino, May 24-25, 2019 (LECTURER)
- 2019 AIOM REVIEW: from Chicago to Verona. Verona, June 4-15, 2019. (LECTURER)
- ESMO Congress 2019. Barcellona, Septmber 27 – October 01, 2019.
- Alpha therapy aimed at clinical practice. Bologna, October 03, 2019 (LECTURER)
- 7th World top communications of the year in Genito-Urinary Oncology. Terni, October 09-10, 2019. (LECTURER)
- XXI National Meeting of the Italian Association of Medical Oncology (AIOM). Rome, October 25-27, 2019 (LECTURER)
- 7th Pavia International Symposium on Advanced Kidney cancer – Pavia, November 08, 2019 (LECTURER)
- Personalized therapy in adenocarcinoma of the prostate. Reggio Emilia, November 12, 2019 (LECTURER)
- KidneyWay metastatic renal carcinoma: comparative treatment pathways. Verona, November 14, 2019 (LECTURER)
- Urological tumors: between scientific progress and clinical practice. Cagliari, November 15, 2019 (LECTURER)
- Genitourinary neoplasms between clinical practice and innovation. Brescia, December 4, 2019 (LECTURER)
- Focal therapy of prostate and renal cancer. Bologna, December 06-07, 2019 (LECTURER)
- The interdisciplinary team in prostate cancer. Negrar (VR), December 06-07, 2019 (LECTURER)
- Prostate Cancer. Parma, December 13, 2019 (LECTURER)
- Mechanisms of action and side effects of immunotherapy: current approaches and future perspectives. Bologna, January 28, 2020 (LECTURER)
- The patient with metastatic prostate cancer: the organization of a multidisciplinary care network. Bologna, February 07, 2020 (LECTURER)
- 14° National Congress AIOM Young. 2020: News in Oncology. Webinar, July 10, 2020 (LECTURER)
- YOUNG TO YOUNG 2020 – The tomorrow oncology. Webinar, September, 07-08 2020 (LECTURER)
- 8th World top communications of the year in Genito-Urinary Oncology. Webinar, October, 01-02 2020 (LECTURER)
- Strategies and therapeutic choices for patients with urothelial tumors. Webinar, October, 08 2020 (LECTURER)
- Blended learning for immuno-oncologist. Webinar, October, 16 and December, 04 2020 (LECTURER)
- XXII National Meeting of the Italian Association of Medical Oncology (AIOM). Webinar, October 30 – November 01 2020
- 8th International Symposium on Advanced Kidney cancer – Webinar, December, 11 2020 (LECTURER)
- MAXI-GUMM 2 – Young Pathologists meet Young Oncologists. Webinar, February, 18-19 2021 (LECTURER)
- Comparison between Triveneto, Emilia-Romagna and Marche. Changes in therapeutic strategies and sequences in advanced urological cancers. Webinar, March, 18 2021 (LECTURER)
- Prostate Cancer Unit Meeting 2021. Bologna, September, 17-18 2021 (LECTURER)
- XXXI National Congres of Italian Society of Oncologic Urology. Virtual, October 02, 2021. (LECTURER)
- Uro-Oncology Challenge. Milano Marittima, November 05-06, 2021. (LECTURER)
- News in Uro-Oncology. Cagliari, November 26, 2021. (LECTURER)
- News in GU Oncology 2022. Matera, March 11-12, 2022. (LECTURER)
- 1982-2022: 40 years of GOIRC. How we were and where are we going. Bologna, April 08, 2022. (LECTURER)
- Focus on nmCRPC. Bologna, May 28, 2022. (LECTURER)